Passive and Acquired Immunity to Respiratory Syncytial Virus in Young Children in Rural Kenya by Ochola-Opiyo, Beldinah R.
Open Research Online
The Open University’s repository of research publications
and other research outputs
Passive and Acquired Immunity to Respiratory
Syncytial Virus in Young Children in Rural Kenya
Thesis
How to cite:
Ochola-Opiyo, Beldinah R. (2008). Passive and Acquired Immunity to Respiratory Syncytial Virus in Young
Children in Rural Kenya. PhD thesis The Open University.
For guidance on citations see FAQs.
c© 2008 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
■ ■ 'O N /^ sfE ic ^ e b
' ^  'K
PASSIVE AND ACQUIRED IMMUNITY TO 
RESPIRATORY SYNCYTIAL VIRUS IN YOUNG 
CHILDREN IN RURAL KENYA
%
Beldinah R. Ochola-Opiyo
(BSc,MSc)
A thesis submitted to the The Open University for the degree of 
DOCTOR OF PHILOSOPHY
LIFE SCIENCES DISCIPLINE
Sponsoring Establishment 
Kenya Medical Research Institute (KEMRI)/ Wellcome Trust Research
Programme, Kilifi, Kenya
Collaborating Establishment 
The Division of Immunity and Infection, School of Medicine, 
University of Birmingham, England
December 2007
/  *. i y. ' .vJ . j
bfrr& of  suGtt/SX/OA/ OL+ 2-OoS*
bPrTB o * fa * M b  IMA"/ 2D O F
ProQuest Number: 13837699
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com plete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13837699
Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States Code
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
DEDICATION
To the memory o f my late grandfather, JH Odonde, andfor my parents, Mama and 
Dad, who always instilled the value o f hard work.
2
ACKNOWLEDGMENTS
Firstly I would like to take this opportunity to extend my heartfelt gratitude to both my supervisors, Dr 
Patricia Cane and Dr James Nokes who provided me with this great opportunity. Pat thank you for 
your dedication, promptness in replying my numerous emails, and above all, for always helping me 
keep up my spirits through it all! To James, asante sana for your dedication, critical analysis as well as . 
your attention to detail which always never failed to amaze me! I have leamt a great deal from you 
both. I would also like to thank Prof. Kevin Marsh for finding time to read through the thesis despite 
his own hectic schedule and for positive feedback.
Special thanks go to the ever dedicated and extremely hard working RSV Team from the field workers- 
Mwaruwa, Benson, Salma, Janet, Karen, Kadzo, Patience, Riziki, Milton, the maternity field staff, our 
clinical officer, MJ- this project would not have been brought to its successful completion without each 
and everyone of your joint efforts. Also, to the ever wonderful and vibrant laboratory staff- Anne, John 
and Sande-what long hours we spent together pipetting back and forth carrying out ELISAs thanks for 
your company, unwavering help and dedication guys. Thank you too to all study participants, and to 
each and every member, past and present, of KEMRI/Wellcome Trust Staff, unfortunately too 
numerous to list asanteni sana. Dr. Paul Scott- thank you too so much for everything- we started 
together in Birmingham and finished off in Warwick, thanks for the many hours of consultation and 
excellent tutelage that enabled me successfully carry out all my experiments here in Kilifi. To Gillian 
Scott (Warwick University) and all staff members at Centre for Virus Research and the Cell Culture 
Lab, KEMRI headquarters Nairobi, I thank each of you for helping out a stranger and giving excellent 
advise on cell culture techniques.
Without Marie Meaden, Isabella and Lucy Ochola and Maureen Jilani, selflessly and consistently 
pulling out publication after publication and sending them on to me, despite their busy schedules, 
carrying out this project would have been decidedly difficult. My sincere gratitude to each one of you. 
To Dr. Lisa White (Warwick University), Dr. Anthony Scott and Dr. Pete Bull, thank you all for 
excellent discussions, which resulted in wonderful outcome. Hellen Gatakaa, Lazarus Mramba, Eric 
Ohuina and Dr Greg Fegan, I extend a special thanks for all your help and wonderful patience with 
Stata and all the statistics, thanks too for demystifying it all for me!
To an exceptional individual, Emelda- for going through it all with me- from the lab to Stata- what an 
experience! As well, my lovely sisters, Lucy, Isabella and Judy, who constantly pepped me up and for 
excellent advice, erokamano urn ahinya. Thank you too to Simon Ndirangu, Noor, Amin, Thuweba and 
Chi and the rest of my friends- thanks guys for all your help and encouragement especially these last 
days.
Last but by no means least, I would love to say a big thank you to all the special people in my 
life, my entire family, Mama, Dad, John, Rob and my wonderful sisters, to my loving husband 
Laban and gorgeous daughter, Serabi, for all allowing me to do this, it would have otherwise 
been impossible. I will always cherish your encouragement, patience and support every step of 
the way and above all thank you for all your love-1 will always be truly indebted. Erokamano 
uru ahinya. My darling Serabi and Laban thank you also very much for allowing Mum to be 
away all this time to finish her studies-1 love you both.
Declaration
I, Beldinah Rachel Ochola-Opiyo, certify that the work embodied in this thesis 
is the result of my own investigations except where reference has been made to 
the published literature.
I declare that this work has not already been accepted in substance, or is being 
currently submitted in candidature for any other degree.
Candidate:..
Signature:..
Date:... 2
Director of studies: Dr. D. James Nokes
Signature:.
Date:
TABLE OF CONTENTS
Abbreviations .................................................................................................................12
ABSTRACT..................   14
CHAPTER ONE
Introduction........................  15
1.1 Respiratory Syncytial Virus................................................  15
1.2 Objectives........................................................................................................................ 16
1.3 The Scope of the Thesis.................................................................................................. 17
1.4 The Burden of RSV Disease..................................................................................  18
CHAPTER TWO
The Biology of Respiratory Syncytial Virus............................................................................. 24
2.1 The Pathogen- Historical Overview................................................................................ 24
2.2 Structure and Genome......................................................  25
2.3 The Replication Cycle of RSV.....................   28
2.4 Molecular Epidemiology.................................................................................................29
2.4.1 Group variability..................................................................  29
2.4.2 Strain variability...............................................................  30
2.4.3 Relative prevalence of strains, hospital vs. community...........................................34
2.5 Clinical Symptoms of RSV Disease............................................................................... 37
2.6 Treatment of RSV Disease..............................................................................................39
2.7 Diagnosis of RSV........................................................................................................... 40
2.8 RSV Vaccine Developments................................................ 42
CHAPTER THREE
RSV Specific Maternal Antibodies......................................................................  47
3.1 Introduction.....................................................................................................................47
3.2 Placental Transfer and the Decay of RSV-Specific Maternal Antibody......................... 49
3.2.1 Literature search methods.........................................................................................49
3.2.2 Placental transfer................................................................................................  52
3.2.3 Risk factors for decreased placental transfer of RSV antibodies........................... 523
3.2.3.1 Maternal antibody concentration.......................................................................53
3.2.3.2 HTV infection.................................................................................................... 54
3.2.3.3 Gestational age/prematurity, birth weight and nutrition....................................55
3.2.3.4 Placental malaria............................................................................................... 57
3.2.4 Decay of RSV-specific matAb..................................................................................57
3.3 Models for Calculation of Mean Rate of matAb Decay................................................. 59
3.3.1 Model I: exponential decline model for maternal RSV Abs................................... 61
3.3.2 Model II: decay in seroprevalence........................................................................... 62
3.4 The Immune Response to RSV and the Implication for Protection by Maternal
Antibodies......................................................................................................................63
3.5 Correlates of Immunity to RSV-Associated Disease - What is the Protective Immune
Threshold?.....................................................................................................................68
3.6 Evaluation of the Induction of the RSV-Specific Immune Responses by RSV
Vaccines ^...........................................................................................  76
3.7 The Suppression of the Infant’s Immune Response by matAb............................. 88
3.8 Other Immune Responses and Factors Affecting them.........................   88
3.9 Summary and Conclusion...............................................................................................90
CHAPTER FOUR
Materials and Methods...............................................................................................................91
4.1 Study Site........................................................................................................................91
4.1.1 Demographic features...............................................................................................91
4.2 Study Design....................................................................................................................93
4.2.1 Definitions................................................................................................................93
4.2.2 Recruitment of cohort...............................................................................................94
4.3 General Characteristics of the Cohort............................................................................. 97
4.4 Ethical Considerations....................................................................................................97
4.5 Methods........................................................................................................................... 98
4.5.1 Sample collection..................................................................................................... 98
4.5.1.1 Nasal washings (NW) and RSV diagnosis........................................................ 98
4.5.1.2 Blood collection.................................................................................................99
4.5.2 Cell and virus culture............................................................................................. 100
4.5.2.1 Culture media.................................................................................................. 100
4.5.2.2 Cell culture.......................................................................................................100
4.5.2.3 Cryopreservation o f HEp-2 cell lines.............................................................. 101
4.5.2.4 Virus stock preparation...................................................................................101
4.5.2.5 Viral antigen (lysate) preparation................................................................... 102
4.5.2.6 Enzyme linked immunosorbent assay (ELISA) procedure..............  102
4.5.2.7 Modified lysate preparation/EUSA procedure............................................... 103
4.5.3 Molecular assays.................................................................................................... 104
4.5.3.1 Clinical specimens......................................................................................... 104
4.5.3.2 Ribonucleic acid (RNA) extraction and complementary deoxyribonucleic acid 
(cDNA) synthesis by reverse transcription......................................................105
4.5.3.3 Primers used.................................................................................................... 106
4.5.3.4 Multiplex polymerase chain reaction (mPCR)................................................ 106
4.5.3.5 Gel electrophoresis.......................................................................................... 107
4.5.3.6 Purification o f PCR products...........................................................................107
4.5.3.7 Ngene PCR......................................................................................................108
4.5.3.8 N  gene restriction fragment length polymorphism.......................................... 108
4.5.4 Methods for statistical analysis...............................................................................109
CHAPTER FIVE
RSV-specific Enzyme Linked Immunosorbent Assay (ELISA): Assay Development...........110
5.1 Introduction................................................................................................................... 110
5.2 Objectives...................................................................................................................... 112
5.3 Results............................................................................................................................113
5.3.1 Optimization of ELIS A Procedure......................................................................... 113
5.3.2 Determination of dilution of capture antigen..........................................................114
5.3.2.1 M ethod.............................................................................................................114
5.3.2.2 Results............................................................................................................1145
5.3.2.3 Interpretation.................................................................................................. 115
5.3.3 Determination of dilution of rabbit anti-human IgG conjugate..............................116
5.3.3.1 M ethod.............................................................................................................116
5.3.3.2 Results..............................................................................................................116
5.3.3.3 Interpretation.................................................................................................. 116
5.3.4 Reproducibility of ELISA......................................................................................116
5.3.4.1 Method.......................................................................................................... 117
5
53.4.2 Results........................................................................................................... 117
5.3.4.3 Interpretation...................................................................................................118
5.4 Sensitivity of ELISA: Validation of ELIS A Method and Optimization of Serum
Dilution........................................................................................................................ 118
5.4.1 Dynamic range of dose response curves................................................................ 119
5.4.1.1 Method.............................................................................................................119
5.4.1.2 Results..............................................................................................................119
5.4.1.3 Interpretation...................................................................................................119
5.4.2 Identification of the dynamic range of the log linear phase...................................121
5.4.2.1 Test fo r parallelism.......................................................................................... 121
5.4.2.1.1 Method..........................................................................................................121
5.4.2.1.2 Results...........................................................................................................121
5.4.2.1.3 Interpretation............................................................................................... 121
5.4.3 Further characterization of log linear phase...........................................................123
5.5 Reference/Standard Serum and Controls...................................................................... 125
5.6 Lysate Preparation Optimization and Assay Troubleshooting...................................... 125
5.7 Discussion...................................................................................................................... 129
CHAPTER SIX
Characterization of RSV Strains Infectiing Children from a Birth Cohort using Multiplex 
Polymerase Chain Reaction (mPCR)...................................................................................... 131
6.1 Introduction...................................................................................................................131
6.2 Objective....................................................................................................................... 132
6.3 Methods......................................................................................................................... 133
6.3.1 Definitions..............................................................................................................133
6.4 Results........................................................................................................................... 135
6.4.1 Clinical specimens................................................................................................. 135
6.4.2 Processing of IF AT positive NW specimens..........................................................136
6.4.3 Distribution of variants during epidemics..............................................................138
6.4.3.1 Relative prevalence ofRSV groups.................................................................. 138
6.4.3.2 Strain typing by RFLP...................................................................................... 139
6.4.4 The effect of strain variation on disease outcome...................................................141
6.4.5 Processing of NW specimens identified from an ELISA-CSR..............................142
6.5 DISCUSSION................................................................................................................144
CHAPTER SEVEN
The level and duration of RSV-specific maternal IgG and its association with risk factors in 
infants in Kilifi, Kenya............................................................................................................150
7.1 Introduction...................................................................................................................150
7.2 Objectives...................................................................................................................... 151
7.3 Definitions..................................................................................................................... 151
7.4 The analysis procedure.................................................................................................. 152
7.5 Methods/Statistical Analysis......................................................................................... 153
7.6 Results........................................................................................................................... 156
7.6.1 Descriptive Analysis of study population...............................................................156
7.6.2 Determination of cut-off for seropositivity.............................................................156
7.6.3 Frequency distribution of RSV-specific antibody titres......................................... 157
7.6.4 Duration of RSV seropositivity..............................................................................159
7.6.5 Characterization of RSV-specific antibody............................................................160
7.6.5.1 Concentration o f RSV-specific antibodies with age...................................... 160
6
7.6.5.2 Analysis o f the antibody response model.....................................................162
7.6.6 Identification of outliers......................................................................................... 167
7.6.6.1 Regression Diagnostics..................................................... 167
7.6.6.2 Distribution o f gradients..................................................................................168
7.6.7 Student’s t-test: possible differences in cord blood titres of non-infected and 
infected population’s ............................................................................................. 169
7.6.8 Factors associated with cord blood titres................................................................ 173
7.6.9 Possible differences in rate of decay of matAbs of non-infected and infected 
population’s ...........................................................................................................174
7.6.10 Factors associated with the rate of decline of matAb titres over the 1st six months 
of life..................................................................................................................... 176
7.7 Discussion.................................................................................................................... 179
CHAPTER EIGHT
The dynamics of RSV infection within the Kilifi birth cohort: characteristics of the RSV IgG 
specific humoral responses......................................................................................................186
8.1 Introduction................................................................................................................... 186
8.2 Objectives...................................................................................................................... 187
8.3 The analysis procedure.................................................................................................. 187
8.4 Methods/Statistical Analysis......................................................................................... 188
8.4.1 Survival Analysis................................................................................................... 188
8.5 Results............................................................................................................................188
8.5.1 RSV-specific IgG responses...................................................................................188
8.5.2 Prevalence of RSV-specific Abs.............................................................................193
8.5.3 RSV-specific Ab responses to clinically confirmed RSV infections..................... 194
8.5.4 The effect of cord blood levels on serological responses of paired samples 199
8.5.5 The role of cord blood levels with disease outcome..............................................200
8.5.6 Estimation of serological correlates of protection against RSV-associated
LRTI......................................................................................................................201
8.5.7 Incidence rates of IF AT and ELISA confirmed RSV-associated infections 202
CHAPTER NINE
Overall Discussion...................................................................................................................217
9.1 Findings and supporting evidence................................................................................ 217
9.2 Generalisability of study findings.......................  219
9.3 Limitations of the study.................................................................................................220
9.3.1 Limitations in our understanding of the problem................................................. 221
9.4 Future work...................................................................................................................222
REFERENCES........................................................................................................................225
APPENDIX I: WHO child growth standards.......................................................................... 260
APPENDIX II: RSV Study: home visit form......................................................................... 262
APPENDIX HI: RSV Study: sick child clinic visit.................................................................263
APPENDIX IV: Information and consent form for birth cohort child..................................... 265
APPENDIX V: Sources of Reagents, Equipment and Consumables......................................269
APPENDIX VI: Growth stages non-infected and infected cultured HEp-2 cells...................272
APPENDIX VH: Sequences of primers used and amplicon sizes..........................................273
APPENDIX VIII: Modified lysate preparation/ELISA procedure.........................................274
APPENDIX IX: Distribution of nasal wash sample results and type of samples collected... 275
7
APPENDIX X: Stem-and- leaf plot for r (Studentized residuals)   276
APPENDIX XI ..........            ...277
APPENDIX XII: Student t-tests .....................   278
APPENDIX XIII: Multiple regression models.......................................................................282
8
LIST OF FIGURES AND TABLES
Figure 1.1. Major causes of death in children younger than age 5 years and in neonates....... 18
Figure 1.2. Number of deaths in children admitted to the KDH, Kilifi Kenya.........................19
Figure 1.3. Comparative incidence of admissions from 2002-2005 of various childhood
diseases at KDH (Kilifi Epi-DSS) stratified into infants and children under 5 years............... 22
Figure 2.1. Structure of respiratory syncytial virus.................................................................. 25
Figure 2.2. Schematic representation of the respiratory syncytial virus (hRSV) ssRNA..........26
Table 2.1. RSV gene and protein lengths.................................................................................. 27
Figure 2.3. A schematic representation of the RSV replication cycle.......................................29
Table 2.2. Major risk factors for RSV infections......................................................................39
Table 2.3. Research and Development Status of RSV vaccine development in human studies.
...................................................................................................................................................44
Figure 3.1. Proposed scheme of decline of maternal specific RSV Ab from birth depicting
putative threshold levels of vaccine response............................................................................48
Table 3.1a. Levels of RSV-specific matAb, maternal: cord blood titres.................................. 50
Table 3.1b. The prevalence of RSV-specific matAb, maternal: cord blood titres to specific
RSV strains................................................................................................................................ 51
Table 3.2. The mean duration of RSV matAb in infants........................................................... 60
Table 3.3. A selection of studies showing the proportion of infants between 0-12 months of
age seropositive for RSV.......................................................................................................... 60
Table 3.4. A selection of studies comparing RSV-specific IgG titres in case/control studies.. 70
Table 3.5. A selection of studies comparing RSV-specific IgG titres in paired samples 72
Table 3.6. A selection of studies comparing RSV-specific IgG responses to F and G
glycoproteins in paired samples................................................................................................75
Table 3.7. RSV-specific Ab responses between acute/convalescent or pre- and post­
vaccination sera as a means of measuring the immune response to RSV infection..................77
Figure 3.3. Trends of Ab levels following vaccination over a period of time.......................... 85
Figure 4.1. Map of Kilifi District and Epi-Dss Area................................................................ 92
Table 4.1. Pneumonia classification at KDH for children aged less than 2 months (young
infant) to 5 years (child)........................................................................................................... 93
Figure 4.2. Study Design.......................................................................................................... 95
Figure 4.3. Collection of NW from child and infant respectively using a NWB..................... 96
Figure 4.4. Flow chart illustrating addition of positive controls during the RT-PCR assay... 105
Figure 5.1. Schematic of layout of ELISA plate.....................................................................114
Figure 5.2. The signal: noise ratio for different capture antigen dilutions..............................115
Figure 5.3. The day-to-day variation over a period of 1 month for Pt R showing dynamic
range of observed ODs and low background values.............................................................117
Figure 5.4. Adjusted (test-mock) average dose response curves of 3-monthly samples (0-9
months) double diluted (1:20-1:40,960) for a group of selected infants...............................120
Figure 5.5. Panel A, Linear portions of 3-monthly samples serially diluted. Panel B, plot of
gradients for these 8 infants. Bars denote standard deviation..................................................122
Figure 5.6. The linear portions of serially diluted (1:20-1:40,960) sera of selected patients.. 124 
Figure 5.7. Variation between assays for high and low controls together with respective
mock/control under old assay conditions.................................................................................126
Figure 5.8. Variation between experiments for high and low controls together with respective
mock/control under new assay conditions...............................................................................128
Table 6.1. Summary of SHL groups with corresponding NP groups.....................................132
9
Figure 6.1. A schematic indicating points at which various NW samples were identified for
further analysis of RS viruses by mPCR.................................................................................134
Figure 6.2. An example of a typical gel showing RSV typing of IF AT positive NW clinical
specimens by mPCR................................................................................................................ 136
Table 6.2. N gene fragment restriction digest patterns............................................................137
Figure 6.3. Gel showing NP typing patterns obtained following N gene PCR and RFLP of
positive nested PCR samples................................................................................................... 138
Table 6.3. Numbers (proportions) of RSV A and B, and NP types in each epidemic isolated
from cohort infants.................................................................................................................. 139
Figure 6.4. Proportions of NP typing patterns in Kilifi District in KDH inpatients (a) and the
community, birth cohort (b).................................................................................................... 140
Table 6.4. RSV-associated disease with strain as depicted by the N digest pattern in children <
6 mo of age.............................................................................................................................. 141
Figure 6 .5. Strain variation with age for children recruited to both phases of the cohort
throughout the 4 epidemic periods...........................................................................................142
Figure 6.6. Serial dilution of IF AT and culture positive samples as a means of working out
detection limit...........................................................................................................................143
Table 7.1. General characteristics of the cohort...................................................................... 156
Figure 7.1. Two-fold serial dilution carried out on pooled adult sera lower threshold cut-off
indicated...................................................................................................................................157
Figure 7.2. Frequency distribution of antibody titres (log AU) for the entire population (a) and
for the population by age groups in months (b & c)................................................................ 158
Figure 7.3. Age-seroprevalence profile (a) at assay cut-off level of seropositivity, 1.49 log AU
and (b) at a cut-off of seropositivity of 2.0 log AU................................................................. 159
Figure 7.4. Mean antibody titres for all samples defined as seropositive by age. The vertical
lines indicate the variance........................................................................................................160
Figure 7.5. Scatter plots of RSV-specific antibody levels (log AU) for all samples (a) and by
age group (b-e) for cohort children in Kilifi, Kenya................................................................161
Figure 7.6. Scatter plots of Ab titres (log AU) during the first 6 months of life with predicted
line of fit.................................................................................................................................. 162
Table 7.2. Linear regression model parameters, with estimated biological half life (T1/2 ) and
mean Ab duration for different population groups.................................................................. 164
Figure 7.7. Regression diagnostic plots following log-linear regression on RSV-specific Ab
levels in children < 6 months................................................................................................... 168
Figure 7.8. Cord blood levels in relation to date of birth, depicting children bom in (N=242)
and out (N=l 19) of epidemics................................................................................................. 169
Figure 7.9. Cord blood levels in relation to date of birth (blue line) with moving average trend
depicted (red line)....................................................................................................................170
Table 7.3a. Two-sample t-test with unequal variances of cord blood titres of infected & non-
infected samples at 2-fold seroconversion level.....................................................................171
Table 7.3b. Two-sample t-test with unequal variances of cord blood titres of infected & non-
infected samples at 4-fold seroconversion level.....................................................................171
Table 7.4a. Two-sample t-test with unequal variances of cord blood titres of infected & non-
infected samples at 2-fold seroconversion level of children bom in an epidemic..................172
Table 7.4b. Two-sample t-test with unequal variances of cord blood titres of infected & non-
infected samples at 4-fold seroconversion level of children bom in an epidemic................. 172
Table 7.5. Two-sample t-test with unequal variances of cord blood titres of infected & non- 
infected samples at 2-fold seroconversion level of children with a birth weight level >2.5 kg 
................................................................................................................................................. 173
10
Table 7.6. Multiple regression models on cord blood levels showing model outcome of main
effects....................................................................................................................................... 174
Table 7.7a. Two-sample t-test with unequal variances of gradient of infected & non-infected
samples at 2-fold seroconversion level of children with a birth weight level < 2.5 kg...........175
Table 7.7b. Two-sample t-test with unequal variances of gradient of infected & non-infected
samples at 4-fold seroconversion level of children with a birth weight level < 2.5 kg...........175
Table 7.8. Multiple regression models showing model outcome of cord blood levels
controlling for all other risk factors at the both seroconversion levels.................................... 177
Figure 7.10. (a) Frequency of cord Ab levels by quartiles; and (b) predicted matAb decay rate
in each quartile by multiple regression analysis......................................................................178
Figure 8.1a. Serological responses for a selection of children who showed no IF AT confirmed
infections over the follow-up period of the study.................................................................... 190
Figure 8.1b. Serological responses for a selection of children in whom only 1 clinically
confirmed infection (IF AT positive) was recorded in the follow-up period of the study....... 191
Figure 8. lc. Serological responses for a selection of children in whom > lclinically confirmed
infection (IF AT positive) was recorded in the follow-up period of the study.........................192
Table 8.1. The frequency of paired sera samples collected following confirmation of positive
IF AT results during entire follow up period (N=281).............................................................194
Figure 8.2. Mean differences between acute and convalescent titres by age category. [Ab]
denotes Ab titres...................................................................................................................... 195
Figure 8.3. Serological responses between paired samples in different age classes................196
Figure 8.4. Mean convalescent titres following consecutive infections compared to cord blood
titres.............................................................................................................................. 198
Figure 8.5. Proportion of children with IF AT positively confirmed infection showing 2-fold
seroconversion with age...........................................................................................................199
Figure 8.6. Mean differences between acute and convalescent paired samples..................... 200
Table 8.2. The number of pneumonia episodes in the cohort and those that were due to RSV
(IFAT confirmed) infections....................................................................................................200
Table 8.3. The number of RSV LRTI stratified by age class in months and cord levels....... 201
Table 8.4. Incident rates of ELISA-CSR and IFAT-CSR for different age groups................202
Table 8.5a. Exponential regression showing the relative harzard with age for ELISA-CSR at
the 2-fold seroconversion level (each age group is compared to < 6 months group)..............203
Table 8.5b. Exponential regression showing the relative harzard with age for ELISA-CSR at
the 4-fold seroconversion level (each age group is compared to < 6 months group)..............203
Table 8.5c. Exponential regression showing the relative harzard with age for IFAT-CSR (each
age group is compared to < 6 months group).......................................................................... 203
Table 8.6. The effect of history of previous infection on general incidence rates of ELISA-
CSR and IFAT-CSR................................................................................................................204
Table 8.7a. Exponential regression showing the relative hazard on adjusting for explanatory
variables, for ELISA-CSR at the 2-fold seroconversion level................................................ 204
Table 8.7b. Exponential regression showing the relative hazard on adjusting for explanatory
variables for ELISA-CSR at the 4-fold seroconversion level................................................. 205
Table 8.7c. Exponential regression showing the relative hazard on adjusting for explanatory
variables for IFAT-CSR.......................................................................................................... 205
Table 8.8. The effect cord levels on general incidence rates of ELISA-CSR and IFAT-CSR206 
Table 8.9. The effect of being bom in or out of an epidemic on general incidence rates of
ELISA-CSR and IFAT-CSR................................................................................................... 206
Table 8.10. Exponential regression showing the relative hazard of being bom in an epidemic 
for IFAT-CSR (comparison to infants bom outside an epidemic)..........................................207
11
ABBREVIATIONS
Ab Antibody
ARI Acute respiratory infection
AU Arbitrary units
BPD Bronchopulmonary dysplasia
CF Complement fixation assay
CHD Congenital heart disease
Cl Confidence intervals
CTL Cytotoxic T-lymphocytes
CYO Child years observation
DC Dendritic cells
DFA Direct fluorescence assay
ELISA Enzyme-linked immunosorbent assay
ELISA-CSR Enzyme-linked immunosorbent assay-confirmed serological
response
Epi-DSS Epidemiological-demographic surveillance system
F protein Fusion protein
FDA Food and Drug Administration, USA
G protein Glycoprotein
GA Gestational age
HIV Human immunodeficiency virus
IF AT Indirect immunofluorescence antigen test
IFAT-CSR Indirect immunofluorescence antigen test-confirmed serological
response
IgA Immunoglobulin A
IgE Immunoglobulin E
IgG Immunoglobulin G
IgM Immunoglobulin M
KDH Kilifi District Hospital
KM Kaplan Meier
Log AU Logarithm arbitrary units
LRTD Lower respiratory tract disease
LRTI Lower respiratory tract infection
mac Macrophages
matAb Maternal antibody
MBL Mannose binding lectin
mcAb Monoclonal antibody
MCHC Maternal child health clinic
MFAT Membrane fluorescence antibody technique
MHC Major histocompatibility complex
min Minutes
MIP Macrophage inflammatory protein
MNA Microneutralization assay
mPCR Multiplex polymerase chain reaction
NA Neutralization assay
NPS Nasal pharyngeal secretion
NW Nasal wash
NWB Nasal wash bulb
12
OD Optical density
OP Out-patient
RANTES Regulated on activation, normal T-cells expressed and secreted
RFLP Restriction fragment length polymorphism
RNA Ribonucleic acid
RSV Respiratory syncytial virus
RT-PCR Reverse transcriptase polymerase chain reaction
s Seconds
sd Standard deviation
T1/2 H alf life
Th T- helper cell
TLR Toll-like receptor
TNF Tumour necrosis factor
URT Upper respiratory tract
URTI Upper respiratory tract infection
WB Western blot
wfh Weight-for-height
WHO World Health Organization
ABSTRACT
The rate of decay and the subsequent antibody responses to RSV are poorly defined in young 
infants and children who possess maternally derived respiratory syncytial virus (RSV) 
antibodies. A birth cohort from rural Kenya was studied intensively to monitor infections from 
whom blood samples were collected at regular intervals to describe the age-related serological 
characteristics. A simple linear regression model was used to calculate the rate of RSV- 
specific maternal antibody decline. In addition, the effect of risk factors on cord blood titres 
was investigated. Using the random effects model, the half-life of RSV maternal antibodies 
was calculated to be 79 days. Although 97% of infants were bom with RSV-specific maternal 
antibodies, it was noted that infants who went on to experience an infection in early life, had 
lower starting titres of RSV maternal antibodies in comparison to infants who did not have any 
clinically confirmed infection in the first 6 months. Additionally, clinically confirmed 
infections within the first 6 months of life had no effect on the rate of decay of maternal 
antibodies.
Both RSV group A and B were seen to circulate in the community in varying amounts, with 
RSV A seen to be the most dominant strain in the 4 epidemics experienced by the cohort. The 
same RSV strain was observed to cause both RSV-associated upper respiratory tract and lower 
respiratory tract infections. It was observed that there existed patterns of antibody decay and 
acquisition of RSV-specific immune responses that groups of children appeared to follow. A 
group of infants were seen to undergo clinical infection that was subsequently confirmed by 
the ELISA, or were observed to seroconvert in the absence of clinical symptoms, or infants 
did not experience any infection at all despite experiencing at least 2 epidemics. Post-infection 
dynamics showed classical boosting of RSV antibodies, which either quickly waned or 
remained elevated over time. Furthermore, the risk of re-infection with clinically identified 
RSV illness decreased with age, from an initial infection rate of 252 to 41/1000 child years 
observation.
In conclusion, the evidence shows that RSV maternal antibodies provide some protection 
against severe disease during the first 6-7 months. Since there is efficient transfer of antibodies 
from mother to child, maternal vaccination against RSV may be a useful strategy to consider. 
However, our observations show that these antibodies decline quickly, hence childhood 
vaccines should also be taken into consideration to augment the immune responses.
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CHAPTER ONE 
Introduction
1.1 Respiratory Syncytial Virus
Respiratory syncytial virus (RSV) is the single most important viral cause of lower respiratory 
tract infection (LRTI) during infancy and early childhood worldwide (Chanock & Parrott, 
1965, Loscertales et al., 2002, Roca et al., 2002, Zambon et al., 2001). Evidence of RSV 
infection has been found in all investigated geographic areas, and it has shown similar 
characteristics in regions with different climates (Cane et al., 1999, Coggins et al., 1998, Peret 
et al., 1998). Outbreaks appear as predictable annual events, during the cold season in 
temperate climates and usually during the rainy season in tropical ones (Cane, 2001, Hall et 
al., 1990). Peak occurrences of morbidity and mortality have been seen to occur in infants 
younger than 3 months of age (Welliver, 1988).
In developing countries, few studies have attempted to quantify the importance of acute lower 
respiratory infections (ALRI) such as bronchiolitis and pneumonia caused by RSV (Robertson 
et al., 2004). Additionally, risk factors have only been poorly defined (Simoes, 1999) despite 
the fact that LRTIs are among one of the leading causes of infant and childhood deaths in 
Africa (Bryce et al., 2005, Loscertales et al., 2002, Williams et al., 2002). It is now well 
established that numerous components of the immune system are activated during RSV 
infection (Brandenburg et al., 2000, Cherrie et al., 1992, Hall et al., 1991, Homsleth et al., 
2001, Murphy et al., 1986) although the critical components contributing to diverse RSV- 
associated disease outcomes still remain poorly defined. The role of RSV antibodies (Abs) in 
infant protection in the developing world where the epidemiology of RSV and related 
infections may differ from that in developed regions, is only now being evaluated (Roca et al.,
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2002, Roca et al., 2003). Furthermore, there is still a paucity of information on the efficiency 
of transfer of RS V-specific maternal antibodies (matAbs) to the child, if these matAbs protect 
younger infants against early onset of infection and hence RSV disease, and if the latter are 
strain-specific. It is also not fully known to what extent the impact of antigenic diversity has 
on RSV epidemiology (Cane, 2001). Conflicting data on the nature of immunity in infancy 
and the development of acquired immunity still remains. Furthermore, very little data of this 
nature exists from the developing world.
This research project aimed to shed light on some of these issues, advancing our 
understanding on the requirements for vaccines in early infancy and/or mothers, and by 
providing baseline data for future immunization programmes. This was achieved by obtaining 
information on the distribution of circulating RSV genotypes in the community, the levels of 
RSV-specific matAbs and their decay rate. Furthermore, the putative threshold level of Abs 
for protection was calculated. The project was undertaken within the existing framework of a 
recently completed longitudinal birth cohort study in Kilifi District, Kenya, in which a birth 
cohort of approximately 600 children was recruited in a staggered fashion in early 2002 and
2003, respectively. These were monitored for respiratory infection by active home visits and 
passive referrals to the research clinic at Kilifi District Hospital (KDH) (Nokes et al., 2004; 
2007),
1.2 Objectives
The main objective of this study was to elucidate the role of passive and active immunity to 
RSV infection in infants and young children in a developing country setting, specifically in 
Kenyan children. The specific objectives included:
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• The description of the decay function for passive anti-RSV IgG in children less than 
one year of age, and its association with child risk factors such as prematurity, birth 
weight, malnutrition, malaria, or other environmental measures (e.g. elder siblings, 
pollution).
• The quantification of the relationship between maternally derived RSV Ab and 
protection against infection, or disease type (upper respiratory tract infection (URTI) or 
LRTI), and determination of thresholds of passive immunity against these outcomes.
. • The characterization by molecular methods of the genetic diversity (group and
genotype) of RSV infecting infants in the study population.
• The investigation of RSV specific Ab responsiveness and kinetics following primary 
infection as well as re-infections, in relation to age at infection, infecting strain, 
homologous or heterologous matAb, and disease severity.
1.3 The Scope of the Thesis
Following this introduction, an overview is presented on the burden of RSV disease as an , 
indication of its importance as a childhood disease both in the developed and developing 
country settings. A concise review follows in chapter two of the biology of RSV, its discovery, 
its structure, life cycle, and molecular epidemiology through to the current status of vaccine 
availability. Chapter three describes the role of matAbs in protection against severe RSV- 
associated disease in early childhood, specifically in a developing country setting drawing 
from earlier studies carried out in the developed world. Chapter four reviews the 
methodologies used in various studies, and based on the analysis, selected the enzyme-linked 
immunosorbent assay (ELISA). Chapter five presents results from using the ELISA 
methodology to investigate the characteristics of passive and acquired immune responses in
early childhood. Chapter six examines the circulating genotypes in Kilifi District during the 
four years of follow up. Chapter seven deals with the characterization of the decay of RSV- 
specific matAbs. Chapter eight examines the relationship between RSV infection and pre­
existing matAb levels. In addition, the immune responses to RSV post-mat Ab were further 
explored. The final chapter, nine, summarizes the findings of the work presented and outlines 
the implications for vaccine design. The chapter also identifies limitation of the research and 
provides suggested areas for further research.
Acute respiratory diseases continue to be important causes of childhood morbidity and 
mortality worldwide. Whereas URTIs are very common, and rarely life-threatening, LRTIs are 
responsible for more severe illnesses such as pneumonia and bronchiolitis. They contribute to 
approximately 4 million deaths each year (Rudan et al., 2004). Figure 1.1 illustrates that 
pneumonia accounts for one in five child deaths.
1.4 The Burden of RSV Disease
Malaria 8%
Causes of
neonatal deaths
Pneumonia 19'Measles 4%
Injuries 3%Diarrhoea 17%
HIV/AIDS 3%
— Congenital 8%
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— Other 7%
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— Diarrhoea 3%
—  Preterm 28%
Sepsis or 
pneum onia 26%
Neonatal 37%
Figure 1.1. Major causes of death in children younger than age 5 years and in neonates 
(yearly average for 2000-03) (Bryce et al., 2005)
Forty-six percent of deaths as a result of pneumonia in children under 5 years of age 
worldwide, were noted to occur in the WHO Africa region (6 WHO regions have been defined 
and include Africa, Americas, Eastern Mediterranean, Europe, Southeast Asia and Western 
Pacific), with an additional 29% occurring in the Southeast Asia region (Bryce et al., 2005). 
From our observations at the KDH in 2004, out of a total of 5019 admissions to the paediatric 
wards, LRTIs final diagnosis constituted 26% of the total, and LRTI-associated deaths were 
estimated at 15% as given in Figure 1.2 (Kilifi epidemiological-demographic surveillance 
system; Epi-DSS). The observed deaths by cause in this region were consistent with 
worldwide estimates.
LRTI Malaria
Malnutrition
16%
O
Severe anaerria 
7%
\  Gastroenteritis 
5%
HIV/AIDS
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Neonatal
34%
Figure 1.2. Number of deaths in children admitted to the KDH, Kilifi Kenya (yearly average 
for 2004).
Efforts in prevention and control of childhood deaths by major causes of mortality and 
morbidity including pneumonia were recently renewed worldwide (Bryce et al., 2005). There 
is rapidly accumulating evidence for RSV being a significant pathogen in young children as 
well as a major contributor to lower respiratory tract disease (LRTD) in infants as similarly 
described in developed countries (Robertson et al., 2004). RSV has been found to be 
pathogenic in young infants throughout the world (Bedoya et al., 1996, Cox et al., 1998, 
Hacimustafaoglu et al., 2004, Hacking & Hull, 2002, Madhi et al., 2000, Nokes et al., 2004, 
Roca et al., 2001, Scott et al., 2004, Venter et al., 2001, Weber et al., 1998a). Additionally, it 
was observed that although bacterial conjugate vaccines prevented between 20-37% of 
radiologically confirmed pneumonia, the overall reduction in the burden of clinically 
diagnosed LRTI was only 6-9% (Cutts et al., 2005, Mulholland et al., 1997), RSV remained a 
major cause of LRTI-associated morbidity.
The two hallmarks of this viral infection in the first several years of life have been described 
as the notably early infection attended by serious disease, especially under 6 months of age,
and repeated infection with eventual development of immunity to serious lower respiratory
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RSV-associated disease (Femald et al., 1983, Henderson et al., 1979, Parrott et al., 1973), In 
this respect therefore, RSV remains unique among the more than 200 serologically distinct 
viruses that have been implicated in the aetiology of respiratory tract infection (Minnich & 
Ray, 1980, Olszewska et al., 2002), in that the incidence of serious disease is highest among 
2-month-old children, who possess matAbs (Boeck, 1996, Lamprecht et al., 1976).
By 2 years of age, virtually all children have been infected with the virus (Glezen et al.. 1986). 
A high incidence of hospitalization associated with RSV infection has also been described 
(Glezen, 2001, Shay et al., 1999). From a longitudinal study spanning 20 years (1973-1993),
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in which babies were recruited from birth (full-term) hospitalization rates were estimated to be 
23.8% of all RSV culture-positive patients (Fisher et al., 1997). Another similar follow up 
study that investigated American children and which spanned a 17 year period (1980-1996), 
was carried out through the US National Hospital Discharge Survey. This study estimated 1.65 
million hospitalizations for bronchiolitis occurred in the under 5 year age group, whilst the 
under 6 month and under 1 year old age bracket accounted for nearly 57 and 81% respectively 
(Shay et al., 1999). This translated to an incidence of 3-9 per 1000 children younger than 1 
year being hospitalized for this condition. Children with underlying conditions such as 
bronchopulmonary dysplasia (BPD), congenital heart disease (CHD), or bom at < 28 weeks’ 
gestation, were observed to have an increased risk of RSV hospitalization until 24 months of 
age (Boyce et al., 2000). Therefore, WHO designated RSV a major target of research and 
therapy (www.who.int/vaccine research/diseases/portfolio/en/index.htmlV
Reports have further noted that within developing countries, the highest incidence of RSV- 
LRTI occurs in infants < 6 months of age, with two-thirds or RSV-LRTIs occurring in 
children younger than 2 years of age (Loscertales et al., 2002). Moreover, the burden and 
severity of disease was high, with the incidence of RSV-associated LRTI being reported as 
2.4-4.8 times the rate of that seen in the US (Wright & Cutts, 2000). Incidence rates of RSV 
however varied from between 18 per 1000 children younger than one year hospitalized with 
RSV-associated disease as in southern Israel (Dagan et al., 1993) to 198 per 1000 children 
years for children up to 18 months in a community based study from Colombia (Borrero et al., 
1990). This compared with admission data from KDH during 2002-2005, in which the 
incidence of RSV at admission was 60 per 1000 child year observations/annum (Figure 1.3).
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Figure 1.3. Comparative incidence of admissions from 2002-2005 of various childhood 
diseases at KDH (Kilifi Epi-DSS) stratified into infants and children under 5 years. Also 
depicted is the contribution of RSV and S. pneumoniae to respiratory illnesses. Pneumo 
stands for severe and very severe pneumonia (WHO defined); GARV for group A rotavirus.
The gap in knowledge with respect to the role of Abs in RSV immunity and pathogenesis is 
yet to be fully elucidated in the different age groups and especially due to matAbs. There also 
remains a significant deficit in our understanding with regards to the most appropriate 
correlates of protection and the ideal or desirable immune response to RSV infection as noted 
following the harmful immune response elicited by the formalin inactivated RSV vaccine 
(refer further to section 2.8). This uncertainty has hampered vaccine intervention. These have 
been especially aimed to reduce the burden of RSV disease. Despite this, there have been 
renewed efforts focussing on these areas. Significant advances leading to some understanding 
of the nature of RSV immunity age-related difference in Ab responses to RSV infection during 
early life, the extent of genotype variation e.g. it has been shown that from one epidemic to the 
next, different genotypes contribute to the makeup of the presently circulating strain at the 
local level (chapter 6) and the pathogenesis of RSV infection since its discovery have been 
realized.
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This present study aims to examine further the protective role of matAb against RSV disease, 
its duration and factors affecting the latter by evaluating regularly collected serum samples 
from infants recuited from birth in the coastal community of Kilifi, Kenya.
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CHAPTER TWO 
The Biology of Respiratory Syncytial Virus
2.1 The Pathogen- Historical Overview
In October 1955, at the Forest Glen facility of the Walter Reed Army Institute of Research in 
Washington, D.C., an apparent epizootic of sneezing, coughing and mucopurulent nasal 
discharge was observed in a group of young chimpanzees housed there (Morris et al., 1956). 
Investigators went on to culture the nasal secretions obtained from these symptomatic chimps 
in human liver epithelial cells (Chang) and recovered an unrecognized virus which they 
subsequently named the chimpanzee coryza agent (CCA). They went on to show that it was 
causally related to the monkeys’ URTI. Seed virus prepared from the original CCA isolation 
was also shown to induce infection and similar respiratory symptoms in other young chimps, 
but failed to induce detectable infections in guinea pigs, mice, rats or chicken embryos. It was 
further noted that there was unintentional spread of CCA between infected and uninfected 
chimps housed in a common facility. Additionally, a laboratory worker seemed to become 
infected with CCA following contact with the infected chimps.
Soon after this discovery and subsequent recovery of CCA, Chanock and colleagues (Chanock 
et al., 1957, Chanock & Finberg, 1957) went on to isolate a CCA-like virus from an infant 
with bronchopneumonia (Long agent) and another from an infant with bronchiolitis (Snyder). 
These agents were shown to be serologically and phenotypically similar to CCA, as 
characterized by the viruses’ cytopathic effect on cells in culture as well as by their 
neutralization by anti-CCA animal sera. Of note, was their ability to induce syncytia and 
multinucleated giant cells in Chang cells. Therefore, respiratory syncytial virus (RSV) was 
suggested as a more suitable name than CCA, due to its propensity to induce syncytia
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formation in tissue culture. Subsequently, RSV was recovered from 57% of young infants with 
bronchiolitis or pneumonia during a 5-month study period (Chanock et al., 1957, Chanock & 
Finberg, 1957). RSV was also recovered from older children with bronchopneumonia and 
bronchiolitis.
2.2 Structure and Genome
RSV is classified in the genus
Pneumovirns of the family
Parcimyxoviridcie. The RSV
virion is about 200 nm in size
and consists of a
nucleocapsid with a lipid
envelope (Figure 2.1). The
nucleocapsid has been shown
Figure 2.1. Structure of respiratory 
syncytial virus (Hacking & Hull, 2002)
to be a symmetrical helix with a diameter of 12-15 nm. The RSV genome is composed of a 
single stranded negative sense, non-segmented RNA and comprises 15,200 nucleotides 
encoding 11 viral proteins (Figure 2.2 and Table 2.1). The lipid bilayer is derived from the 
host plasma membrane and contains virally encoded transmembrane surface glycoproteins, 
which are 11-20 nm in size and closely spaced at intervals of 6-10 nm. There are 3 
transmembrane glycoproteins, i.e. the attachment glycoprotein (G), the fusion protein (F) and 
the small hydrophobic protein (SH). As well, two matrix proteins, M and M2 (or 22K); three 
proteins associated with the nucleocapsid, nucleocapsid (N), phosphoprotein (P) and 
polymerase (L); and two non-structural proteins, NS1 and NS2 have been described.
G attachment protein
F (fusion) protein 
\
M (matrix) protein
Negative strand RNA  
genom e
SH protein
N , P and L nucleocapsid 
proteins
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 kb
NS1 Mil N I I p M SH G 1  j M2
L
Figure 2.2. Schematic representation of the respiratory syncytial virus (hRSV) ssRNA 
(negative-strand) genome based on GenBank accession no. NC_001781. (kb denotes 
kilobase)
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Table 2.1. RSV gene and protein lengths. (Collins et al., 1996, Collins et al., 1990, Collins & 
Wertz, 1985, Hacking & Hull, 2002, Olmsted & Collins, 1989, Pastey & Samal, 1995)
Gene Gene
Length3
Protein
Length15
Functions Comments
NucleocaDsid-
associated
proteins0
N 1 203 391 Nucleocapsid protein: 
nucleoprotein essential 
for transcriptional activity
Binds tightly to genomic and 
R1 RNAs
P 914 241 Nucleocapsid protein: 
phosphoprotein 
essential for 
transcriptional activity
Exhibits anomalous 
electrophoretic mobility due to 
charged residues
L
Transmembrane 
surface proteins0
6 578 2 165 Nucleocapsid protein: 
RNA polymerase
Contains highly conserved 
putative functional domains
F 1 903 574 Fusion protein: viral 
entry and syncytia 
formation
Major protective antigen
G
SH (1A)
Matrix proteins0
923
410
298
64
Glycoprotein: viral 
attachment to the cell
Small hydrophobic 
protein: function 
unknown
Highly divergent between 
RSV antigenic subgroups; 
major protective antigen
M 958 256 Matrix protein: viral 
assembly
Counterpart to the typical 
paramyxovirus M protein
M2 (or 22K)
Nonstructural
proteins
961 194 M2-1 transcription 
elongation factor 
M2-2: regulation of viral 
transcription
Unique to pneumoviruses; 
M2-1 and M2-2 overlapping 
genes encoded by the 1st and 
2nd open reading frame of M2 
gene respectively
NS1 (1C) 
NS2 (1B)
532
503
139
124
Non-structural proteins: 
anti-interferon a and (3 
activity
Unique to pneumoviruses 
Unique to pneumoviruses
agene length in nucleotides. The encoded mRNA would be this exact length plus a 3’ poly (A) tail. 
bLength in amino acids of complete, unprocessed protein deduced from gene sequence 
cVirion structural proteins
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The F and G proteins have been shown to be important antigenically as a result of their ability 
to stimulate the production of neutralizing Ab responses (Anderson et al., 1988, Olmsted et al;, 
1986, Taylor et al., 1984, Walsh et al., 1984). Their importance is emphasized by the 
observation that effective humoral immunity is only conferred by Abs to these proteins as 
reviewed by Hacking and Hull (2002).
2.3 The Replication Cycle of RSV
RSV predominantly infects the airway epithelial cells (nose, large and small airways). For 
infection to occur, the first step is viral attachment to the cell through the G glycoprotein 
(Levine et al., 1987, Martinez & Melero, 2000, Schlender et al., 2003, Smith et al., 2002) 
followed by fusion of the viral envelope or infected cell membranes with uninfected cell 
membranes via the F protein (Smith et al., 2002, Walsh & Hruska, 1983). The viral envelope 
is then incorporated into the cell membrane and the nucleocapsid released into the cytoplasm. 
RNA replication and transcription occurs followed by viral assembly through a series of 
interactions mediated by the M protein which in turn also co-ordinates assembly of the 
envelope proteins (F and G) with nucleocapsid proteins into new virions (reviewed by 
Hacking & Hull, 2002). The packaged viral particles leave the cell either through fusion with 
adjacent cells or following cell rupture (Figure 2.3).
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Figure 2.3. A schematic representation of the RSV replication cycle. RSV attachment occurs 
via the G protein. Budding appears to be the reverse of penetration and occurs in vitro on the 
apical cell surface. (Hacking & Hull, 2002).
2.4 Molecular Epidemiology
2.4.1 Group variability
Two antigenic groups, A and B, have been described based originally on serological reactivity 
both with monoclonal Abs (Anderson et al., 1985, Gimenez et al., 1984, Gimenez et al., 1986, 
Mufson et al., 1985) and polyclonal animal sera (Coates et al., 1963). These were later shown 
to be distinct at the nucleotide level. The nucleotide sequence similarity between groups 
ranges from 53% for G protein to 86% for N protein (Johnson & Collins, 1989, Johnson et al., 
1987b). Additionally, there exist differences in the apparent size of the FI and F2 cleavage 
products, and the P proteins between the 2 groups as detected by SDS-PAGE (Gimenez et al., 
1986, Norrby et al., 1986). However, the most variable protein between these groups is the G 
protein and up to 47% amino acid variability between prototype strains of the different groups 
was earlier demonstrated (Johnson et al., 1987a).
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2.4.2 Strain variability
. In addition to group variability, it was noted that numerous strains existed in both groups. The
latter showed variability amongst themselves and between themselves, i.e. intra- and inter-
group antigenic differences. Within groups, differences between RSV was initially
demonstrated using monoclonal Abs (Anderson et al., 1991, Orvell et al., 1987, Storch &
Park, 1987). These results were soon confirmed by ribonuclease A (RNase A) mismatch
cleavage method (Cristina et al., 1991, Storch et al., 1991) and nucleotide sequencing of the G
gene where up to 20% amino acid variability was noted within the group A (Cane et al., 1991)
and 9% in group B (Sullender et al., 1991).
%
Infection and re-infection of infants with RSV occurs despite the existence of serum anti-viral 
Abs, which have been noted to provide protection in animal models (Walsh et al., 1984). 
Antigenic variation may play an important role in aiding immune evasion.
The 2 transmembrane surface glycoproteins, G and F, appear to be the most important of the 
RSV proteins in inducing protective immunity (Connors et al., 1991, Glezen et al., 1986). 
Antigenic variation in RSV groups and within groups resides mainly in the C-terminal third of 
the G glycoprotein and to a lesser extent the F glycoproteins. Moreover in G proteins, 
mutations (insertions, deletions, replacement or substitutions) can lead to the progressive 
accumulation of amino acid changes within the variable regions (Cane & Pringle, 1995, 
Frabasile et al., 2003, Martinez et al., 1999, Sullender et al., 1991, Trento et al., 2003), with 
several studies highlighting a high number of nucleotide substitutions causing amino acid 
changes in both RSV groups (Coggins et al., 1998, Martinez et al., 1999, Sullender et al., 
1991, Venter et al., 2001). The high ratio of non-synonymous mutations to synonymous
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mutations implies a selective pressure on viruses of both groups. The regions of amino acids in 
which these changes are found are on either side of a putative binding site (Figure 2.4).
NH2 c
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specific epitopes
Figure 2.4: Schema of primary structure of G protein. Indicated are the 
cytoplasmic, transmembrane (CU) and extracellular domains; cysteine residues 
(CCCC) of the putative receptor binding site, potential sites for N- (^, and O- 
glycosylation (i), the presence and/or position of these sites varies between 
isolates. Also indicated is the conserved ( - ) and variable (—) segments of the 
protein. Adapted from (Cane, 1993, Melero et al., 1997, Palomo et al., 2000).
Mutation rates for the G glycoprotein of RSV have been said to be similar to other quickly 
evolving respiratory virus surface proteins, such as hemagglutinin protein of influenza A, 
being reported to be 1.83 x 10'3 and 1.95 x 10'3 nucleotide substitutions/site/year for RSV A 
and B, respectively (Zlateva et al., 2005, Zlateva et al., 2004). However, it has been proposed 
that natural RSV B isolates accommodate more drastic changes in their attachment G proteins 
(Zlateva et al., 2005).
It has been shown that during primary infections, the carboxy terminal region of the G protein 
is recognized by human Abs (Cane et al., 1996, Jones et al., 2002, Palomo et al., 2000). 
Moreover, infants exhibit responses to the G protein that are specific to the infecting genotype 
(Cane et al., 1996, McGill et al., 2004). In addition to these responses being dependent on the 
infecting genotype, recognition was shown to be also dependent to a great degree on the amino 
acid sequences of the peptides used as targets in the assay. There appears to be more than one 
antigenic site or several overlapping epitopes on RSV as has been previously described for
influenza virus haemagglutinin (Schoofs et al., 1988). However, these Ab responses have not 
been analyzed with respect to their ability to neutralize the virus:
The response to these proteins is complex due to the diversity in the types of neutralization 
responses. From studies carried out to characterize the in vitro function of specific epitopes 
through their interaction to their respective monoclonal antibodies (McAbs), neutralization or 
enhancement by these virus-specific Abs (Anderson et al., 1988, Gimenez et al., 1996) were 
described. RSV-specific McAbs were thus classified into three groups: (i) McAbs possessing 
neutralizing activity, (ii) McAbs possessing only enhancing activity, and (iii) McAbs 
possessing both neutralizing and enhancing activities. Within this framework, neutralization 
responses have been described as being partial (strain-specific) or complete (cross-protective) 
(Anderson et al., 1988). It is thus possible that following infection, varying amounts of each 
category may be induced on an individual level. It is proposed that a balance of both activities 
determines the net activities of sera specific to RSV (Gimenez et al., 1996). If for some reason 
or another, an imbalance in the Ab categories occur, this could result in suppression of 
circulating RSV-specific Abs with respect to matAb, or neutralization of infection leading to 
resolution of primary or re-infections, or enhanced disease in terms of the FI-RSV vaccine. 
Indeed, formalin treatment of RSV appeared to selectively obliterate the protective 
neutralization epitopes on the virus surface (Olmsted et al., 1986, Prince et al., 1986). An 
unbalanced immune response ensued in which the host developed high titres of F- and G- 
specific Abs lacking neutralizing activity, but formed immune complexes that may have 
contributed to exaggerated pathology following natural infection.
The mechanisms involved during neutralization would encompass the independent interaction 
of McAbs and the synergistic interaction of different McAbs (Anderson et al., 1988) coming
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into interplay. During an investigation on the capacity of mixtures of anti-G McAbs to 
neutralize RSV infectivity, Martinez & Melero (1998) observed a reduction of virus titre 
(about 800 times) with a pool of Abs. Therefore, a single infection would stimulate partial 
protection, whilst successive infections, which would be reminiscent of the McAb pool or 
infant polyclonal sera, would result in enhanced or complete protection. The authors suggested 
that for a maximal effect to be seen in terms of a reduction of virus titres, this would need the 
contribution of Abs to the 3 epitopes identified on the G molecule working in synergy. 
Additionally, maximal synergy would be realized if these Abs do not compete for the same 
antigen binding site (Grarcia-Barreno et al., 1989). It is therefore possible that the binding of 
several Ab molecules to the same G protein and the cross-protective epitopes on the F protein 
allows for complete protection.
Some investigators have found that G proteins were less able to stimulate neutralizing Abs or 
protective immunity than F protein (Table 3.6). Additionally, Anderson and others (1988) 
found that G McAbs gave only partial and enhanced neutralization, which perhaps they 
suggested, were less effective than complete neutralization afforded by F protein McAbs. 
However, it has also been observed that some subgroup specific anti-F Abs do exist and that 
they possess noticeably higher neutralizing activity than cross reactive Abs (West et al., 1994), 
despite the high levels of conservation noted in the F genes between the 2 subgroups of RSV. 
Mufson & Stanek (1996) also identified a group A variant that differed in its levels of 
antigenic reactivity to two anti-F McAbs generated against a group B strain. This implies that 
antigenic variation does occur not only in the G gene, but also in F.
Recently, a rapid molecular biology technique was used to screen large numbers of clinical 
samples from epidemics. The technique involved the reverse transcription polymerase chain
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reaction (RT-PCR) of defined sections of both the G and N genes followed by restriction 
digestion analysis (RFLP). This therefore allowed for the investigation by molecular analysis 
of circulating strains, as well as allowing for an estimation of variability within an epidemic 
(Cane et al., 1991, Cane & Pringle, 1992, Sullender et al., 1991). Additionally, sequence data 
can be utilized in phylogenetic analysis of G gene nucleotide sequences, defining a number of 
genotypes or lineages of RSV within both groups (Cane et al., 1994, Cane & Pringle, 1992, 
Peret et al., 1998). However to date, the genotype nomenclature is not consistent between 
laboratories, and it is clear that new genotypes are continuing to emerge while others are no 
longer detectable (P. Cane, personal communications).
2.4.3 Relative prevalence of strains, hospital vs. community
The epidemiology of RSV disease is characterized by marked seasonal patterns (Chanock et 
al., 1970). RSV causes annual epidemics usually during the winter in temperate climates 
(Cane et al., 1994) although there are exceptions such as Finland where every 2 years a minor 
RSV peak has been observed in April followed by a major peak in December (Waris, 1991). 
In the tropics outbreaks have often been associated with the rainy season, although these 
epidemics tend to be less predictable in terms of date of occurrence (Cane & Pringle, 1991, 
Cane et al., 1999, Hazlett et al., 1988, Roca et al., 2001, Nokes et al., 2004, Venter et al., 2001, 
Weber et al., 1998). Additionally, Madhi et al., (2000) observed that HTV-positive children in 
South Africa show infection with RSV year round.
Extensive studies have been carried out on strain variability within epidemics, with most 
studies focusing on hospitalized infants. Thus, characteristic recurrent epidemics are observed 
through hospital surveillance (Cane, 2001). Outbreaks have been characterized as being abrupt 
in onset, the beginning usually being anticipated by the increased number of hospitalized
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infants for bronchiolitis and/or pneumonia (Hall, 1999a). Epidemics have also been recorded 
in community and family study settings, and the link between the schooling siblings and the 
primary infant cases being shown to be strong (Hall et al., 1976, Weber et al., 1999). The 
mean duration of RSV epidemics was noted to vary, from 3.5 - 6 mo as noted from a 12-year 
surveillance in Chile (Avendano et al., 2003). Additionally, RSV is known to cause repeat 
infections throughout life although these re-infections are usually observed to be less severe 
and more often than not, are limited to the URT, especially in children older than 2 years. 
Intra-group antigenic variability may play a role in re-infections but as yet has not been fully 
defined (Sullender et al., 1998). Re-infections may be caused by either viruses from the same 
or different group (Mufson et al., 1987), and estimates of re-infection rates in children infected 
as infants varied from 74-83% in the second year and 46-65% in the third year of life (Glezen 
et al., 1986, Henderson et al., 1979). The exact role however, of re-infections in maintaining 
RSV transmission in communities together with its relationship with observed epidemics of 
primary infections remains unclear.
Both RSV groups and strains have been shown to circulate concurrently in individual 
epidemics (Hendry et al, 1989, Hendry et al., 1986). However, the relative proportions of 
groups vary from year to year (Hall et al., 1990, Hendry et al., 1989). The same genetic 
lineages have been shown to be present worldwide during the same period, as well, analysis of 
strains from successive epidemics showed that different lineages could predominate each 
epidemic, neither were all lineages present in every epidemic (Cane et al., 1994). Additionally, 
outbreaks caused by genetically distinct strains could follow an outbreak caused by a single 
strain (Hall, 1999b, Imaz et al., 2000, Walsh et al., 1997). It was observed that isolates of 
some lineages increased in numbers over several years and then declined. Cane and colleagues 
(1994) suggested that this was due to the herd immunity, a build up of resistance, in the
community to a particular genotype. In general though, group A strains are detected more 
often than group B (Cane et al., 1994, Cane & Pringle, 1992, Cane & Pringle, 1995, Cristina et 
al., 1991). Fluctuations in circulating strains from one site to the next may contribute to the 
variation seen in the severity of these annual outbreaks (Domachowske & Rosenberg, 1999).
Comparison of strains from hospitalized infants with those isolated from patients presenting to 
the out-patient department, that are thus representative of community circulating strains, 
showed that very similar viruses circulate in these 2 groups of patients (Zambon et al., 2001). 
Similarly, Venter and colleagues (Venter et al., 2002) conducted a study in South Africa in 
which they compared isolates from children hospitalized in Soweto with those from children 
attending rural community clinics. The authors observed that the same RSV strain could cause 
LRTIs, severe RSV-associated disease and mild URTIs in infants. Likewise, a rural 
community-based study in Kenya of a cohort of infants found similar results (Nokes et al., 
2004, Scott et al., 2004).
However, less well defined is the influence of viral factors, which includes the effect of strain 
variation on severity. Some studies concluded that group A viruses causes more disease than B 
(Imaz et al., 2000, Walsh et al., 1997), yet in others, despite the observation of a predominance 
of group A RSV infection, there was no difference in severity between group A and B 
infections (McConnochie et al., 1990, McIntosh et al., 1993); and finally, others showed that 
group B infections were more severe than those by group A (Homsleth et al., 1998). It is 
possible that certain viruses within an individual group are more virulent than others (Hall et 
al., 1990). These authors noted in a 15 year study period on RSV isolates from which 1209 
hospitalized and ambulatory children were examined, strains from the different groups, 
denoted as A2 and B4, were more frequently found in hospitalized patients and Al in
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outpatients, whilst the two years with the highest rates of intensive care admissions, were 
those in which group A2 dominated. Differences in viral replication between the 2 groups 
have also been observed; group A viruses replicate to higher titres than group B viruses both 
in animals and in vitro cells cultures. Additionally, in many studies overall, group A viruses 
are isolated most frequently, despite group B strains predominating in some epidemics 
(Morgan et al., 1987, Scott et al., 2004),
2.5 Clinical Symptoms of RSV Disease
RSV has been shown to be a highly contagious pathogen, its transmission occurring through 
direct or close contact with contaminated secretions, droplets or fomites (Bricks, 2001). The 
agent survives on contaminated hands for more than a half hour, and thus, the latter is a 
common route of transmission for self-inoculation infections. It also survives for several hours 
on surfaces of contaminated objects (Mufson et al., 1991, Steinhoff et al., 1980). The organism 
then infects the respiratory tract mucosa. In addition, the conjunctiva can be affected. 
Symptoms subsequently appear following a 2-8 day incubation period, but commonly within 
4-6 days (Johnson et al., 1961). If the infection is restricted to the upper airway, then the 
symptoms are similar to those of a severe URTI and includes cough, nasal congestion and 
commonly otitis media (Heikkinen et al., 1999, Monobe et al., 2003, Sagai et al., 2004).
The clinical picture of RSV infection however, varies according to age. Although RSV 
infection is rare in the first 4 weeks of life, epidemics in neonates have been identified (Hall et 
al., 1979). RSV infections were observed in 20-30% of babies studied in a neonatal unit. In 
this study, 61% of babies had a respiratory illness, and of these, approximately half had 
URTIs, whilst the remaining half experienced pneumonia. Moreover, from all viruses isolated 
in patients with pneumonia during the first month of life, 55% were identified as RSV (Hall et
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al., 1979). The risk of serious infection in early life (1-3 months of age) when matAbs are 
present may lead to hospital admissions, which were observed to he as high as 1 in 40 in 
industrialized countries (Clarke et al., 1978). Consequently, the role of matAbs in protection 
against RSV disease is a subject of debate and remains a controversial issue as will be further 
examined in Chapter 3.
It has however been noted that severe life-threatening LRTD is most often seen during 
primary infection of 2-4 month old infants (Hemming et al., 1995) in whom airway infection 
takes the form of bronchitis, bronchiolitis (the most common RSV-associated disease), 
bronchopneumonia and/or laryngotracheitis. In immunocompromised individuals, the 
infection frequently (> 50% of infections) descends into the lower airways and progresses to 
give typical signs of LRTI (Wendt & Hertz, 1995, Whimbey et al., 1996). Additionally, both 
infants and immunosuppressed individuals have been shown to excrete large quantities of 
RSV in respiratory secretions for prolonged periods (Bricks, 2001). Several authors (Martinez, 
2003, Sigurs et al., 2000) have suggested that RSV may predispose the infant to development 
of asthma later in life. Despite all the possible complications associated with RSV infection, 
the latter usually resolves in less than a week, although it tends to be more severe in children 
aged 8 to 30 weeks as mentioned above. Following RSV infection, solid immunity is not 
achieved and consequently, further infections occur throughout life (Hacking & Hull, 2002), 
but thereafter, the severity of illness decreases with increasing age, and especially more 
rapidly for bronchiolitis than for pneumonia (Parrott et al., 1973).
Various host factors have also been implicated in severe RSV disease during primary RSV 
infection. Foremost among these are young age (< 3 months), prematurity and the presence of
underlying cardiopulmonary or immunosuppressive conditions (Parrott et al., 1973). These 
have been listed in Table 2.2 below.
Table 2.2. Major risk factors for RSV infections (Englund, 1999, Englund et al., 1991, Glezen 
etal., 1981, Hall etal., 1979, Hall etal., 1986, Kaneko et al., 2001, Wang etal., 1995)
□ Under one year of age, especially under 3 months of age
□ Prematurity
□ Presence of chronic pulmonary disease, particularly BPD and cystic fibrosis
□ Presence of CHD, especially children with left-to-right shunt and pulmonary 
hypertension
□ Cell immune deficiency; malignancies, chemotherapy, spinal cord or solid organ 
transplants
□ Hospital admission during RSV seasonal outbreaks
In addition, other factors such as low social status, malnutrition, living in crowded 
environments (two or more individuals sharing the same bedroom, nursery attendance), birth 
within previous six months from the beginning of the RSV seasonal outbreaks, the mothers’ 
low educational level, lack of breast feeding, and the domestic exposure to cigarette smoke 
have been considered and been said to act as risk factors predisposing to more severe disease 
(Glezen et al., 1981, Holberg et al., 1991, Law et al., 2002, Simoes, 1999, Simoes, 2003).
2.6 Treatment of RSV Disease
Medical intervention for the prevention (prophylaxis) and management (treatment) of RSV 
infections is basically supportive and involves close monitoring of the clinical evolution of the 
disease (Chavez-Bueno et al., 2005); additionally, nutritional status, oral hydration and 
ventilatory support are important (Chavez-Bueno et al., 2005, Simoes, 1999). Passive 
immunization with RSV hyperimmune immunoglobulin (RSV-IGIV) or Palivizumab, a 
neutralizing humanized mouse monoclonal Ab (95% human origin and 5% murine) directed 
against the F protein, is an alternative intervention method. Both however, are indicated in a
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subgroup of selected high-risk infants and children -  especially those who are premature, 
have BPD or CHD, and are usually administered in the months immediately preceding the 
RSV season (Groothuis et al., 1991, Hemming et al., 1987, Simoes et al., 1998). Usage of 
these agents as noted from these studies, showed a reduction in the incidence and duration of 
hospitalization due to RSV. On the other hand, with regards to Ribavirin, the only antiviral 
drug approved by the FDA, it is argued that this should be utilized early, as the greatest 
replication rate of RSV occurs up to 3 days following the onset of LRT symptoms (Bricks, 
2001, Chavez-Bueno et al., 2005).
2.7 Diagnosis of RSV
Initially, viral isolation in conventional tissue culture was widely used to diagnose RSV 
infections, and has become the gold standard for laboratory diagnosis, despite results taking 
between 3-7 days, although this can range from 2-10 days (Piedra et al., 2002). Combinations 
of human epithelial cell lines have been used and include: human epithelial (HEp-2), human 
lung fibroblast (WI-38 or MRC-5), or rhesus monkey kidney cells which have been shown to 
be appropriate for recovery of RSV. As RSV is highly thermolabile, it requires stringent 
adherence to transport and storage guidelines, together with almost immediate inoculation of 
specimens in permissive cells for optimal recovery (Piedra et al., 2002). If this is not possible, 
the specimens need to be stored carefully to allow for recovery. Despite these shortcomings, 
cell culture still remains invaluable as it allows for the maintenance of a source for genetic 
analysis and antigenic change in virus populations as well as the discovery of new viruses. 
Many modifications to tissue culture exist such as the use of low-speed centrifugation in shell 
vial culture tubes that has been recently described (Matthey et al., 1992, Schirm et al., 1992).
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Early detection of RSV infections is necessary to allow for early treatment such as the 
initiation of antiviral treatment with ribavirin and to prevent nosocomial transmission (Hall et 
al., 1985). Recently, it has become possible to do so using antigen-based rapid diagnostic 
methods. Previously, the radioimmunoassays (Sarkkinen et al., 1981) as well as the reverse 
passive haemagglutination assay (Cranage et al., 1981) were used as antigen detection 
methods and more recently new sensitive molecular techniques, RT-PCR (Coiras et al., 2003, 
Stockton et al., 1998) and real time PCR (Mentel et al., 2003, O'Shea & Cane, 2004) have 
been developed for the detection of RSV nucleic acid. However, the most popular methods of 
choice for detection of RSV antigen are immunofluorescence (IFAT) and rapid antigen tests 
especially in clinical settings. Both direct and indirect immunofluorescence techniques are 
available for the detection of RSV in exfoliated nasopharyngeal epithelial cells, with several 
kits being commercially available. Results of these tests are generally well accepted by 
clinicians due to their excellent sensitivities and specificities, the rapidity with which results 
are available, and their relative low costs (Englund et al., 1996). Furthermore, these techniques 
have helped provide an appreciation of how RSV spreads amongst hospitalized patients and 
has thus afforded an opportunity for early therapeutic intervention (Welliver, 1988). 
Specimens most frequently used for the detection of RSV from the respiratory tract have 
included throat swabs, nasal swabs, tracheal aspirates, nasopharyngeal washes and 
nasophyarangeal aspirates (Ahluwalia et al., 1987, Blanding et al., 1989, Englund et al., 1996, 
Hall & Douglas, 1975, Hughes et al., 1988, Stensballe et al., 2002),
In terms of serological detection methods, the complement fixation (CF) method has long been 
available for such diagnostic purposes. The membrane immunofluorescent antibody technique 
(MFAT) of Scott and others (Scott et al., 1976) enhanced serological diagnosis o f RSV 
infection through the detection of IgG, IgA and IgM Abs. The ELISA has also been utilized
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for the detection of human serum Abs (IgG, IgM and IgA) to RSV. It has been suggested that 
all methods of detection, viral antigen-based, isolation in cell culture or serologically-based 
detections should be undertaken in order to ensure maximal detection as a case missed by one 
method can be uncovered by another (Puthavathana et al., 1995).
In this project we utilized IF AT and RT-PCR to detect virus and ELISA to detect Ab as spelt 
out in Chapter 4, in order to diagnose RSV infection in a birth cohort.
2.8 RSV Vaccine Developments
For a vaccine to be effective against RSV, it most likely has to target the multiple strains of 
RSV that co-circulate during an outbreak. Moreover, a balance between a level of attenuation 
that is safe for infants and one with immunogenicity that is sufficient to protect against natural 
infection (Piedra, 2003) especially during early infancy should be sought. This is a time when 
immunological responsiveness is poor, and the presence of maternally transmitted Abs can 
exert a dampening effect upon infant immune responses (Murphy et al., 1988). Furthermore, 
the vaccine must not potentiate naturally occurring RSV disease, as was earlier observed with 
the formalin-inactivated RSV vaccine (FI-RSV) administered in the 1960s (Kim et al., 1969). 
FI-RSV was administered intramuscularly to infants and children, aged 2 months- 7 years. 
Unfortunately, the vaccine not only failed to protect against disease due to natural infections 
with RSV in naive infants, but it induced an exaggerated clinical response; in addition, 2 
infants who received FI-RSV died at 14 and 16 months following RSV infection (Kim et al., 
1969). It has thus been suggested that the goal for vaccine design against RSV is not to 
prevent infection, but rather, to prevent virus-associated LRTI and complications (Durbin & 
Karron, 2003, Polack & Karron, 2004).
Various strategies have been employed in the search for RSV vaccines and include subunit 
vaccines, subunit vaccines combined with non-specific immune activating adjuvants, live 
attenuated vaccines, live attenuated genetically engineered vaccines and polypeptide vaccines 
(Karron & Ambrosino, 1998, Piedra, 2002, Piedra, 2003, Piedra et al., 1995). Of these, the 
purified F glycoprotein subunit (PFP) and live attenuated virus (cold passaged, temperature- 
sensitive mutants and genetically engineered strains) candidate vaccines are being evaluated 
clinically and may show promise with further development. As serious disease occurs in both 
high risk individuals who have previously experienced RS V infection, as well as in RSV-naive 
infants, it seems likely that more than one type of RSV vaccine will be needed to immunize all 
those who would benefit from vaccination (Polack & Karron, 2004). To this end, a number of 
key groups have been identified for RSV vaccine programmes and these include young 
children, women of child-bearing age, as well as the elderly, although the rationale for 
vaccinating each group may differ slightly (Zambon, 1999). These vaccines are listed in Table 
2.3.
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Protection against severe disease during the first months of life by the acquisition of passively 
acquired Abs, either through maternal immunization or natural infection, or alternatively by 
boosting humoral Abs through vaccination is of great importance. This project examines the 
rate of decay of matAbs, which has a bearing on the time of immunization as the latter have 
been said to impact negatively on immunization. The establishment of minimal protective 
thresholds in a developing country setting will further enhance our knowledge on expected 
levels that ought to be achieved following vaccination.
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CHAPTER THREE 
RSV Specific Maternal Antibodies
3.1 Introduction
A considerable body of evidence indicates that maternally derived Abs to the viral surface 
proteins - F and G, provide protection against serious lower respiratory tract infection in a 
majority of infants (Connors et al., 1991, Glezen et al., 1981, Ogilvie et al., 1981). It has been 
demonstrated that the presence of high levels of maternally derived Abs, as well as the 
administration of prophylactic intravenous immunoglobulin enriched for high levels of RSV 
neutralizing Abs (RSV-IGIV) or humanized monoclonal Ab against F protein have been 
shown to be associated with reduction of RSV-associated disease (Glezen et al., 1981, 
PREVENT, 1997, The IMpact-RSV Study Group, 1998). The use of maternal immunization to 
augment this protection in young infants against disease lends itself to further consideration. 
As there are few data on the role of factors such as co-morbidities, malnutrition and other risk 
factors on matAb levels within developing country settings, it therefore remains important to 
establish what the protective threshold would be. This would facilitate prediction of effective 
vaccination schedules. A schematic indicating the putative protective threshold with age 
following matAb decline is shown in Figure 3.1.
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Protection from disease and probable matAb 
interference with vaccine response
Log Ab 
titre
Incomplete protection from disease and probable 
matAb interference with vaccine response
No protection from disease and probable 
response to vaccination
Age -----------►
Figure 3.1. Proposed scheme of decline of maternal specific RSV Ab from birth depicting 
putative threshold levels of vaccine response.
A minority of otherwise healthy young infants have been observed to suffer RSV-associated 
disease. Additionally, acquired immunity to RSV remains incomplete resulting in individuals 
being susceptible to reinfection throughout life (Hall et al., 1991, Muelenaer et al., 1991, 
Wagner et al., 1989). It is plausible therefore that due to inadequate matAb levels and/or 
matAbs not being fully protective (strain-specific), this results in RSV disease under 6 months 
of age. The latter have also been said to interfere with the vaccine efficacy which in turn may 
lead to vaccine failure (Englund et al., 1998). The protective threshold against RSV infection 
is poorly defined. However, Piedra et al., (2003a) attempted to define this and reported it as 
being >6.0 log2  (95% Cl 1.4 -  9.1) and > 8.0 log2  (95% Cl 1.1 -  7.7) against RSV associated- 
hospitalization for neutralizing Abs to RSV A and RSV B, respectively.
To estimate a baseline level for the protective threshold against RSV-associated disease, 
further investigation of convalescent phase Ab titres and/or Ab titres achieved in controls of
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hospitalised patients not suffering severe RSV-associated disease but hospitalised at the same 
instance as cases (as similarly done in the Piedra study) should be carried out. This study will 
attempt to establish an immune correlate to RSV disease in infants from a developing nation, 
using convalescent titres of infants above 6 months who experienced RSV-associated disease. 
This information would be of importance for vaccine development.
This chapter provides an overview of RSV matAb acquisition and its role during the first year 
of life; in addition, primary RSV infection and hence early acquired immunity and re­
infections in the child will be discussed.
3.2 Placental Transfer and the Decay of RSV-Specific Maternal Antibody
3.2.1 Literature search methods
A MEDLINE search of the literature from 1967 to 2006 was conducted using the National 
Library of Medicine and the National Institutes of Health’s PubMed Services and Web of 
Knowledge on-line services. A review of the literature was conducted on passive immunity 
and placental exchange of RSV Abs. Keywords included: ‘Maternal-Foetal Exchange’, 
Respiratory Syncytial Viruses’, ‘Respiratory Syncytial Virus Infections’, ‘Immunity’, 
‘Maternally-Acquired’, ‘decay maternal antibodies’. Except in a few instances, all searches 
were limited to the English language and humans. Furthermore, the reference lists from the 
selected retrieved articles were examined by searching the ‘related articles’ hyperlink to 
expand the search and thus identify other relevant literature. The articles found to be relevant 
are listed in Tables 3.1a and 3.1b.
i
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MNA: microneutralization 
assay; CF: complement fixation 
assay; ELISA: enzyme 
linked 
immunoassay; VN 
assay: virus 
neutralization 
assay; NA: 
neutralization 
assay; M
FAT: membrane 
fluorescence 
Ab 
technique; WB: western 
blot; anti-RSV, F- and 
G- are 
whole 
RSV, F-protein 
and 
G-protein 
respectively; com: community; Hsp: hospital 
f: RU/ml - relative units; *: standard error of the mean
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A further search using the key search terms ‘Vaccines’ AND ‘Respiratory Syncytial Viruses’ 
OR ‘Respiratory Syncytial Virus Infections’ OR ‘Respiratory Syncytial Virus, human’ being 
restricted to articles on studies on humans and in English, was undertaken and this resulted in 
362 articles which was inclusive of 133 reviews. An additional search was also performed 
using the following combination of key terms: ‘Immunization, Passive’ OR ‘Immunity, 
Maternally-Acquired’ AND ‘Respiratory Syncytial Viruses’ OR ‘Respiratory Syncytial Virus 
Infections’ OR ‘Respiratory Syncytial Virus, Human’ AND ‘Viral Vaccines’, and again 
restricted to English and human studies, gave an additional 28 articles of which 19 were 
reviews. A final search using the “related articles” link to the study by Munoz et al., 2003 gave 
one extra article. Despite specifying a search for human based studies, the search engine also 
displayed studies on animal models. Immune responses to RSV vaccines will be discussed in 
section 3.6.
3.2.2 Placental transfer
MatAb transfer from mother to newborn is of the IgG class and is mediated by an active 
transport system via the Brambell Fey receptor localized to the placental membrane (Brambell, 
1966, Gotlieb-Stematsky et al., 1983, Junghans & Anderson, 1996). Transfer occurs after the 
28th week of pregnancy during the third trimester, the amount of matAbs in the foetal 
circulation increasing sharply thereafter, reaching maternal levels at around 35-40 weeks 
depending on IgG subclass (Madani & Heiner, 1989), and then exceeding maternal levels by a 
ratio of 1.2:1 to 1.8:1 (Kohler & Farr, 1966, Nicoara et al., 1999).
Few studies have measured RSV matAbs in both mother and their newborns. Usually the ratio 
of titres in cord or newborn blood to the titres in mothers is used as a common measure of 
placental transfer. It appears from Table 3.1a that cord blood titres are similar to or exceed
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matAb titres on a case-by-case comparison, despite the various assays used. Additionally, 
infants admitted to hospital due to RS V infection, exhibited no apparent selective deficiency in 
matAb to viral glycoproteins of infecting virus strain or lineage (Table 3.1b). Due to 
methodological issues together with the small number of children and/or mothers sampled 
(Table 3.1a), this did not allow for a global ascertainment of the actual range of Ab titres 
transported across the placenta. This would be of great importance as it can be deduced that 
the highest levels of matAbs in the child would give protection against RSV-associated 
disease and hence give an indication of the putative protection threshold (Figure 3.1). Only 
one study made a comparison between maternal:cord blood titres between study populations in 
two geographically distinct areas, a developing country, Gambia, and a developed country, 
USA (Suara et al., 1996). As expected therefore from this mother-infant data, it can be 
assumed that cord blood samples from our Kilifi cohort will all have measurable titres, due to 
efficient transfer that approximates 1.0 (Suara et al., 1996) across the placental surface.
3.2.3 Risk factors for decreased placental transfer of RSV antibodies
There exist various factors that may influence RSV matAb transfer from mother to child 
including the following: maternal plasma concentration of Abs, gestational age, birth weight, 
nutritional status and co-infections such as malaria or HTV.
3.2.3.1 Maternal antibody concentration
It was noted that there existed seasonal variation in matAb titres, these being highest following 
a RSV season and have been reported to persist for 6 months (Le Saux et al., 2003, 
Nandapalan et al., 1986). Furthermore, higher titres were noted in mothers who had other 
children at home (Le Saux, 2003) perhaps due to frequent stimulation resulting from viral
spread from children to adults resulting in possible sub-clinical infections (Hall et al., 1976, 
Hall et al., 2001) and hence allowing for the boosting effects of the vims. As a result of active 
transport there is a preponderance for higher levels of virus-specific Ab on the foetal side of 
the circulation (Griffiths et al., 1982). Wilczynski and Lukasik (1994) suggested that there is a 
RSV IgG class specific transfer from mother to newborn, with this being most efficient for 
IgG 1, less so for IgG 2 and 3 and at similar levels for IgG 4. However, they mentioned that 
these observations were not statistically significant.
Additionally, and especially in developing countries due to poor sanitation, there are large 
numbers of infectious pathogens which all result in generation of Abs. This results in 
increasing amounts of the total maternal IgG and is associated with a lower fraction of 
maternal-specific IgG (Hartter et al., 2000) which is conserved across the placenta. A 
limitation in IgG transport may occur in such situations of hypergammaglobulinemia due to 
the limited number of available Fc receptors (Brambell, 1966). Nonetheless as noted from the 
study of Suara and others (1996), maternal: foetal transfer efficiencies were similar in the 
Gambia and USA.
3.2.3.2 HIV infection
In 2005, there was an estimated 17.3 million women living with HTV globally, with three- 
quarters or 13.2 million in sub-Saharan Africa. Around 59% of all adults in this region are 
women (http://data.uiiaids.org/pub/GlobalReport/2006/200605-FS SubSaharanAfrica en.pdf). In 
addition, the overall RSV case fatality rate in HIV-infected children have been described as 
being 12.7-fold greater than HTV-uninfected children, from studies carried out in South Africa 
(Madhi et al., 2006). RSV has been observed to cause increased morbidity and mortality in
immunocompromised children (Madhi et al., 2000, Madhi et al., 2001) under 2 years, and 
therefore it can be postulated that children bom to HIV-infected mothers become susceptible 
to viral infection at a relatively early age. Recent studies describe the incidence of 
hospitalisation from RSV-LRTI as 45.0 per 1000 in HIV-infected, compared to 19.4 per 1000 
in HIV-negative infants (Madhi et al., 2006). These newborns to HIV-infected mothers, may 
therefore display lower matAb levels as compared to their uninfected counterparts as noted for 
measles (de Moraes-Pinto et al., 1996, de Moraes-Pinto et al., 1993, de Moraes-Pinto et al., 
1998). This may be due to a reduction in placental transfer of RSV-specific Ab as a result of 
immune complex formation that impairs transplacental IgG transport, the existence of 
defective IgG which may impair binding to the Fc receptor on trophoblasts, or a decrease in 
levels of Fc receptors during HIV infection (de Moraes-Pinto et al., 1993). The exact 
mechanism remains to be elucidated. To the best of our knowledge no data on the levels of 
RSV matAb in HIV-infected children have been published and thus it still remains unclear to 
what extent HIV infection influences RSV matAb levels.
There is also evidence to suggest that HIV infection increases the risk of prematurity and low 
birth weight (Leroy et al., 1998), both of which are potential risk factors for lower Ab transfer 
(see below for further details).
3.2.3.3 Gestational age/prematurity, birth weight and nutrition
A premature infant is bom at less than 36 weeks gestation. Additionally, premature infants 
bom small for gestation weight are even more compromised. Several factors predispose the 
premature infant to an increased severity of RSV-related illness. Two of the most important 
mechanisms are probably an inadequate immune response or defense against infection and
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incomplete airway development (de Sierra et al., 1993). A term infant at birth has IgG levels 
approaching adult levels due to efficient matlgG transfer late in gestation, i.e. gestational age 
(GA) vary directly with the degree of placental transfer of Ab as the Brambell Fey receptor is 
expressed in the third trimester. This is not replicated in the preterm infant. Previous studies 
noted that immature infants displayed levels of anti-RSV that were significantly lower when 
compared to term infants (de Sierra et al., 1993) and as previously described for measles, 
tetanus toxoid, herpes simplex virus type 1 virus amongst other viruses (Okoko et al., 2002b, 
Okoko et al., 2001b, Wesumperuma et al., 1999). Low levels of RSV-specific Abs would 
therefore be expected in premature infants with higher frequencies of lower GA births 
observed in developing countries resulting in newborns starting with reduced amounts of Ab 
(Caceres et al., 2000) compared to their counterparts in the developed world. Madhi and 
colleagues (2006) observed that the burden of RSV-LRTI in children <32 weeks of GA in 
comparison to children bom at 32-35 weeks GA was greater -  incidence rates of 79.2 versus
34.2 (P=0.008) respectively, in a cohort of South African children followed over a 5-year 
period. These rates were similar to those reported in the developed countries (Boyce et al., 
2000).
The effect of nutrition on cord blood titres has not been fully examined and remains unclear 
(Madico et al., 1996), although studies carried out to investigate the implication for 
vaccination schedules in light of the role of maternal measles Ab in rural Bangladeshi infants, 
have suggested that maternal nutritional status does not influence Ab level (de Francisco et al., 
1998). Black (1982) however argues to the contrary and suggests that nutritional status affects 
immune status and may result in lower initial levels of matAb, which would thus imply that 
babies of these mothers would receive lower matAb during transplacental transfer.
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3 2.3.4 Placental malaria
Maternal malaria results in the increased delivery of premature babies. Furthermore, the rate 
of low birth-weight babies is significantly higher if the placenta is parasitized by malaria 
(Okoko et al., 2002a), this frequency being higher for primigravidae. This occurs by parasite 
binding to chondriotin sulphate and other ligands located in the placenta thus resulting in 
premature and low birth weight babies (Menendez et al., 2000) and impairment of function, 
which may interfere with the beneficial effects of matAbs in various ways:
(a) Suppression of the immune response: Active malaria has been shown to suppress the 
immune response to some antigens (Duffy, 2003), including polysaccharides, and thus 
in pregnant women a similar mechanism implies that inadequate levels of matAb 
would accumulate on the maternal side and this would thus be reflected on the foetal 
side.
(b) Impairment of placental function. Malaria infection of the placenta impairs the transfer 
of Abs from mother to fetus (de Moraes-Pinto et al., 1998, Okoko et al., 2001a) as 
described for tetanus Abs (Brair et al., 1994) and would thus be expected to have 
similar effects on RSV matAb transport from mother to child,
3.2.4 Decay of RSV-specific matAb
Ab decay in the literature is reported as either biological half-life, this being the half-life 
before adjusting for the dilution effect of increased body weight, or as biochemical/catabolic 
half-life, which takes into account the dilution effect of increased body weight and is therefore 
a standardization method. For measles, mumps and rubella, clearance rates (biological half-life 
of matAbs) have been estimated to be between 35-40 days (Sato et al., 1979) or as long as 60 
days for measles from studies performed in both the developed and developing nations 
(Caceres et al., 2000), and 51 (42-60) days for human parainfluenza type 3 (Lee et al., 2001).
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From the various studies listed in Table 3.2, the decay of RSV-specific Abs appears to vary 
greatly from 26-100.3 days. However, no study reported 95% confidence intervals (CIs) for 
their estimates. While biological factors in some instance may account for the broad variation 
noted in these clearance rates, methodological issues and experimental design -  longitudinal 
(which estimates the half-life in each individual), versus cross-sectional analysis (which 
estimates the mean half-life of the population) together with the small sample size used may 
also play a part.
Studies on several childhood infections spread by close contact, such as measles, mumps and 
rubella have also aided in the elucidation of virus transmission (Vyse et al., 2002). These 
viruses exist as single antigenic strains, with primary infections usually leading to solid 
immunity. This has allowed for simple models of transmission and statistical methods for 
analysis of Ab prevalence and mathematical models to aid design vaccination programmes 
(Brugha et al., 1996, Christie et al., 1990, Cutts & Vynnycky, 1999, Goncalves et al., 1999, 
Griffiths, 1974, Kebede et al., 2000). The half-life is useful in determining the duration of 
RSV matAbs in the infant, but does not give any information on whether infants are protected 
against RSV-associated disease, nor the age at which RSV matAbs will no longer interfere 
with vaccine responses. To this end, the proportion of children seroprevalent by age since birth 
is a much better indicator. A limitation of this approach is that it only provides an indirect 
measure of the decay rate. Eighty three to one hundred percent of newborns have been 
reported to be positive for RSV matAb, which has been noted to decline linearly with age 
(Table 3.3). Similar models have thus been used to estimate the duration for which RSV- 
specific Ab levels remain high in the population under study and this study will also estimate 
the probability of being seropositive over time and this is discussed further in section 3.3.
3.3 Models for Calculation of Mean Rate of matAb Decay
The biological decay rate, which represents an overall half-life (Lee et al., 2001) rather than 
the catabolic decay rate appears to be of greater importance especially if vaccine 
implementation is to be effective, as it allows for regional variation to be taken into 
consideration. For instance, it has been shown that in low-income developing countries 
protection by measles-specific matAb seems to decline faster in comparison to developed 
countries (Black, 1982, Black et al., 1986, Muller, 2001). Several factors could account for 
this difference and include income, which correlates with nutritional status which in turn 
affects immune status resulting in either increased matAb catabolism or lower initial levels 
(Black, 1982) and hypergammaglobulinemia (Muller, 2001).
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It is assumed that both matAbs and seroprevalence decay exponentially and constantly, and 
the mean rate of decay can be estimated from either parametric models (Cox et al., 1998, 
Hartter et al., 2000, Kebede et al., 2000, Lee et al., 2001) or linear regression on log Ab 
concentrations (Cox et al., 1998).
3.3.1 Model I: exponential decline model for maternal RSV Abs
The exponential change in Ab levels (y) with age (a) can be depicted as
dylda = -ay (1)
solving this, if a = 0, y(0) = yQ
and, if a> 0, yi&) =yQ e'"* (2)
Where, a  is the rate of decay 
yQ is the initial Ab level at birth
>>(a) is obtained from the model, Ab titres at a given age, a
Taking logs on both sides of equation gives us our model:
In V(a) = In Vo- aa (3)
Where, -a is the slope, b of the line on the log scale and gives the rate of decay 
and log y0 is the constant coefficient.
If the time taken for Ab to decay to half their initial value, T1/2 , then it follows from (3)
Then, \ny0l 2 - \n y 0-a T m
And Ti/2 = ln(2)/a (4)
Also m e a n D = l/a
median D = log y0/~ a (5)
where D is the average duration of matAb protection
3.3.2 Model II: decay in seroprevalence
P(a) = p(0)(l-e'6') (6)
Where,
p(a) is the proportion seropositive at age a 
p(0) is the proportion seropositive at birth (a=0)
6 is the rate of decay 
t is age
And D = 1/5 is the average duration of seropositivity
T1/2 — ln2/ 5
It should be borne in mind that when calculating the cut-off point for seropositivity for the 
population under consideration, children with no detectable Ab (i.e. below the cut-off point for 
seropositivity) will influence the estimation of the decay rate. Furthermore, the inclusion of 
infected children in the calculation of T1 /2 will affect the value of this variable.
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3.4 The Immune Response to RSV and the Implication for Protection by 
Maternal Antibodies
As mediators of disease may well differ between the lower and upper respiratory tract, 
quantitative data are required on the role of Abs or immune correlates to protection against 
RSV disease. The response to viral infection is complex; all facets of the immune system 
including Ab (secretory, serum and matAb), complement, mediators of inflammation, T and 
other types of lymphocytes and phagocytic cells (e.g. dendritic cells (DC), macrophages (mac) 
participate (Figure 3.2). Furthermore, host factors such as major histocompatibility complex 
(MHC) class I- and II-restricted cytotoxic cells (Brandenburg et al., 2001, Crowe, 2001, 
Openshaw, 2002, Welliver, 2003, Wright et al., 2002) work in concert to protect the child 
against or aid recovery from RSV-associated LRTI allowing for recovery from RSV infection. 
The prominence of one component over another in vivo or from one individual to the next may 
vary depending on the type of infection and on whether the host is limiting primary infection 
or resisting re-infection (Fishaut et al., 1980) with parasite factors also playing an important 
role. Following acute infection, the resulting immune response is characterized qualitatively 
and quantitatively by changes in specific Abs that include changes in immunoglobulin class 
distribution and Ab affinity (Meurman et al., 1992), protecting against URTI and LRTI. There 
also exists the possibility that breastfed children also benefit from matAbs in the form of 
colostrum (Bulkow et al., 2002, Downham et al., 1976, Holberg et al., 1991, Kristensen & 
Olsen, 2006).
Abs are described as the principle means of protection against diseases caused by viruses 
(Crowe, 2001). Virus-specific T cell responses, on the other hand, are involved in the 
clearance of RSV infection through the recognition of at least 6 major RSV proteins (N, M,
SH, NS2, F and M2 - see Table 2.1) (Anderson et al., 1991; Cherrie et al., 1992). It is the
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cytotoxic T-lymphocyte (CTL) through the recognition of MHC class I molecules that control 
infection hy direct destruction of infected cells or by the release of antiviral cytokines (Russell 
& Ley, 2002). Despite this, it is argued that the F protein primarily induces a ThI type 
immune response, while the G protein induces primarily a Th2 type response, contributing to 
both protective immunity and disease pathogenesis respectively (Alwan et al., 1993, Cannon 
et al., 1988, Connors et al., 1992, Jackson & Scott, 1996, Openshaw, 1995, Waris et al., 1996). 
These findings were also confirmed from studies using the BALB/c mouse model (Bright et 
al., 1995), which is often used as a model for the study of RSV infection. Children with 
defects in their cell-mediated immune response, as well as athymic or gamma-irradiated mice 
were observed to shed virus indefinitely (Cannon et al., 1987, Fishaut et al., 1980, Hall et al., 
1986). Paradoxically however, a recent study described a novel role for the G protein showing 
that it was critical for the generation of CTL responses during infection independently of virus 
titres but dependent on the conserved cysteine-rich region (see Figure 3.2 below).
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(Bukreyev et al., 2006). However, both the humoral and cell-mediated responses to RSV have 
heen shown to be age dependent (Murpihy et al., 1986a, Popow-Kraupp et al., 1989) initially 
being weak in the young. The role of matAbs on subsequent T- cell responses is conflicting. 
Bangham (1986) argues that passively acquired Abs to RSV can significantly inhibit the 
secondary cytotoxic T-cell responses in the mouse model, whilst Crowe et al. (2001) described 
a significant independent contribution hy T cells (CD4+ and CD8+) to resistance to replication 
of RSV also in mice in the presence of passive Abs. The various facets of the immune 
response to RSV are shown in Figure 3.2.
The incidence of bronchiolitis in infants below 2 months of age has been observed to be 
markedly lower than in children 2 months and older (Parrott et al., 1973) as already 
mentioned. The incidence of pneumonia has also been documented as being lower but less 
strikingly so. Additionally, pneumonia is uncommon and bronchiolitis very rare in infants 
under 3 weeks of age (Hall et al., 1979, Neligan et al., 1970). Within this context therefore, 
matAbs play an important role in protection against severe RSV-associated illness. To further 
illustrate their importance in protection against disease, infants bom during or just prior to the 
RSV season and hence experiencing low matAb titres have been described as being at 
maximum risk of admission to the hospital with RSV infection in the ensuing RSV season 
(Nandapalan et al., 1986). Moreover, the administration of passive polyclonal or monoclonal 
RSV-specific Abs to premature infants, who are at greatest risk of RSV-associated disease by 
virtue of having lower levels of matAb, prevents severe disease in this vulnerable population 
(Groothuis et al., 1993) if administered before the onset of infection. No protection was 
afforded by the latter when administered during acute infection (Collins & Pollard, 2002), 
These studies on passive transfer of neutralizing Abs demonstrate the beneficial role of
matAbs in offering infants protection; but the latter do not significantly affect viral replication 
in the URT (Brandenburg et al., 2001, Crowe, 2001, Wright et al., 2002). A number of studies 
have shown the relationship of neutralizing Ab titres to RSV with severity of LRTI, noting an 
inverse correlation between the two parameters (Glezen et al., 1981, Glezen et al., 1986, 
Lamprecht et al., 1976, Ogilvie et al., 1981, Roca et al., 2002, Ward et al., 1983). These 
observations underscore the importance of high matAb concentration in reducing the risk of 
severe disease in early months. However, severe disease is noted in children under 6 months 
of age at a time when matAb is virtually universal. Some clinical studies failed to find a 
relationship between the severity of illness and RSV Ab titre (Bruhn & Yeager, 1977, Wright 
et al., 2002). Furthermore, the results of the earlier vaccine trial with a formalin inactivated 
RSV vaccine, Lot 100, which led to the induction of high titres of RSV-specific Abs, however, 
still led to an exaggerated RSV-associated disease in the vaccinated group upon natural 
infection (Kapikian et al., 1969, Kim et al., 1969b). This group showed a worse prognosis in 
comparisons to the non-vaccinated group.
Several mechanisms in addition to the immature nature of the child’s immune system may 
account for the occurrence of RSV-associated illness and will be further discussed later. The 
above evidence taken together is suggestive of the existence of a minimum protective 
threshold for matAbs against RSV-associated disease in the first few weeks of life, below 
which disease most likely occurs, and above which there is matAb interference with vaccine 
(refer to Figure 3.1).
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3.5 Correlates of Immunity to RSV-Associated Disease - What is the 
Protective Immune Threshold?
The protective threshold against severe RSV-associated disease can be said to be the critical 
Ab titre that must be attained to ensure optimal protective efficacy against such disease. Ab 
titres include both matAbs and the child’s own repertoire of neutralizing Abs stimulated upon 
primary infection. It can thus be argued that Abs measured in acute sera during primary 
infection therefore largely comprise matAb, whilst convalescent sera reflect both matAbs and 
the child’s immune repertoire under 6 months. It has been shown that a low level of viral 
replication is important for an effective RSV immune response as inactivation of the virus 
with even minute quantities of Ab was sufficient to abolish immunogenicity of a candidate 
vaccine tested in the cotton rat model (Prince et al., 1982).
Therefore, it is important to define the matAb protective threshold as this impacts age of 
infection and hence, would aid in the appropriate timing of vaccination schedules. However, 
resolution of this threshold may be complicated by the fact that RSV undergoes antigenic 
variation. Moreover, the assay used to detect these isolates will also influence the quantity of 
Ab measured. For instance, Roca et al. (2003) observed higher titres to the locally circulating 
strain (MozOO) in comparison to the prototypes (A2 and 8/60) and even more so when the 
membrane fluorescence antibody technique (MFAT) was used in comparison to a neutralizing 
Ab assay. Each strain would therefore most likely give rise to its own threshold. This was 
recently described from studies carried out by Piedra and colleagues (2003a). The 
investigators noted that children with neutralizing Ab titres to RSV A of > 6.0 log2  were 3.5 
times less likely to have an RS V-associated hospitalization compared to children having titres 
below this value. Likewise, infants with neutralizing Ab titres > 8.0 log2 to RSV B in
comparison to infants with titres below this level were 2.9 times less likely to experience an 
RSV-associated hospitalization. It is reasonable to assume therefore, that the determination of 
various thresholds arising from infection from different strains, would inform choice on the 
minimum protective threshold, irrespective of infecting strain, which should be attained by a 
vaccination regime. At this threshold, the child’s own immune response may not be optimal -  
qualitatively (presence of immunoglobulins with correct avidity, optimal ratios of Ab classes 
e.g secretory Ab etc) and quantitatively, but the matAbs would nevertheless be protective 
against severe RSV-associated disease.
As mentioned above, it has been shown that high levels of matlgG protected against severe 
infection in the early months of life. One study in particular, on children, by Piedra and others 
(2003a) calculated 2 threshold values for infection by RSV A and B respectively. The authors 
therefore proposed minimal protective threshold values for Ab titres of > 6.0 log2  (95% Cl 1.4 
-9 .1 )  and > 8.0 log2 (95% Cl 1.1 -  7.7) against RSVA and B respectively as correlates to 
immunity against RSV-associated hospitalization. Study participants with RSV-associated 
hospitalization were observed to have significantly lower GMT to RSV A (6.1 ± 2.9 versus 7.9 
± 2.4, p < 0.001) and RSV B (7.3 ± 3.2 versus 9.4 ± 2.3, p < 0.001) in comparison to controls.
It is difficult to compare studies due to variation in methods used. Kasel and others (1987) and 
Karron et al., (1999) had earlier attempted to similarly establish correlates of RSV immunity, 
but it is only the study by Piedra and others (2003a) that explicitly attempted to establish a 
minimal threshold serum Ab level. The former study found evidence for a protective effect 
against the occurrence of severe RSV illness to be associated with especially IgG anti-F. Pre­
infection GMT against URTI being 8.1 ±0.5 and 9.1±0.77 against the G protein and F protein
69
respectively, whilst against lower respiratory disease, it was 6.4 ± 0.62 and 6.6+0.63 against G 
protein and F protein respectively. The assay used was an ELISA that was G and F specific, 
but no controls were defined. Additionally, the authors appear to be defining an URTI as a 
severe RSV illness. Karron and others (1999) noted that from the 219 children (< 6 months) 
who displayed Ab titres < 1200, this was strongly associated with the occurrence of severe 
disease (OR 6.2, p=0.03) using a rapid antigen EIA (enzyme immunoassay Test Pack) but a 
control group was not defined.
Table 3.4. A selection of studies comparing RSV-specific IgG titres in case/control studies
Reference Sample # Assay Age
(mo)
Comments Ig G (log2± sd)
Brandenburg 
et al., 1997
38 VN < 6 control
case
GMT: 51 
GMT: 48
Glezen etal., 
1981
68 cases & 
575 controls
MNA < 6 Pre-epidemic:
control
case
Epidemic:
control
case
GMT: 125 
GMT: 97
GMT: 158 
GMT: 62
Nielsen et al., 
2003
1272 cases 
6360 
controls
ELISA <24 control
case
277
276
Piedra et al., 
2003a
175 MNA 1 - 1068 control
case
7.9+2.4 -  9.4±2.3 
6 .1 + 2 .9 -7 .3  ±3.2
Roca et al., 
2002
62 MFAT < 12 control
case
GMT: 47.83 
GMT: 10.94
Bulkow et al., 
2002
175 MNA <36 control 
case 
High-risk status 
control 
case
GMT: 266.9 
GMT: 255.4
GMT: 357.5 
GMT: 193.8
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It is also possible that observed titres of controls in case/control studies (Table 3.4) as well as 
convalescent titres from studies investigating acute/convalescent titres would additionally aid 
the establishment of a minimum protective threshold titre. Ab titres of control were noted to be 
typically at higher levels than cases. Additionally, convalescent sera displayed more often than 
not, higher Ab levels than the respective acute sera, resulting in concomitant resolution of 
disease symptoms. Such studies either measure anti-RSV Abs (Tahle 3.5) or Abs to 
glycoprotein specific antigens (Table 3.6). As noted, in most instances, titres to the F protein 
were higher than those to G protein irrespective of the sample tested. These ahove findings 
nevertheless do not exclude a role for anti-G in host resistance to infection. From the latter 
studies therefore, it appears that the principal protective effects against RSV infection appear 
to be associated with IgG anti-F titres.
Age has also been shown to play a critical role in the determination of an individual’s risk of 
hospitalisation (Glezen, 1977, Glezen et al., 1986, Henderson et al., 1979, Queiroz et al., 
2002) and hence should be taken into consideration. In this regard, it was noted to primarily 
influence the immune response to F glycoprotein (Kasel et al., 1987, Murphy et al., 1986a, 
Murphy et al., 1986b, Welliver et al., 1989). A comparison of the convalescent titres from 
either sera or nasal pharyngeal secretions (NPS), from studies using the same assay and 
restricted to F glycoproteins gave a titre range from 5.4-13.8 log2 . This range encompasses 
the RSV A and B thresholds suggested by Piedra and others (2003a).
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3.6 Evaluation of the Induction of the RSV-Specific Immune Responses by 
RSV Vaccines
It is assumed that boosting matAb titres though either maternal immunization or the child’s 
own immune repertoire through early childhood vaccination, should protect against severe 
disease. This would thus result in a decrease of severe RSV-associated disease, an increase in 
the age of primary disease as well as offering protection to infants below the age of 2 mos with 
underlying risk factors. It is therefore important to elucidate Ab titres and duration attained 
following vaccination to ascertain their effectiveness. Furthermore, this would further aid in 
the establishment of a minimum protective threshold against RSV disease.
Animal models have been used extensively to elucidate possible immune mechanisms to RSV 
infection. However, despite undergoing a series of laboratory and animal model evaluations, 
the immunogenicity of promising candidate vaccines do not always translate to humans. For 
example, the RSV ts-2 (temperature sensitive-2) mutant was seen to be overly attenuated and 
thus unsuitable for use in immunoprophylaxis of RSV illness as susceptible young children 
could not be uniformly infected with high dose of virus (Wright et al., 1982). Additionally, the 
same authors in a later study (Wright et al., 2000) also noted that following a second vaccine 
dose, this only led to a slight boost in immunity but did not lead to enhanced neutralizing Ab 
response in vaccine recipients as predicted by a chimpanzee model (Crowe et al., 1994). It was 
also demonstrated on numerous occassions that RSV vaccine candidates might retain 
sufficient residual virulence to cause mild symptomatic URTI or even enhancement of clinical 
disease in infants that was not predicted from animal models (Kapikian et al., 1969, Wright et 
al., 2000). Thus, this review will not consider animal models. Table 3.7 summarizes data from 
human vaccine studies.
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From the majority of the above studies, seroconversion occurred in vaccine recipients. Despite 
this, these responses never attained the same magnitude as that seen following natural 
infection. These titres seen post-vaccination are similar to those observed in Tables 3.4-3.6. 
Again, it is observed that younger vaccinees, aged between 1-6 mos, did not develop a robust 
immune response to the G protein as do older vaccinees. The mean Ab titres of anti-F IgG Ab 
were seen to be 4-fold or higher than placebo recipients, with seroconversion occurring from 
between 54-97% of recipients. However, neutralizing Ab responses were seen to be modest or 
significantly lower in comparison to F Ab levels, despite the development of high-level F Ab 
responses. It has also been argued that the inability to infect seropositive children even though 
challenged with live attenuated RSV vaccines is indicative of RSV immunity (Wright et al., 
2000). Additionally, in some instances, upon natural RSV infection post-vaccination, a 
significant rise in Ab titres was not realized. It is thought that the stimulated vaccine-specific 
Ab titres may be of sufficient magnitude, that an additional increase in boosting titres is not 
realized on subsequent natural RSV infection (Piedra et al., 2003b). This is thus suggestive of 
a minimal protective threshold allowing for the protection of infants from serious RSV- 
associated illnesses.
For the young children who failed to respond to vaccination, the authors account this to the 
presence of circulating matAbs, which in turn prevented Ab stimulation. From 4 studies (7, 8, 
9, and 11) and an additional 3 studies (1, 3 and 10) listed in Table 3.7 that monitored RSV- 
specific Ab titres to the end of the RSV season and for a period of 2-4 mo post-vaccination 
(Figure 3.3) respectively, high Ab titres were still realized by the end of the season.
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Figure 3.3. Trends of Ab levels following vaccination over a period of time (see Table 3.7 
for details and references)
Consequently, the above studies on PFP and cpts in some instances, showed either no increase 
in frequency or severity of RSV-associated illness, or, a reduction in respiratory disease 
morbidity during the entire RSV season in infants of vaccine recipients when compared with 
controls and as such conferred protection against RSV-associated illnesses to young vaccinees. 
With regards to adults, this implies that as they are able to maintain high Ab titres throughout 
the RSV season, maternal immunization lends itself to further investigation, with a more 
immunogenic vaccine having the potential of resulting in higher serum and breast milk Abs 
against RSV in infants of vaccinated mothers (Munoz et al., 2003). On the other hand,
vaccinees who were infected with RSV were observed to experience significantly fewer 
ALRTIs (Piedra et al., 1998, Wright et al., 2000), required fewer courses of antibiotics and 
had fewer days of illness during the RSV season and this was especially so in children with 
underlying conditions such as cystic fibrosis and bronchopulmonary dysplasia, in comparison 
to RSV-infected controls (Groothuis et al., 1998, Piedra et al., 1996).
Munoz and colleagues (2003) from their observations postulated that transplacental transfer of 
RSV specific anti-F IgG as well as neutralizing Abs to both RSV A and B remained efficient, 
being greater than 100% in the case of anti-F IgG. Furthermore they calculated that for all 
vaccine recipients who initially began with low pre-vaccination titres, were able to achieve 
GMT of neutralizing Abs to both RSV A and B of > 6.0 Log2 . This is equivalent to the 
protective threshold value calculated by Piedra and others (2003a) as mentioned above. 
Another study (Gonzalez et al., 2000) observed that vaccine response rates (ELISA and 
neutralizing Ab titres) correlated with pre-vaccination titres, not age. They postulated that the 
diminished immune responses to vaccines may be as a result from the levels of pre-existing 
Abs rather than immunosenescence. Previous studies (Falsey & Walsh, 1998, Falsey et al., 
1999, Walsh & Falsey, 2004a) have noted that older adults (> 65 years) with low titres of Nt 
Abs may be at greater risk of developing symptomatic RSV infections in comparison to those 
who display higher Ab titres. Moreover, their immune response to RSV infection can be as 
vigorous as younger subjects (18-40 years). It is therefore plausible as mothers possess 
varying titres of RSV-specific Ab titres, their infants will receive varying titres of matAb. It is 
consequently important to resolve what the critical protective threshold ought to be, above 
which pre-existing Abs will suppress the child’s own immune response leading to risk of
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infection and similarly, below which the child remains at risk of infection in the subsequent 
RSV season.
Vaccine efficacy may be predicted by serological correlates of protection based on the level of 
Ab achieved by the immunized population (Siber, 1997), which is also affected by the decay 
rate of Abs. One study (Piedra et al., 2003a) calculated the rate of decay of monthly GMTs for 
both Nt and ELISA binding Abs as occurring at approximately 0.25 log2 per month, implying
protective levels are short-lived. Neutralizing Abs appear to be a more accurate predictor of
\
infectability (Lee et al, 2004) as these responses are to both RSV groups A and B, these are 
only -50% related through their G gene amino acid sequence and only 5% related 
antigenically (Johnson et al., 1987). As both decay at similar rates this needs to be taken into 
consideration when calculating the protective threshold. Additionally, it should be 
remembered that Ab concentrations achieved following immunization are not always absolute 
predictors of individual protection although they allow for the estimation of the probability of 
protection in the individual or in a population (Siber, 1997).
Therefore, as matAb are protective for a limited period after birth, the susceptible infant 
population includes those infants whose initial level of passively acquired Ab is low, as well, 
infants old enough at the time of RSV season who had their levels fall below the protective 
threshold levels. As a result, this group of infants are uniquely susceptible as they lack both 
cross-reactive immunity from prior exposure and passive protection (Puck et al., 1980). 
Despite the short-lived nature of protection, it remains important to establish immune 
correlates which might be complicated by such factors as presence of matAb to high decay 
rate, as this is not only critical for vaccine development, but allow prediction of vaccine
§7
efficacy in populations other than those in whom efficacy was initially demonstrated (Siber, 
1997).
3.7 The Suppression of the Infant’s Immune Response by matAb
Suppression of infant Ab response by matAb to the virus may occur if, for instance, antigenic 
load happens to be sub-optimal as a result of these circulating Abs partially suppressing viral 
replication (Watt et al., 1986). Thus, the infant’s own immune system is ineffectively primed 
with no Ab response. Above a certain protective threshold, matAb could suppress the infant’s 
immune response accounting for RSV disease in the presence of matAb. It has been observed 
in experimental animals that the immune response is suppressed on administration of passive 
Abs (Belshe et al., 1982, Prince et al., 1982). Alternatively, the child’s immune system could 
still be stimulated; however, the Abs that result may not be associated with appreciable 
neutralizing activity (Murphy et al., 1988). In other words suppression by matAb results in 
either suppression of the total Ab response (quantitative response) or is selective for epitopes 
(qualitative) involved in induction of neutralizing Abs (Murphy et al., 1988). Qualitative 
changes also embrace changes in the IgG class distribution as well as affinity of Abs 
(Meurman et al., 1992).
3.8 Other Immune Responses and Factors Affecting them
The inability of the infant to develop a solid protective immune response following primary 
RSV infections and re-infections remains unexplained, but the percentage of RSV-associated 
hospitalizations has been observed to decrease with age. Piedra and others (2003a) noted that 
40.7%, 38.1% and 11.8% of children with LRTI in age groups <1 year, 1 - 4  years and > 5 
years respectively were RSV-associated hospitalizations. Similar trends were noted in other
studies with a decreased frequency of lower respiratory involvement, primarily a decrease in 
bronchiolitis, being associated with increasing age (Fernald et al., 1983, Glezen et al., 1986, 
Hall et al., 1991, Henderson et al., 1979). So, immunity induced following a single infection 
has no demonstrable effect on RSV illness associated with re-infection a year later, but a 
considerable reduction in severity of third infection was observed (Glezen et al., 1986, 
Kawasaki et al., 2004) The mechanism for mildness of clinical features at re-infection has 
been attributed to maturation of the respiratory system and immunity with age and the high 
acquisition of immunity after primary RSV infection (Kawasaki et al., 2004). The authors 
suggested an inverse relationship between neutralizing Ab levels and illness severity.
Protection against re-infection with RSV is mainly conferred by both serum (IgG-discussed 
above) and mucosal (IgA) Abs (Domachowske & Rosenberg, 1999). IgA is the major Ab 
isotype of respiratory tract secretions and is hence targeted to mucosal surfaces (Kerr, 1990). 
As a result, this immunoglobulin can bind and neutralize viral proteins intracellularly at the 
site of initial replication in the epithelial cells thus having an important protective role against 
infection (Fisher et al., 1999, Kaul et al., 1981, Tsutsumi et al., 1995) In this regard, the 
stimulation of IgA would play an important role against RSV, a mucosally restricted pathogen. 
Indeed, multivariate analysis found that low RSV-specific nasal IgA was an independently 
significant risk factor for RSV infection (Walsh & Falsey, 2004b). Indeed, several studies 
have demonstrated that viral shedding stops coincident with the emergence of secretory IgA 
(McIntosh et al., 1978, McIntosh et al., 1979, Mills et al., 1971). This local immunity thus 
appears to be the main mechanism responsible for the resistance to RSV in the URTI (Olmsted 
et al., 1986). Nonetheless, it has been suggested that matAb also affects IgA response during
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primary infection (Yamazaki et al., 1994a), and it remains important to establish the minimal 
threshold level for optimal immune response.
3.9 Summary and Conclusion
MatAb of the IgG class is transferred to newborn from mother during gestation. At birth, cord 
titres can equal, exceed or be at levels that are lower than maternal titres. Various risk factors 
have been noted to decrease placental transfer, otherwise, transfer is efficient and 
approximates a maternal:cord titres of 1.0. RSV clearance rates were observed to vary from 
26-100.3 days, whilst the proportion of children with RSV-specific matAb decreased as 
children got older. In one study, by 6 months of age, the proportion of children with matAbs 
was 2%.
The role of matAbs as immune correlates of protection against RSV-associated disease in 
early childhood remains controversial. There possibly exists a protective immune threshold 
above which matAb may interfere with vaccine efficacy as well as cause suppression of the 
infant’s immune response. Additionally, below this level both vaccines and the child’s 
immune response would be optimal.
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CHAPTER FOUR 
Materials and Methods
4.1 Study Site
4.1.1 Demographic features
These studies were carried out at the Kenya Medical Research Institute (KEMRI)/Centre for 
Geographical Medicine Research-Coast (CGMRC), Kilifi, situated at the Kilifi District 
Hospital (KDH) in Kilifi District, an area of 4779 km2 (Central Bureau of Statistics, 2001) in 
rural coastal Kenya. The population of the district at the last national census was 544, 303 
(Central Bureau of Statistics, 2001; http://www.statoids.com/yke.htmlT
KDH is situated 60 kilometres north of Mombasa on the Kenyan Coast and serves people 
living in the two areas separated by the Kilifi Creek. The population is predominantly 
Giriama, a subgroup of the main ethnic group Miji Kenda that consists of nine closely related 
subgroups. An area, including Kilifi township extending 40 km along the Indian Ocean 
between 2 creeks and 30 km inland was defined in 1991 for intensive epidemiological- 
demographic surveillance (EPI-DSS, Figure 4.1) and has been the base for several 
epidemiological, public health, bed-nets and drug intervention research projects (Snow et al., 
1993). The population figure of the Epi-DSS area is estimated to be 213, 152 (Round 4 census, 
August-November, 2003).
The total population in Kilifi district comprises approximately 45% of people <14 years, with 
children under the age of 5 comprising 18% (Central Bureau of Statistics, 2001; 
http://www.statoids.com/vke.htmlT More than 80% of paediatric admissions to KDH originate
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from the demographic surveillance area. In 1999, infant mortality for the district was 85.3 
deaths /1000 births (English et al., 2003).
E pi-D ss in Kilifi- K enya
Figure 4.1. Map of Kilifi District 
and Epi-Dss Area
1 centim eter equa ls  7 .3 4 4 0  kilometers
Subsistence farming is the main occupation, with farmers growing maize, cassava, beans and 
coconuts. They also keep a variety of domestic animals (cattle, goats, sheep and chicken). The 
town dwellers are involved in commercial activities, the hotel industry and local 
administrative jobs. Various forms of fuel are utilized by this community and include 
firewood, charcoal, gas or paraffin, their access to water being either open/closed wells or 
piped.
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4.2 Study Design
4.2.1 Definitions
Acute respiratory infections (ARI) were classified as URTIs or LRTIs following modified 
World Health Organization (WHO) definitions for pneumonia (WHO, 2000; Table 4.1). An 
episode of LRTI was defined as the presence of cough or difficulty in breathing in addition to 
one or more of the following symptoms: chest in-drawing or increased respiratory rate. 
Children presenting with cough, nasal congestation/secretion or difficulty in breathing but no 
signs suggestive of LRTI were considered as having an URTI (Table 4.1). These definitions 
were mutually exclusive.
Table 4.1. Pneumonia classification at KDH for children aged less than 2 months (young 
infant) to 5 years (child) - adapted from the WHO guidelines (WHO, 2000). Acute cough or 
difficultly in breathing are prerequisite signs
Syndrome Characteristic (Modified WHO) Definition
Very severe pneumonia (i) Prostrate (or inability 
to feed)
(ii) Unconscious
(iii) Oxygen saturation < 
90% if accompanied 
by clinical LRTI 
diagnosis
Severe LRTI
Severe pneumonia (i) Chest indrawing AND 
no sign of very severe 
pneumonia
Severe LRTI
Pneumonia (i) Fast breathing for
age* AND no signs of 
very severe or severe 
pneumonia
LRTI
No pneumonia None of the above signs URTI
♦Fast breathing is present if the rate is > 60 in those aged < 2 months, > 50 if aged 2-11 months and > 
40 if 11 months or older.
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4.2.2 Recruitment of cohort
About 300 children each were recruited in 2 phases to a birth cohort in Kilifi District. They 
were recruited between February -  May 2002, and December 2002 -  May 2003, respectively, 
were intensively monitored for ARIs as shown in the schematic below (Figure 4.2). Infants 
were recruited at birth, in the maternity ward, or within 2 weeks of birth, at the maternal child 
health clinic (MCHC) at KDH. A child was eligible if, in relation to KDH, the road access to 
their home was good, the travel cost (single) was < 50 Kenya shillings (US $0.7) and the 
journey time was <1 hour. Active household surveillance for ARI was weekly during RSV 
epidemics and monthly otherwise. Passive surveillance was carried out principally through 
parental referral to outpatient (OP) research clinic (Monday- Friday, 8 a.m- 5 p.m.) at KDH 
(Nokes et al., 2004). Passive referral was encouraged for a child with any ARI symptoms (or 
worse).
At each contact, a nasal washing (NW) was collected (Figure 4.3) if the child had > 1 signs of 
acute cough, difficulty in breathing or if nasal congestion/discharge was observed or elicited 
by the history from the preceding week. A blood film for malaria diagnosis was collected if 
the child had a history of fever in previous week or an axillary temperature > 37.5°C on the 
day of visit, with appropriate treatment being provided if found positive. Infant vaccination 
records were also checked, with advice to attend MCHC for any vaccination overdue. During 
an active visit, the child would be referred to the research clinic if she/he had a respiratory rate 
of > 50 breaths/min if an infant, or > 40 hreaths/min if one year or over, and accompanied by 
cough or difficulty in breathing on the day of the visit. The number of complete weeks of 
absence from the district since the previous active visit was also recorded (Appendix II). 
Infants attending the OP research clinic underwent medical review by a clinical officer using a
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standardized pro forma method (Appendix III) to ascertain the severity of ARI. Transport 
costs were reimbursed and definitive medicines provided without charge. RSV-positive 
children were contacted as soon as possible following diagnosis, and the parents were 
requested to refer the child to the research clinic if his/her condition did not improve or 
deteriorated.
Figure 4.3. Collection of NW 
from child and infant 
respectively using a nasal 
wash bulb (NWB).
Additional passive surveillance of cohort infants was done through admissions to KDH (the 
majority of children could be linked to the admission records by their Epi-DSS number 
ascertained at the point of admission). NW were collected if the child presented with either 
severe or very severe pneumonia (Table 4.1) or had an admission diagnosis of LRTI. The 
baseline symptoms for sample collection in the field or at the OP clinic were runny 
nose/congestion, difficulty in breathing or cough (either on the day of visit or presentation, or 
with a history over the preceding 7 days).
Venous blood samples which included cord blood (when possible from maternity ward 
recruits) and repeated blood samples taken at approximately 3 monthly intervals were
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collected from each child (Figure 4.2). If a child experienced a positive RSV event identified 
using IFAT, an acute phase blood sample was collected, and 1 month later, a convalescent 
sample. With regards to in- or out-patients, appointments were arranged for their return to the 
OP clinic, if the mothers failed to turn up on the appointed day however, their child (or 
children) was followed up at home.
4.3 General Characteristics of the Cohort
A total of 33,894 visits (passive, active or in-patient) were made and of these, approximately 
78% were active whilst 21% were passive, with each child being visited between 1 and 104 
times during the follow up period. Families ranged in size from 3-32 members of which the 
total number of children varied from 1—18 children. The average family comprised 4 children. 
Ninety-one percent of the births in this cohort were single births and infants were breast fed 
for 3-27 months. Thirty percent of these children were still being breast fed at the end of the 
follow-up period. Most children at birth were between 2.7- 3.4 kg in weight (Appendix I).
4.4 Ethical Considerations
The research project was one of several studies nested within a birth cohort study of RSV in 
Kilifi District, which was reviewed and passed as ethically acceptable by the Kenya Medical 
Research Institute/National Ethic Review Committee Kenya and Coventry Research Ethics 
Committee, UK. Informed consent (Appendix IV) for participation in the study was obtained 
from each infant’s mother (Nokes et al., 2004) .
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4.5 Methods
The suppliers of all the reagents and consumables used in these studies are listed in Appendix 
V.
4.5.1 Sample collection
4.5.1.1 N asal washings (NW) and R SV  diagnosis
NW were collected by the method of Hall & Douglas (Hall & Douglas, 1975), that utilized a 
NWB (Figure 4.3) and 5 mL of normal saline for infants <6 months old, 7 mL for those 7-11 
months old, and 10ml if older than 11 months. Samples collected in the household were stored 
in a cool box and transported to the microbiology laboratory at the end of the day; those 
collected in the OP clinic were delivered within 1 hour. Samples were stored at 4°C until 
screening for RSV antigen using light diagnostics™ RSV direct immunofluorescence assay 
(DFA) as per the manufacturer’s (Chemicon International Inc.) protocol. This usually occurred 
within 24 hours and invariably within 3 days. Briefly, mucus was broken up by pipetting up 
and down several times and then slides prepared from 200 pL of specimen by use of a 
cytology centrifuge (67 X g, 10 min). Following this, slides were air-dried, fixed in chilled 
acetone (2-8°C) for 10 min and then a drop of RSV/FITC (fluorescein isothiocyanate) Ab 
placed on re-dried slides. Slides were placed at 37°C in a humid chamber for 30 min, air-dried 
before mounting with mounting fluid, whereupon they were examined under a fluorescent 
microscope (X 20- 40 objective). This assay is an immunoflurorescence antigen test (IFAT) 
and cells in positive specimens fluoresced apple green, while uninfected cells, stained dull red 
(counter stain).
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4.5.1.2 Blood collection
The field worker used a butterfly needle (B-23G) and syringe (5 mL) to collect venous blood 
in the home of each participating individual. If any failure occurred, a second attempt would 
be made whilst out in the field, and in the OP clinic, one of the attending medical personnel 
would try a further time, before indicating on the form that no blood was drawn. For 
individuals attending the OP clinic, venous blood was withdrawn also using a butterfly needle 
(B-23G). Blood (2 mL) was placed in a bijou bottle, and transported to the laboratory. Those 
collected in the OP clinic were delivered within an hour of collection, whilst those in the field 
were stored in a cool box and transported upon return at the end of the day. In the 
microbiology laboratory, samples were left to clot at 4°C, then centrifuged (1400 X g for 5
i
min) and serum collected by use of a plastic Pasteur pipette, into an apex (2 mL) tube. 
Samples were stored at -70°C until further analysis.
Both thick and thin blood smears were prepared from a finger prick. Slides were transported 
back to the laboratory for processing as earlier described (Warhurst & Williams, 1996). 
Briefly, slides were fixed by immersion into methanol (30- 60 sec), air-dried and then stained 
with 10% Giemsa in phosphate buffered water (20-30 min), rinsed (tap water) and then left to 
dry vertically before examining for malaria parasites (XI00 magnification) by personnel in the 
Haematology laboratory.
Serum from 6 adults was collected for later use as reference and controls in the ELISA 
(described later). From each of 6 adults, 5 mL of venous blood was withdrawn using a sterile 
needle and syringe. Samples were immediately taken to the Microbiology laboratory, left to 
clot at 4°C, centrifuged (3000g for 5 min) and sera from 5 of these 6 sera pooled by using a
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plastic Pasteur pipette into a 15 mL falcon tube. Pooled sera, as well as the remaining serum, 
were kept as 250 pL aliquots at -20°C until further use.
4,5.2 Cell and virus culture
4.5.2.1 Culture media
Culture media was made up using minimal essential medium with Earles salts and L- 
glutamine (MEM) which was supplemented with 1M HEPES buffer, non-essential amino 
acids (100X), penicillin/streptomycin (10,000U/mL penicillin and 10 mg/mL streptomycin 
diluted 1:100) and 5% fetal calf serum (FCS). Maintenance MEM was made as above, except 
2% FCS was used.
4.5.2.2 Cell culture
\
HEp-2 cells were retrieved from liquid nitrogen cryopreservation and placed gently into 5-7 
mL pre-warmed (37°C) supplemented MEM (CMEM) in 25 cm2 tissue culture flasks (T-25 
cm2). All flasks were incubated at 37°C in a 5% CO2 enriched atmosphere. Cells were 
examined microscopically using phase contrast, after 24 hours. Culture medium was initially
- changed 24 hours following retrieval, and then every second day thereafter, sub-culturing as
•  2 2necessary into tissue culture flasks of the same size or scaling up into T-75 cm or T-150 cm ,
Sub-culturing of cells was carried out as follows. Spent medium was removed from confluent 
cell monolayers, which were washed twice using a volume equivalent to half the volume of
f j ,  *>1
culture medium with phosphate buffer saline (PBS) without Ca /Mg . Cells were then 
incubated with 1 mL trypsin/EDTA per 25 cm2 of surface area until they began to detach; this
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was microscopically confirmed. The side of the flask was gently tapped to dislodge the 
remaining attached cells, then the reaction quenched by adding the appropriate volume of 
CMEM. The required number of cells was transferred into new flasks containing pre-warmed 
CMEM. All flasks were incubated as before.
4.5.2.3 Cryopreservation o f  HEp-2 cell lines
Flasks (T-150 cm2) were viewed microscopically to confirm the degree of cell density and 
confirm the absence of bacterial and fungal contaminants. Cell viability was in excess of 90% 
in order to achieve a good recovery after freezing. Adherent and semi-adherent cells were 
brought into suspension using typsin/EDTA and cells re-suspended in fresh CMEM as above. 
Cells were centrifuged (157 X g, 10 min) and supernatant carefully decanted, and then the 
pellet gently re-suspended at a concentration of 2-4 X 106 cells per ml in freezing medium 
(10% dimethyl sulphoxide, 50% FCS in CMEM). Aliquots of 1 mL of cells were placed in 
appropriately labeled cryoprotective ampoules. Ampoules were placed inside a passive freezer 
(Nalgene Mr Frosty) and placed at -80°C overnight; these were then transferred to liquid 
nitrogen.
4.5.2.4 Virus stock preparation
A semi-confluent (50-70%) T-25 cm2 flask of HEp-2 cells was used and spent medium 
decanted. One mL of 1:1 ratio of maintenance MEM and RSV type A2 strain (ATCC 
VR1540) was inoculated onto these cells. Flasks were then incubated at 33°C in a 5% enriched 
CO2 atmosphere, for 2-3 hours, with gentle swirling every 15 min to allow for virus 
attachment. Maintenance MEM was added to make up to the appropriate volume. The flasks
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were re-incubated and checked on a daily basis for signs of syncytia formation and cytopathic 
effects (CPE) by the majority of cells, which were also characterized by a change in pH in the 
medium. Uninfected flasks were set up in parallel as controls. When 50-70% CPE occurred, 
sterile glass beads were utilized to gently dislodge the disrupted monolayer and the resulting 
cell suspension aliquoted (1 mL) into ampoules and stored at -70°C until further use.
4.5.2.5 Viral antigen (lysate) preparation
HEp-2 cells in T-150 cm2 flasks were infected with RSV A2 strain as described above at 33°C. 
When extensive CPE was observed (Appendix VI), usually 3-5 days post-infection, mock and 
infected cell lysates were prepared by scraping cells off into the medium. Cells were then 
pelleted by centrifugation (352 X g for 10 min) and resuspended in 10 mL PBS. A further 
centrifugation step was carried out (352 X g for 10 min) before resuspending pellet in 0.5% 
Nonidet-P40 (NP40) in 10 mL water. The suspension was thoroughly mixed by whirli-mixing 
and then debris pelleted (352 X g for 10 min). The supernatant was aliquoted and stored at - 
70°C until required.
4.5.2.6 Enzyme linked immunosorbent assay (ELISA) procedure
The method used was adapted from Wilson et al (2000) used for the detection of RSV specific 
IgG in oral fluid. Ninety-six-well plates (Immulon-2 HB) were coated overnight with 50 pL of 
appropriate dilutions of either RSV-A2-infected or mock-infected cell lysates (chapter 5) 
prepared as described above, and allowed to dry within wells. These constituted the test and 
control wells, respectively. Plates were then fixed at room temperature for 10 min using 80% 
acetone, drained and allowed to dry, then stored at -20°C until use.
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The ELISA procedure was carried out as follows. The optimal concentration of reagents and 
sera was determined by checkerboard titration (chapter 5). Plates were blocked with 200 
pL/well of 5% dried skimmed milk powder in PBS-Tween (0.05% Tween, PBS-T) at 37°C for 
60 min. 100 pL of serum, appropriately diluted in blocking buffer, were carried out, then 
added in duplicate to both RSV-A2 and mock lysates for 90 min. Plates were washed four 
times with PBS-T, followed by incubation with 100 pL horseradish peroxidase-conjugated 
rabbit antihuman IgG (1:1000 dilution in 5% dried skimmed milk powder in PBS-T) at 37°C 
for 60 min. Plates were washed again four times in PBS-T. 100 pL of freshly prepared O- 
phenylenediamine (30 mg tablet dissolved in 30 mL PBS with 30 pL H2O2) substrate was 
added for 10 min in the dark. The reaction was quenched with 50 pL (2.5 mol/L) sulphuric 
acid and absorbance (OD) read at a wavelength of 492 nm using an ELISA plate reader. 
Further details of the optimization of assay are presented later in the following chapter. An OD 
of >0.2 was considered positive following subtraction of corresponding mock-infected cell 
lysate reading (Wilson et al., 2000).
4.5.2.7 M odified lysate preparation/ELISA procedure
The original lysate preparation and ELISA assays (sections 4.5.2.5 & 4.5.2.6) resulted in 
inconsistencies (see chapter 5 for further details) and therefore both assays were modified 
further (for further details see Appendix VDI). Briefly, lysate preparation was carried out as 
previously described above (4.5.2.5), however, prior to storage at -70°C, supernatant (10 mL) 
was sonicated (70% amplitude, 3X 1 min cycles with Is pulse and Is pause) and resulting 
lysate pooled then vortexed thoroughly. Lysate was then stored.
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Ninety-six well plates (Nunc-Immuno™ MaxiSorp™) were used. 25 pL of appropriately 
diluted lysate in PBS coating buffer was placed in each well and allowed to adsorb over night 
(37°C) in a rotating incubator then coating buffer flicked off before proceeding with ELISA as 
previously described above (4.5.2.6) with one modification. Blocking buffer comprised 5% 
skimmed milk powder in PBS only.
4.5.3 Molecular assays
4.5.3.1 Clinical specimens
RSV IF AT positive NW specimens collected by both active and passive surveillance as earlier 
described, as well as those samples that were shown to be IF AT negative but positive by 
ELISA for RSV-specific IgG, (see chapter 6, section 6.3) were tested. The positive controls 
included HEp-2 cells infected with either RSV A or B which were used in all PCR runs, and 
the first round cloned PCR products (kindly supplied by Dr Paul Scott, Warwick University) 
for the remaining virus strains (Influenza A HI and H3 strains, and Influenza B) was 
incorporated into the assay (Figure 4.4). First round products (Influenza controls) were 
included during the secondary round. This thus allowed for discrimination between all 5 viral 
amplicons. Negative controls included template-free reaction tubes.
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Figure 4.4. Flow chart illustrating addition of 
positive controls during the RT-PCR assay
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4.5.3.2 Ribonucleic acid (RNA) extraction and complementary deoxyribonucleic acid (cDNA) 
synthesis by reverse transcription
Ribonucleic acid (RNA) from NW was extracted using the QIAamp Viral RNA Mini kit 
following the manufacture’s instructions with the following modification: carrier RNA was 
omitted. (All buffers were supplied by manufacturer). Briefly, AVL buffer (560 pL) was 
added to NW (140 pL), vortexed and then incubated at room temperature (10 min). Absolute 
ethanol (560 pL) was added, the sample mixed by vortexing and then carefully transferred to 
QIAamp spin column (in a 2 mL collection tube). A centrifugation (6000 X g, 1 min) step 
followed. After each centrifugation step, the spin column was placed in a clean collection 
tube. The remainder of the sample was added, and centrifugation was repeated. Buffer AW1
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(500 (jL), was added, and the tube then centrifuged. This was followed by addition of buffer 
AW2 (500 pL), centrifugation at full speed (20,000 X g, 3 min) and finally, buffer AVE (60 
pL) added. The column was incubated at room temperature (1 min) and a final spin carried out 
(6000 X g, 1 min). The resultant eluted RNA was stored at -20°C or used immediately to 
synthesise complementary deoxyribonucleic acid (cDNA). Following extraction, cDNA 
synthesis was carried out using reagents from the Qiagen Omniscript Reverse Transcriptase
Ikit. 20 pi of RNA was added to a reaction mix (20 pi) containing lOx RT (reverse 
transcriptase) buffer, 5 mM of each deoxynucleoside triphosphate, Omniscript reverse 
transcriptase (200 units) and 250 ng/pl random hexamers [pd(N)6]. The reaction mixture was 
incubated at 37°C for 60 min. Reverse-transcription reactions were stored on ice if proceeding 
directly with PCR, or for long-term storage at -20°C.
4.5.3.3 Primers used
Previously described primers (Cane & Pringle, 1991, Stockton et al., 1998) were utilized. Each 
primer was 20 nucleotides long with a base composition that ranged from 50-60% in GC 
content. Primers were synthesized by Alta Biosciences, Birmingham, and these are listed in 
Appendix VIL
4.5.3.4 M ultiplex polymerase chain reaction (mPCR)
Following cDNA synthesis, the method of multiplex polymerase chain reaction (mPCR) as 
described by Stockton et al. (1998), was used. First round primers (Appendix VII) at 5 pM 
were used to cany out the primary amplification step and 2.5 pM of second round primers 
(Appendix VII) for the secondary amplification. For the primary PCR round, 20 pL of cDNA
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was added to 80 pL of a reaction mix containing Taq PCR Master Mix and 25 mM MgCb. 
Amplification with a DNA Engine thermocycler consisted of 1 cycle at 94°C for 2 min; 35 
cycles of 94°C for 1 min; 50°C for 1 min and 72°C for 1 min; 1 extension cycle at 72°C for 5 
min and then cooled. Two microlitres of the primary product was then transferred to 48 pi of 
secondary amplification mixture as above. The samples were then incubated for 1 cycle at 
94°C for 2 min; 35 cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 1 min; and 1 
extension cycle at 72°C for 5 min and then cooled. Resulting amplicons were visualized by gel 
electrophoresis.
4.5.3.5 Gel electrophoresis
Each amplicon (8 pL) was mixed with loading buffer (2 pL), in addition, 5 pL lOObp DNA 
ladder (5+ Units) in 2 pL loading buffer were loaded onto a 1% agarose gel in 0.5x TBE 
buffer (0.045 M Tris-borate, 0.001 M EDTA) stained with ethidium bromide. Electrophoretic 
separation was performed for 30 min at 130 mA. Following electrophoresis, the remaining 
aliquot of products was stored at -70°C until further use.
4.5.3.6 Purification o f PCR products
PCR products were purified using the QIAquick PCR purification kit following the 
manufacture’s instructions, prior to undergoing further analysis. Briefly, buffer PB (5 
volumes) was added to PCR sample (1 volume) and mixed thoroughly. The sample was added 
to a QIAquick spin column that was previously placed in a collection tube and centrifuged (> 
10, 000 X g, 30-60 s). Flow-through was discarded, the spin column placed in a clean
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collection tube and buffer PE (0.75 mL) added. The sample was centrifuged (> 10, 000 X g, 
30-60 s) again, flow-through discarded and spin column replaced in the same tube for a 
another centrifugation step (> 10, 000 X g, 1 min). The spin column was then placed in a clean
1.5 mL microcentrifuge tube and 50 pL of buffer EB (lOmM Tris-Cl, pH 8.5) or water added 
to the spin column (1 min) and then centrifuged (> 10, 000 X g, 30-60 seconds). The purified 
product was stored at -20°C until further use.
4.5.3.7 N gene PCR
This was carried out as a nested PCR using the purified positive first round products 
synthesized from the mPCR protocol above, and N gene primer pair at 10 pmol/pl as earlier 
described (Cane & Pringle, 1991). One microlitre of first round mPCR product was added to 
49 pi of a reaction mix containing Taq PCR Master Mix, and then incubated for 1 cycle at 
95°C for 2 min; followed by 35 cycles of 95°C for 45 s, 54°C for 45 s and 72°C for 1 min; and 
finally 1 extension cycle at 72°C for 5 min and then cooled. Amplicons were visualized 
following electrophoresis on 1% agarose gel as above. All products were stored at -70°C until 
further use.
4.5.3.8 N gene restriction fragment length polymorphism
N gene typing by restriction fragment length polymorphism (RFLP) was carried out by 
digesting N gene PCR products at 37°C for 1 hour (Cane & Pringle, 1991) with Hind HI, Pst I, 
Bgl II, Hae HI and Rsa I. Amplicons were visualized by ethidium bromide staining following 
electrophoresis as described above but using a 2% agarose gel instead. The resulting banding 
patterns were then used to determine the N gene pattern (NP, see table 6.2).
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4.5.4 Methods for statistical analysis
All data analysis was carried out using Stata 9.0™ and will be described in detail later, refer to 
sections 7.5 and 8.4.
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CHAPTER FIVE 
RSV-specific Enzyme Linked Immunosorbent Assay (ELISA): 
Assay Development
5.1 Introduction
Previously, complement-fixation (CF) and hemagglutination inhibition (HAI) tests were used 
as the basis for serological diagnosis of viral infections (Julkunen, 1984, Yolken, 1980). The 
immunological response to RSV infection was measured,by the detection of a rise in CF Abs 
in convalescent phase relative to acute phase serum from infected individuals. However, 
serological investigation of RSV can be unreliable when performed by CF on infants 
(Steinhoff et al., 1980) due to its reduced sensitivity: titres measured by CF have been shown 
to be lower in comparison to ELISA (Homsleth et al., 1984, Richardson et al., 1978), with 
some authors describing Ab titre levels of up to 100-fold lower (Richardson et al., 1978) than 
those obtained by ELISA.
In comparison with other serological techniques such as the plaque reduction assay, it has 
been stated that the ELISA technique detects a serological response to RSV in approximately 
50% of infants under 6 months of age infected with the virus, i.e. those most vulnerable to 
serious disease (Richardson et al., 1978, Meurman et al., 1984). The plaque reduction assay 
measures only those serum Abs which neutralize virus and therefore render it incapable of 
initiating a plaque i.e. Abs to one or more surface antigens, whereas the ELISA measures both 
neutralizing and many other Abs directed against internal epitopes and other epitopes that bind 
Abs without virus neutralization. Non-neutralizing antigens are particularly abundant in RSV- 
infected cells (Richardson et al., 1978). Abs detected in ELISA should be characterized as
binding rather than neutralizing and caution must be exercised in the interpretation of ELISA 
results, as the Abs measured may not be protective. This assay therefore, should not act as a 
surrogate for protective immunity. Various applications of ELISA for the measurement of 
RSV serology have been carried out by using various antigens which include purified antigens 
(Nandapalan et al., 1984), cell lysate antigens (Steinhoff et al., 1980) or crude extracts from 
infected cells (Richardson et al., 1978).
Over the past 20 years, enzyme immunoassay methods have been developed for the diagnosis 
of viral infections of members of the Paramyxoviridae family such as parainfluenza virus, 
measles virus (Julkunen, 1984, Kacica et al., 1995, Kurstak et al., 1986, Yolken, 1980) and 
RSV (Steinhoff et al., 1980). ELIS As have also become an important alternative to cell-culture 
techniques (Kurstak et al., 1986) allowing for diagnosis of infection within hours rather than 
the traditional 2 or 3 weeks. The ELISA is both reproducible and an objective test that can be 
„ performed on small amounts of serum (Steinhoff et al., 1980). The versatile nature of the 
ELISA, the ability to adapt this assay to microplate format, to detect isotype-specific or 
isotype subclass-specific responses, its relatively cheap cost, the relative ease of performance, 
the rapidity with which test results are made available, in addition to its sensitivity, led us to 
adopt the assay for analysis of serum samples collected from the birth cohort which was 
followed for 3 calender years.
An indirect ELISA method using a crude extract from RSV infected cells and mock infected 
cells, coated onto 96 well plates was used in this project. This method was attractive as it did 
not require any antigen purification or cellular treatment. For all Ab titrations, all specimens 
(control, standard or reference and test sera diluted appropriately) were tested in parallel
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against both RSV and control (mock) antigen-coated wells. The primary objective was 
primarily to identify infections, i.e. determine RSV-specific Ab responses between paired 
acute and convalescent samples (for which the ELISA is well adapted) in the presence or 
absence of matAbs. Secondarily, the ELISA was to be used to detect matAb decay, and to 
identify protective levels of Ab. Moreover, it was envisaged that the assay would also detect 
missed infections, in addition to confirming RSV IF AT (clinically identified) positive results. 
Additionally, the assay being developed had to be reproducible, accounting for variation 
within and between plates and from one batch to the next.
The setting of appropriate assay cut-off values is of importance in the development procedure 
as a means of evaluating assay performance. A further consideration is the availability of well 
characterized positive, and particularly negative controls, that have usually been assessed 
using the gold standard (Kurstak, 1985). The mean result of a population of negative samples 
confirmed from the gold standard assay, plus either 2 or 3 standard deviations is a commonly 
used method for setting the cut-off value. The appropriate cut-off values will thus be evaluated 
for our assay, following optimization of assay conditions.
5.2 Objectives
The main objective of this chapter was the development of a simple, sensitive and robust 
ELISA-based Ab detection method for RSV that is reproducible with minimal inter- and intra- 
plate variation.
Specifically the objectives included the following:
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• Investigation of whether the optimized ELISA could measure the decay kinetics of 
RSV-specific matAb and the resulting dose response curves in the presence or absence 
of an infection.
• Identification of the dynamic range of the log linear phase, and hence assess whether 
this phase for each child is parallel; this therefore allowed for the determination of an 
optimal dilution to assay serum samples,
• Identification of both high and low saturation zones of dose response curves in which 
the assay is insensitive to changes in Ab concentration and hence determine high and 
low assay cut-off titres respectively.
• Determination of whether the assay parameters and chosen dilutions could resolve 
serologically a recent infection event in the presence or absence of matAbs.
5.3 Results
5.3.1 Optimization of ELISA Procedure
Initially, optimization of the ELISA parameters (dilution of capture antigen, conjugate dilution 
and so on) was undertaken before going on to further investigate the sensitivity of the assay.
A variety of stages in the indirect ELISA can be varied to obtain the desired characteristics of 
assay performance and these have been previously described (Hendry & McIntosh, 1982, 
Richardson et al., 1978, Wilson et al., 2000). What follows is an account of a series of 
experiments performed to obtain assay performance suitable to move to large-scale screening. 
A systematic approach was adopted to modify only one or two stages or components of the 
assay at any one time.
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5.3.2 Determination of dilution of capture antigen
5.3.2.1 Method
Previously harvested lysate was used to coat 96 well plates, as described in Materials and 
Methods (Section 4.5.2.5). A 96 well plate was divided into half lengthwise and widthwise. 
The first 6 columns were coated with RSV A2-infected lysate, whilst the next 6 columns with 
mock infected control lysate. Wells in rows A-C were coated in triplicate with doubling 
dilutions of appropriate lysate, starting with a starting dilution of 1:2 to 1:64; this was repeated 
in rows E-G. Rows D and H were not coated and acted as control for the Ab (Figure 5.1). 
Initially, two monoclonal Abs against the G protein, 021/1G and 021/2G [Kindly donated to 
Dr. P Cane by Dr. J.A. Melero, (Madrid, Spain)] were used at a dilution of 1:500 as primary 
Ab in rows A-D and E-G respectively. Subsequently, adult sera at a dilution of 1:100 were 
used once it was confirmed that harvested lysate showed specific reaction to RSV Abs. The 
rest of the ELISA procedure is as previously described before (Section 4.5.2.6).
dO O O O O O O O O O O O
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Figure 5.1. Schematic of layout of ELISA plate. Red and blue circles depict RSV infected and 
mock infected lysates respectively. Lysate dilutions in rows A-C are depicted as follows, O  
1:2; ©  1:4; O 1:8; <D 1:16; O 1:32; O 1:64. This was repeated in E-G.
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5.3.2.2 Results
Figure 5.2 illustrates the signal: noise ratios observed for each dilution of capture antigen and 
respective mock lysates. The best lysate dilution that gave a good positive signal with the 
infected lysate but not uninfected lysate was determined for each lysate preparation and shown 
to occur at dilutions of between 1: 8  to 1:64.
5.3.2.3 Interpretation
Using lysates at concentrations higher than 1:8 was not feasible in terms of the logistics of 
lysate production. Suitable dilutions following 6  experiments fell between 1:32 to 1:64; 
therefore the concentration used was 1:64.
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Figure 5.2. The signal: noise ratio for different capture antigen dilutions (serum tested 1:100). 
Dilutions carried out in triplicate; Ag and mock are the virus infected and mock infected 
lysates, respectively. Bars indicate standard deviation.
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5.3.3 Determination of dilution of rabbit anti-human IgG conjugate
5.3.3.1 Method
Three adult sera were titrated in triplicate against antigen in a checkerboard assay. Four-fold 
serial dilution starting at 1:50 to 1:12,800 of serum was titrated against conjugate at the 
following dilutions: 1:500, 1:1000, 1:2000 and 1:4000.
5.3.3.2 Results
OD readings with conjugate at 1:4000 for all test sera were observed to be too low and this 
dilution was subsequently omitted in repeat analysis; conjugate at 1:1000 gave higher ODs at a 
dilution of 1:50 for all test sera. With test sera at a dilution of 1:200 and conjugate at 1:1000, 
this gave higher or similar results to the other dilutions.
5.3.3.3 Interpretation
Therefore, a working dilution of 1:1000 of rabbit anti-human conjugate was adopted for 
subsequent assays.
5.3.4 Reproducibility of ELISA
The ability of the assay to produce reproducible ELISA OD values over time was tested using 
sera from healthy Kenyan adults, and this was repeatedly tested over one month.
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53.4.1 Method
Sera from 3 healthy Kenyan adults were tested using the assay 15 times, initially in duplicate 
and then in triplicate, over a period of 1 month. A two-fold serial dilution, starting at 1:200 to 
1:6400, was carried out on all test sera. The starting serum dilution was 1:200 as this was 
earlier observed to give good signal, during the optimization process for the conjugate.
53.4.2 Results
The OD4 9 2  decreased with increasing serum dilution (see Figure 5.2). The dynamic range 
observed was wide, with OD492 values ranging from 0.02-1.9. At the outset OD492 varied from 
0.2-0.5 between replicate readings, with time this improved to within a range of 0.06-0.16 
with background ODs remaining relatively low. However, there appeared to be a systematic 
decrease in OD for triplicate readings over time as illustrated in Figure 5.3. Additionally, the 
coefficient of variance within plates was seen to be 15-17% and similarly high between plates.
Pt R: day to day variation of ELISA
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Figure 5.3. The day-to-day variation over a period of 1 month for Pt R (serum tested at 1:200 
dilution) showing dynamic range of observed ODs and low background values. Ag and mock 
are the virus infected and mock infected lysates respectively. Bars indicate standard 
deviation.
5.3.4.3 Interpretation
Due to the variation noted over successive occasions, it was decided that (a) all samples for 
one child should be screened on the same day and, (b) a set of standards should be used 
consistently to take into account this variation. With respect to the high coefficient of 
variance, new batches of antigen were produced and tested in parallel.
5.4 Sensitivity of ELISA: Validation of ELISA Method and Optimization of 
Serum Dilution
As the ELISA was shown to be reproducible on establishing the optimal dilutions of capture 
antigen and conjugate, the sensitivity of the assay was investigated. This was done by testing a 
subset of samples with different expected titres, inclusive of convalescent sera, which were 
anticipated to exhibit the highest titre, together with known negatives (sera collected during 
the inter-epidemic period where the likelihood of a child being infected was minimal therefore 
there would be no RSV-specific Ab detected) as a means of identifying the dynamic range, 
optimal dilution(s) to assay test sera and control, as well as assay cut-off values and the level 
of inherent assay variation expected. Thus, this would give an indication of the levels of 
saturation at high titres, in addition to what constituted too dilute a concentration with respect 
to samples with possibly “low” Ab titres, such as acute samples.
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5.4.1 Dynamic range of dose response curves
5.4.1.1 Method
Initially, sera from 5 inpatient infants whose ages ranged from 0-2 months (it was expected 
that matAbs would be at maximal titres during this age range) were used. Two-fold dilutions 
ranging from 1:20 to 1:40,960 were carried out. Subsequently, sera of patients from the cohort, 
the target population, were examined over a wider age range (0 - 1 2  mos) in the validation 
process as this took into consideration sera of both high and low titres, to give a better 
assessment of the assay.
5.4.1.2 Results
It was noted that the dose response curves for most patients were approximately sigmoidal 
(Figure 5.4); occasionally, the prozone or (high-dose) hook effect was noted as for Pt 4102-0 
mos (Figure 5.4A) and Pt 3735-6 mos (Figure 5.4B). Not all samples showed saturation at the 
highest concentration. All samples plateaued at the highest dilutions.
5.4.1.5 Interpretation
With increasing dilution, from 1:20 to 1:40,960, the typical dose-response curve for children 
tested was approximately sigmoidal. Furthermore, with increasing age it appeared that there 
was a decrease in specific Ab levels, most likely to be the decay in matAb. For most children 
tested, by the age of 12 months there was negligible Ab detected.
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Figure 5.4. Adjusted (test-mock) average dose response curves of 3-monthly samples (0-9 
months) double diluted (1:20-1:40,960) for a group of selected infants. Each patient is 
represented by a different colour and the symbols represent age groups:--A -  0 months;
3 months; — 6 months; ->£- 9 months of age. Each point represents average of duplicate 
OD readings.
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5.4.2 Identification of the dynamic range of the log linear phase
5.4.2.1 Test fo r parallelism
An important problem with Ab dose-response curves is that differences in Ab concentration 
and affinity means that these curves are not always parallel (Balfour & Harford, 1990). Thus, 
at one dilution a given serum may appear to have the higher Ab level, but at a different 
dilution - where the curves crossed -  the relative Ab level would appear lower (Kurstak, 
1985). With this in mind, it was ascertained whether dose response curves were parallel or not.
5.4.2.1.1 Method
The indirect ELISA was carried out on 3-monthly samples from 8  patients over the range 1:20 
to 1:40,960. Log linear portions of each curve were then plotted (Figure 5.5a) and following 
on from this, the means of gradients, with corresponding standard deviations calculated and 
plotted (Figure 5.5b)
5.4.2.1.2 Results
There was no significant difference between gradients of test samples based on observations 
rather than statistical analysis as shown below (Figure 5.5b).
V .
5.4.2.1.3 Interpretation
Hence, sample dose response curves were parallel and it is therefore possible to use 1 dilution 
in future assays.
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Figure 5.5. Panel A, Linear portions of 3-monthly samples serially diluted (1:20-1:40,960) for 
8 infants (0-12 mos). Each point represents duplicate adjusted (test-mock) OD readings. 
Each patient is represented by one colour; different markers depict various 3 monthly 
samples. Panel B, plot of gradients for these 8 infants. Bars denote standard deviation.
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5.4.3 Further characterization of log linear phase
Further analysis of the various dose response curves generated was carried out to ascertain the 
range of the log linear phase as age increased (0 - 1 2  months), as well as dilution ( 1 : 2 0  to 
1:40,960). Initially only cord and 3-month samples were investigated. It was noted that the log 
linear phase of the sigmoid curves fell between 1:80 to 1:2560 for cord or 0-month samples, 
the lower saturation zone occurring below 1:80 dilution; whilst for 3-monthly samples this 
saturation occurred later, at dilutions below 1:640. As such, a dilution of 1:100 was chosen as 
the working dilution as this occurred in the straight part of the curve, in other words, the 
portion where the highest sensitivity could be measured. To confirm the validity of this chosen 
dilution as age varied, additional analysis was carried out on the log linear portions of the 
remaining age groups. Only plots for cord bloods, 3- and 6 - month samples are depicted 
below, Figure 5.6a-d. Figure 5.6d is a plot for 1 patient as a typical example of the relationship 
of the linear portions of the 3 monthly samples; also shown is proposed working dilution of 
1 :1 0 0 .
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Figure 5.6. The linear portions of serially diluted (1:20-1:40,960) sera of selected patients. 
Panel A-C are cord, 3-monthly and 6-monthly sera respectively, panel D is a plot of 3 monthly 
samples of Pt 3720. Each point represents duplicate adjusted (test-mock) OD readings. In 
panel A-C the symbols represent the following patients: — Pt 3737; —1■— Pt 4132;
Pt 4102; Pt 3720; Pt 3865; Pt 3735. In panels A-D dashed line, -  -  • 
denotes 1:100 dilution (proposed working dilution).
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5.5 Reference/Standard Serum and Controls
RSV IgG positive sera from healthy Kenyan adult donors were identified during the ELISA 
procedure and shown to have different levels of IgG to RSV. Pooled adult sera, constituting 
reference serum was run as 6  doubling dilutions (1:50-1:1600) as single replicates per assay 
run. The 6 th adult serum collected constituted the control, and was run at 2 dilutions, 1:100 
(high control) and 1:400 (low control) in duplicate on each plate.
5.6 Lysate Preparation Optimization and Assay Troubleshooting
The experiments described above were carried out with lysate provided by Dr; Paul Scott. 
Subsequently, lysate prepared in the course of the project performed inconsistently. Great 
inconsistency between duplicate readings of test sera and especially between standards and 
controls on different plates was observed (Figure 5.7). Various batches of lysate were utilized 
to carry out analysis of all samples. Batches of lysate were either harvested on the same day 
but used to coat plates on different days, or harvested on consecutive days -  but were from the 
same parent cell line. On coating ELISA plates, it was subsequently noted that lysate drying 
rates varied from one well to the next, as well as from one plate to the next and could have 
contributed to some of the variation in OD readings noted. The variation in ELISA results 
could have also been due to the existence of very different concentrations of viral proteins 
despite the same total antigen concentration.
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Figure 5.7. Variation between assays for high and low controls together with respective 
mock/control under old assay conditions (respective Ag and mock/control OD readings 
indicated by same colour). He: high control; Lc: low control; Ag: antigen
Furthermore, the ELISA detects non-native antigens. Despite efforts taken to try and minimize 
manipulation during lysate production in order to conserve epitope structures, it was plausible 
that different degrees of conformationally relaxed or otherwise altered epitopes not typical of 
the virion were produced. Therefore, peptides representing regions of the molecule that are 
normally buried may have been exposed generating an antiviral response not typical of intact 
virus or protein and could have added to the variation described.
In an attempt to minimize assay variation, liberation of more viral antigen was carried out. In 
addition to using the non-ionic detergent NP40 that is known to have a solubilizing effect on 
cell membrane components (Helenius & Simons, 1975), lysate was disrupted by ultrasonic 
treatment with a sonicator at an output of 70% amplitude 3X lmin cycles with 1 sec pulse and
1 sec pause, as sonication had previously been shown to increase OD readings (Sarkkinen et 
al., 1981).
The permissive temperature (a temperature which permits optimal pathogen replication and 
hence growth) for RSV is said to be around 32°C (Broughan et al., 1997, Schnitzer et al., 
1976) and therefore it can be presumed that temperatures greatly above this will be non- 
permissive or restrictive, leading to diminished virus titres with the resultant production of less 
Abs. This too could have been a contributing factor to some of the low OD readings observed 
from time to time. Initially due to logistics, all cell cultures infected with the A2 isolate were 
carried out at the non-permissive temperature of 37°C, therefore infection was attempted at 
32°C and using the sonicated lysate, checkerboard analysis under the initial ELISA conditions 
was carried out again. This helped increase OD readings. However, different rates of 
evaporation from plate-to-plate and well-to-well still persisted.
In addition, the presence of Tween-20 in the block was omitted, however it was still retained 
in the washing buffer as low concentration of detergent are effective components of washing 
buffers, strongly inhibiting non-specific interactions
(http://www.kpl.com/technical/techdocsearch.cfin?tcat=3V PBS was also investigated as 
coating buffer. Plates were sealed to prevent evaporation, and coating carried out at various 
temperatures and for varying periods of time e.g. 4°C overnight, room temperature overnight, 
37°C for 4 hours etc. Incubation at 37°C overnight gave higher OD readings.
To further increase the sensitivity of the assay, apart from carrying out routine steps of 
optimizing the blocking solution, washing and incubation times or testing different plates,
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covalent linkages to plate has been suggested overcomes low level attachment of bound 
molecule which in turn gives low signal (http://www kpl.com/technical/techdocsearch.c f m ?tcat=3). 
The latter method was not investigated, but new ELISA plates, Nunc-Immuno™ MaxiSorp™ 
were tested as they comprise surfaces of high and uniform binding capacity 
(http://www.nalgenunc.co.jp/data/bulletins/Q6.htmT and in conjunction with the above 
modified conditions, it appeared that we had achieved inter- and intra-plate consistency. The 
coefficient of variance within plates varied between 6-7% and between plates was 6%. 
Moreover, a greater signal: noise ratio and consistently high OD readings for the high control 
were realized (Figure 5.8). Although there appears to be some decay with time with regards to 
the high control, this was not noted in the long term quality control of the controls for the full 
data set. The modified ELISA procedure can be found in section 4.5.2.7.
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Figure 5.8. Variation between experiments for high and low controls together with respective 
mock/control under new assay conditions (respective Ag and mock/control OD readings 
indicated by same colour). He: high control; Lc: low control; Ag: antigen
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5.7 Discussion
From the checkerboard analysis, the optimal dilution of the capture- solid phase antigen was 
1:64, whilst that of the rabbit anti-human IgG conjugate was 1:1000. Test sera were tested in 
duplicate at a dilution of 1:100. At higher serum concentrations, high background ODs from 
uninfected tissue culture control wells obscured readings from test wells. Furthermore, the 
sensitivity of the test was dramatically reduced on testing sera at low titres.
The prozone-like effect observed for some children was perhaps due to the presence of excess 
analyte or matAb in this case, that caused saturation of both specific and non-specific binding 
sites during antigen-Ab binding to the inert support (Killeen et al., 1993). When eventually 
desorbed, it could have attached to signal Ab thus preventing the formation of the ‘sandwich’ 
(Selby, 1999) and leading to the hook effect. Steric inhibition could also have occurred as a 
result of specific immunoglobulin attachment, the presence of non-specific inhibitors in 
human sera, or both. A 1:100 dilution appeared to capture the log linear phases of a majority 
of the 3-monthly samples tested and was therefore chosen as the appropriate dilution for 
assaying samples. Additionally at this dilution, the prozone effect was excluded. Also, as log 
linear phases of dose response curves for different children were shown to be parallel (Figure 
5.6a-b), the use of one dilution was representative of RSV IgG levels. Finally, background 
ODs remained low and readings were reproducible, although it was sometimes noted that an 
occasional serum reacted with control cell antigens to a similar extent as with the test RSV 
cells.
Thus, preliminary results from the assay detected rising titres between paired samples and 
therefore confirmed recent infection. In addition, both low and high Ab titres in paired
samples were measured by the assay. Dose response curves were observed to be 
approximately sigmoidal, and decay of matAb occurred over a period of 6  months to a 
minimal level.
It was decided therefore, that the ELISA had been optimized as far as possible, and hence 
extensive analysis of cohort samples, which constituted paired sera, 3 monthly and cord sera 
could be carried out and analyzed at a 1:100 dilution on appropriately coated ELISA plates. 
Under these optimized conditions, reference serum was to be run in parallel with the test 
samples, on every plate over a range over of 1:50-1:1600 that captured the log linear portions 
of dose response curves. Over this range, Abs could be measured at the highest sensitivities. 
The inclusion of standards allowed standardization of results and took into account both inter- 
and intra-plate variation possibly caused by the slow deterioration of coating antigen. 
However, reference serum would be run as single replicates. Controls were assayed in 
duplicate at 1:100 and 1:400 dilutions respectively.
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CHAPTER SIX
Characterization of RSV Strains Infecting Children from a Birth 
Cohort using Multiplex Polymerase Chain Reaction (mPCR)
6.1 Introduction
Two RSV groups were originally identified on the basis of reactions with monoclonal Abs 
(Anderson et al., 1985, Gimenez et al., 1986, Mufson et al., 1985). The protoypes of group A 
were identified as Long (isolated in 1956) and A2 , and for group B as CH-18537 (isolated in 
1962) by early investigators (Coates et al.,. 1963). Later, these groups were shown to be 
distinct at the nucleotide sequence level (Johnson & Collins, 1989, Johnson et al., 1987).
The G protein is the most variable protein between groups. Amino acid similarity of this 
protein from a group A and a group B strain was shown to be only 53% (Johnson et al., 1987), 
with the G protein displaying up to 20% amino acid variability for group A isolates and 9% 
for group B isolates (Cane et al., 1991, Sullender et al., 1991). It was therefore realized that 
heterogeneity existed within groups (genotypes or lineages), in addition to the variation earlier 
noted between groups. Group A genotypes were initially designated SHL1-6 (their 
corresponding NP groupings are shown in table 6.1) and group B genotypes NP1 and NP3 
(Cane & Pringle, 1991, Cane & Pringle, 1992). SHL groupings were designated by sequencing 
and NP groups by RFLP
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Table 6.1. Summary of SHL groups with corresponding NP groups (Cane & Pringle, 1991, 
Cane & Pringle, 1992)
SH lineage NP group Group
SHL 1,3, 4 NP 2 A
SHL 2 NP 4 A
SHL 5 NP 5 A
SHL 6 NP 4 A
Stockton et al. (1998) described a multiplex polymerase chain reaction (mPCR) assay and this 
has proved to be faster and more sensitive than conventional viral culture or antigen detection 
methods (Coiras et al., 2003). The assay distinguishes between A and B groups and uses a 
combination of several different primer pairs in the same amplification reaction with the 
objective of producing different specific amplicons that are easily discriminated between on 
the basis of their sizes.
We used a modified version of the method by Stockton et al (1998) and N primers as earlier 
described by Cane and Pringle (1991) to investigate the children in rural Kilifi community for 
RSV during 4 consecutive epidemic periods (2002-2005). The 4 epidemics occurred as 
follows: Epidemic 1: 01 Mar-31 July 2002; Epidemic 2: 01 December 2002- 30 April 2003; 
Epidemic 3: 01 January- 31 July 2004 and Epidemic 4: 01 November, 2004- 30 April 2005. 
Viruses were characterized into group, and variability within the groups was assessed by 
RFLP of amplified N gene products.
6.2 Objective
To analyze the strain variation of RSV isolated from NW of children recruited to the birth 
cohort using the methods of mPCR and RFLP as a means of characterizing the circulating
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strain(s) and hence, the molecular epidemiology of RSV in the community during each 
epidemic. Additionally, the genotypic variation in RSV strains causing infection in the birth 
cohort (which were generally non-severe) was compared with those causing severe disease 
requiring admission to KDH,
6.3 Methods
Briefly, the assay has two main stages: firstly, nested mPCR was carried out on extracted 
RNA to distinguish between RSV A and B, and secondly, a round of N gene PCR was carried 
out. The final analysis was carried out by RFLP of N gene PCR products and this allowed for 
delineation of groups on the basis of the NP typing patterns (motifs) or lineages as previously 
described (Cane & Pringle, 1991, Cane & Pringle, 1992). For a detailed description of the 
method, refer back to the molecular assays (Section 4.5.3). There were 2 types of NW RSV 
positive samples as defined below that were identified and analyzed.
6.3.1 Definitions
•  Symptomatic IF AT confirmed NW samples were identified during passive and active 
surveillance and subsequently prompted collection of acute and convalescent sera 
samples one month apart (Section 4.2.2),
• ELISA confirmed NW samples were identified upon completion of analysis of all sera 
samples by ELISA. On visual confirmation of rising titres within epidemics in which 
no positively confirmed IF AT results existed, all NW samples collected from the 
beginning of the epidemic up to the peak of the rise in titre were typed.
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Figures 6.1 shows a schematic of the points where NW samples had been collected during 
ARI surveillance, and found to be IF AT negative. These were later retrieved from archives for
further testing by mPCR.
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Figure 6.1. A schematic indicating points at which NW samples (those that were IFAT 
positive and those collected weekly in epidemic period between 2 consecutive 3 month 
samples that showed ELISA confirmed serological response) were identified for further 
analysis of RS viruses by mPCR
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6.4 Results
6.4.1 Clinical specimens
During the entire 4 years of follow up, which amounted to a total of 926 child years of 
observation, of the 8717 episodes of ARI requiring a NW, 97% (8493, Appendix IX) were 
taken. The remaining 3% were not taken due to various reasons including refusals by the 
infant’s mother, discomfort of the child and failure to collect adequate sample after 2  attempts. 
NW samples were processed as soon as possible upon being brought into the laboratory. This 
allowed for feedback to the field workers for follow-up. RSV project laboratory staff tested 
these samples. A total of 457 (5%) and 7,905 (93%) samples were identified as being positive 
and negative by IF AT, respectively, and the remainder equivocal (110) or untested (21) 
(Appendix IX). Subsequent screening of birth cohort sera by anti-RSV ELISA confirmed a 
majority of these antigen positive cases (IFAT confirmed serological responses, IFAT-CSR), 
and picked up additional IF AT negative but serologically positive samples (ELISA confirmed 
serological responses, ELISA-CSR). This will be discussed further in chapters 7 and 8 . To 
further investigate the the exact date of infection and virus strain responsible for 
seroconversions that were noted between 2 consecutively collected 3 month samples, 80 NW 
samples collected around this time (Figure 6 .1 ) were also analyzed by PCR.
Most cases of RSV infection observed from 2002 to 2005 were diagnosed in the first half of 
each year, with the peaks of the epidemics occurring at varying times, i.e. May/June 2002; 
February 2003, April/May 2004 and February 2005 respectively,
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6.4.2 Processing of IFAT positive NW specimens
6 8 % of IFAT positives yielded mPCR products. IFAT positive/mPCR positive samples were 
further analyzed by molecular techniques for genotype. A typical gel depicting bands detected 
from IFAT positive NW samples is shown in Figure 6.2. Both RSV A and B were identified.
Primer
dimers
Figure 6.2. An example of a typical gel showing RSV typing of IFAT positive NW clinical 
specimens by mPCR. Lanes 1-7, clinical specimens; lanes 8 and 9, are positive and negative 
controls respectively. Lanes 1, 3, 6 and 8, RSV group A; Lanes 2 and 4 RSV group B. Lane 
M, molecular size marker. Numbers on the left are in base pairs.
Following the screening process, N gene PCR was run on 1st round amplicons/products of 
positively identified NW samples. RFLP was carried out on the PCR products for further 
identification of infecting genotype. The resulting banding patterns obtained following 
digestion by the five restriction enzymes, Hind m , Pst I, Bgl II, Hae HI and Rsa I comprised 
the NP typing patterns (Table 6.2).
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Table 6.2. N gene fragment restriction digest patterns (Cane & Pringle, 1991)
NP group Enzymes (cut = +; Uncut = -) RSV A or B 
type
Hind III Pstl Bgl II Hae III Rsa 1
NP1 - - - - + B
NP2 - - - + + A
NP3 - - + - + B
NP4 - - + + + A
NP 10 - - + + + A
NOVEL - - - + - A
The table shows how the 5 restriction enzymes loaded in this order on the gel i.e, Hind III, Pst I, Bgl II, 
Hae III and Rsa I cut the N gene PCR products for the NP types detected in this study.* depicts 
digestion by Rsa gives 3 bands compared to the 2 bands formed following Rsa digestion in NP4 
pattern.
A novel banding pattern was observed in epidemics 1 and 4. This banding pattern is shown in 
Figure 6.3 below. This figure shows typical RFLP results on a selection of positive samples 
identified in Figure 6.2; the banding pattern for the positive control is also shown. Typical 
NP4 pattern is shown for 2 patients in Row A, lanes 1-5 and 7-11. The positive control was 
also an NP4 banding pattern, Row B lanes 13-17. Typical NP3 pattern for 2 patients is shown 
in Row A lanes, 13-17 and Row B, lanes 7-11. The novel banding pattern for 1 patient is seen 
in Row B, lanes 1-5.
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Figure 6.3. Gel showing NP typing patterns obtained following N gene PCR and RFLP of 
positive nested PCR samples (positive 1st round amplicons from samples and control 
identified in Figure 6.2). Row A, lanes 1-5, 7-11 and 13-17 are restriction of PCR products 
from individual patients of banding patterns NP4, NP4 and NP3 respectively. Row B, lanes 1- 
5, 7-11 are individual patients of banding patterns Novel and NP3 respectively, and lanes 13- 
17 depicts the control, NP4 banding pattern. The enzymes used in lanes 1, 7, 13 was Hind III; 
lanes 2, 8, 14 was Pst I; lanes 3, 9, 15 was Bgl II; lanes 4,10,16 was Hae III and lanes 5,11, 
17 was Rsa I. Lane M, molecular size marker. Numbers on the right are in base pairs.
6.4.3 Distribution of variants during epidemics
The following sections describe RSV variants from IFAT positively identified NW samples 
that were characterized in each epidemic.
6.4.3.1 Relative prevalence of RSV groups
Ninety-eight percent (271/276) of isolates identified from infants, during epidemic 1 were 
from RSV group A. In the next epidemic, RSV A and B co-circulated in relatively equal 
proportions, whilst in epidemics 3 and 4, 100% (252/252) RSV A and 98% (122/124) RSV A 
were detected respectively as shown in Table 6.3.
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6.4.3.2 Strain typing by RFLP
The results of N gene RFLP typing further demonstrated that the epidemics were not 
homogeneous (Table 6.3). The majority of group A samples were genotyped as NP4, and NP3 
comprised the majority of group B. Group A samples consisted of 4 N gene banding types all 
of which were present in the first epidemic, with both group B types being observed in 
epidemic 2. During the 1st’ 3rd and 4th epidemics, NP4 was the most dominant strain, whilst 
NP4 and NP3 co-circulated in equal proportion in the 2nd epidemic. The relative proportions 
of both group A and B strains are shown in Table 6.3. The proportions of RSV strains isolated 
from cohort infants were compared with those isolated from inpatients at the KDH (Figure 
6.4).
Table 6.3. Numbers (proportions) of RSV A and B, and NP types in each epidemic isolated 
from cohort infants
Total RSV-A NP Pattern RSV-B NP Pattern
Total
Positive
Epidemic
#
NW
tested
NP2 NP4 Novel NP 10 Total
RSV-A
(%)f
NP1 NP3 Total
RSV-B
(%)f
1 540 64 195 10 2 271
(98)
5 5
(2)
276
2 228 84 84
(52)
2 76 78
(48)
162
3 444 1 251 252
(100)
252
4 337 102 20 122
(98)
2 2
(2)
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rTotal percentage values for RSV A and B N gene based on proportion of the total N gene RT-PCR 
positive samples (final column) rather than total samples tested
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Figure 6.4. Proportions of NP typing patterns in Kilifi District in KDH inpatients (a) and the 
community, birth cohort (b)
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6.4.4 The effect of strain variation on disease outcome
It was noted that disease severity was not affected by circulating strain. With respect to infants 
recruited within the birth cohort, the same strain was seen to cause both URTIs and LRTIs as 
noted in Table 6.4, however, not much can be deduced on the effect of strain variation on 
disease outcome due to the small number of children who went on to experience RSV- 
associated pneumonia.
Table 6.4. RSV-associated disease with strain as depicted by the N digest pattern in children 
< 6 mo of age
N digest 
pattern No/URTI
Pneumonia status 
Mild Severe Very severe
New 0 1 0 0
NP2 10 2 4 0
NP3 5 2 1 0
NP4 16 17 23 1
Total 31 22 28 1
It was noted NP4 was the most dominant strain in infants, aged 0-4 months, recruited in the 1st 
round (cohort 1). NP2 and NP3 were also identified, but at reduced levels. In the following 
seasons NP3 and NP4 co-circulated in both sets of children. However, NP3 was observed to 
infect all age groups (cohort 1: 0-2 months and cohort 2: 6-13 months) whilst NP4 was 
restricted to older children of cohort 1. As more epidemics were experienced, NP4 was seen to 
be the most abundant isolate in all age groups, children from both phases of the cohort being 
affected (Figure 6.5).
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Figure 6.5. Strain variation with age for children recruited to both phases of the cohort 
throughout the 4 epidemic periods, (a) depicts epidemic 1 (b) epidemic 2 (c) epidemic 3 and 
(d) epidemic 4 (d), respectively. The different strains identified were New ■, NP4 ■ , NP3 ■ , 
NP2 ■ and NP1B
6.4.5 Processing of NW specimens identified from an ELISA-CSR
Only NW samples collected, within an epidemic, following identification of ELISA-CSR 
between 2 consecutive 3 month samples (see Figure 6.1) were tested. Eighty NW samples 
were identified from these defined periods and further tested by mPCR. Despite repeated 
attempts, none were shown to be positive.
To further investigate the detection limit of IFAT positive samples by RT-PCR as a proxy for 
detection of amplicons in ELISA-CSR positive samples, 4 known IFAT positive NW samples 
were tested in parallel with 1 RSV A HEp-2 culture positive sample. Five 10-fold serial 
dilutions were carried out on the 4 samples, with five 5-fold serial dilutions being carried out 
for the positive control. The results are illustrated in Figure 6.6. Some faint bands could be
142
seen in the diluted culture sample up to a dilution of 1:3125; the clinical specimens were 
positive at dilutions of 1:10 (3 samples) or only neat.
ROWB
Figure 6.6. Serial dilution of IFAT and culture positive samples as a means of working out detection 
limit. Row A, lanes 1-6, lanes 7-12, lanes 13-18 and Row B, lanes 1-6 are 4 individually serially diluted 
positive clinical specimens. Row A, lanes 1, 7, 13 and Row B, lane 1 depicts the undiluted sample, 
successive lanes are 1:10, 1:100, 1:1,000, 1:10,0000, and 1:100,000 dilutions respectively of that 
sample. Row B, lanes 7-12 is RSV A HEp-2 culture positive; in which Row B, lane 7 is the undiluted 
culture, successive lanes depict 1:5, 1:25, 1:125, 1:625 and 1:3125 dilutions respectively. Row B, lane 
13 is positive control; Row B, lanes 14-15 are the negative controls. Lane M is molecular size marker. 
Numbers on the left are in base pairs.
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6.5 DISCUSSION
The study presented here was designed to assess RSV variability over a period of 3 years of 
follow up per child in a rural community in coastal Kenya. Analysis of the diversity of RSV 
was monitored by a birth cohort and compared to in-patient samples. The samples analyzed 
were collected from infants or children exhibiting > 1 signs of acute cough, difficulty in 
breathing or nasal congestion/discharge, observed or elicited by the history from the preceding 
week. As there was a lack of infrastructure initially, it was not practical to culture viruses. It 
should also be noted that although RFLP analysis proved to be relatively easy to perform, it 
has been said that the genotypes obtained by this method provides limited information 
(Kuroiwa et al., 2004). G gene analysis by the method of DNA sequencing in contrast, would 
give a more definitive identification of RSV genetic variability within groups. This method 
however had not yet been set up in Kilifi, and as such, G genotyping and sequencing were not 
undertaken. Despite this, the mPCR still proved useful in facilitating molecular analysis of 
available clinical specimens in-house allowing for characterization of RSV circulation patterns 
in communities as previously described (Mufson et al., 1988, Sato et al., 2005).
The nested RT-PCR was found to be reasonably sensitive (detecting up to 6 8 % of IFAT 
positive NW samples). The 32% of samples not detected however, implies that the circulating 
genotypes were most likely underestimated. Additionally, the tendency of RSV B being less 
likely to be detected than RSV A, could have accounted for part of the 38% negative samples 
and thus may have been systematically biased. Furthermore, the assay was noted to be 
specific, i.e. there was no cross-reaction with non-RSV specific primers i.e. flu primers. The 
presence of five primer sets within the reaction mixture, did not compromise the RT-PCR 
assay detecting all virus types tested. This allowed for the classification of RSV to groups,
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when archived specimens, frozen within 24 hr from collection, were tested. Viruses were 
further characterized by RFLP of amplified N gene cDNA products revealing additional 
genetic variability within each group, with 3 to 5 restriction patterns observed during each 
period
By virtue of the existence of RSV strains, outbreaks caused by genetically distinct strains can 
follow an outbreak caused by a single strain (Hall, 1999, Imaz et al., 2000, Walsh et al., 1997)
as was noted in epidemic 3 in which the outbreak genotype was NP4, following an epidemic
v
of multiple genotypes (NP4 and NP3). Furthermore, it was observed that there was hardly any 
NP3 (group B) in the first season, whilst in the subsequent season, there were more infections 
being caused by this strain. Similar variability was previously described in other studies 
(Anderson et al., 1991, Cane et al., 1994, Hendry et al., 1989). Our results therefore provided 
further support for genotype designation by RT-PCR methods as an effective tool for the 
characterization of circulating RSV within communities, as previously observed (Anderson et 
al., 1991,'Cane, 2001, Cane et al., 1999, Hall et al., 1990, Imaz et al., 2000, Loscertales et al., 
2002, Roche et al., 2003, Venter et al., 2002, Wang et al., 1995, Wilcox et al., 1991).
From our study over the 4 year time span, no significant differences were observed in strain 
distribution between community cases and severe inpatient cases, the same strain seen to cause 
both URTIs and LRTIs. Previously, Coiras et al. (2003) performed analyses on RSV 
variability on isolates from hospitalized babies. They argued that it had not been proven that 
these samples were entirely representative of the virus that is generally circulating in the 
community. However, it appears from our study, data with regards to isolates from
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hospitalized infants, whom constitute a very selective group of patients, can be extrapolated 
back to the community and epidemics as a whole.
Analysis of NW samples from all 4 epidemics revealed that RSV A (NP4) was the 
predominant group as previously described (Morgan et al., 1987, Peret et al., 1998, Venter et 
al., 2001, Rajala et al., 2003). Genotype variability was described for both group A and B 
RSV, although to a lesser extent for group B. Additionally, both RSV groups were observed to 
co-circulate in the 2nd epidemic. The genotypes identified in this epidemic were NP3 and 
NP4. Co-circulation of RSV isolates have been previously documented by numerous authors 
(Cane et al., 1999, Coggins et al., 1998, Mufson et al., 1988, Peret et al., 1998). This 
predominance ofNP4 in all epidemics may have been an artefact due the low sensitivity of the 
nested RT-PCR noted above, or its inability to consistently detected RSV B. However, when 
RSV B was detected, the actual prevalence of strains varied, and due to these observed 
differences, it is suggested that separate and independent circulation of group A and B RSV 
isolates occurs (Hendry et al., 1986). Moreover, this genotype displacement or shift in RSV 
strains is consistent and thus suggests that it is an important feature of the epidemiology of 
RSV infections. A higher sensitivity of detection of RSV in clinical samples could be obtained 
by a combination with additional techniques* such as virus cultivation.
During the first epidemic Jhat comprised infants recruited to the 1st cohort, it was noted that 
NP2 and NP4 strains were common, with NP3 strains circulating at very low levels (Figure 
6.5a). In this regard, matAb levels in the community to these abundant strains were probably 
boosted (herd immunity), leading to what seemed like effective protection for children bom 
and recruited to the 2 nd cohort as none of the infants < 6 months of age in the subsequent
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epidemic season experienced infection caused by either NP2 or 4 (Figure 6.5b). This was as 
similarly noted in previous studies (Ward et al., 1983) where the authors illustrated that 
mothers of protected babies had significantly higher levels of a specific virus-specific protein 
that was also described in infant sera. It was therefore possible that the circulating strain in the 
previous epidemic comprised this virus-specific protein, culminating in boosting of specific 
maternal titres, and thus an efficient maternal-foetal transport mechanism allowed for the 
protection of these babies from strains displaying a protein that offered cross-protection. The 
role of RSV-specific matAbs will be further explored in chapters 7 and 8 .
These temporal patterns in RSV group dominance and genotype predominance displacement 
have been observed to vary between locations (Cane et al., 1991, Cane & Pringle, 1992, Hall 
et al., 1990, Loscertales et al., 2002, Peret et al., 1998, Venter et al., 2001). At the local level, 
it might be that the varying patterns of dominance are suggestive of immunity, associated with 
the presence or absence of matAbs which in turn dictates susceptibility of the child with 
respect to infection by homologous or heterologous genotypes. It is likely that the multiple 
lineages seen during epidemics emerged under the influence of immune responses in the 
different communities (Cane & Pringle, 1995) leading to an inadequate immune response due 
to virus evasion of the immune system. The impact of antigenic diversity on RSV 
epidemiology is not fully understood, but may in part explain susceptibility to re-infection 
throughout life and yearly variation in the severity of epidemics within communities (Cane et 
al., 1994). In this study, the same genotypes were identified both in the community and in­
patients. Given the confusing relationship between Ab status, strain variation and re-infection, 
it is clear that additional longitudinal studies are required for investigation of the transmission 
dynamics of RSV as early information about RSV variants causing disease might help the
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clinician decide on appropriate therapy, especially in younger infants. This is further 
discussed in the chapter 7, in an attempt to try and assess the dynamics of maAbs in the first 
year of life, as well as to characterizing the association of the presence or absence of matAb 
and acquired immunity with circulating strain in Kilfi.
None of the 80 NW samples collected following ELISA-CSR gave any RT-PCR products 
despite repeated attempts. Plausible explanations for the negative PCR results could be due to 
the presence of low viral copy number in clinical sample, presence of viral inhibitors and poor 
specimen handling or collection (Henrickson, 2004). The most likely explanation however is 
that the presence of very low levels of virus in secretions, in addition to the low detection limit 
observed for positive samples (Figure 6 .6 ). Furthermore, the series o f ‘freeze- thaw’ steps that 
occurred between nasal sample collection and RT-PCR processing, could have contributed to 
the degradation of low-level RNA. The detection limits of the RT-PCR could be improved 
further, especially in patient groups exhibiting low titres of RSV, and in environments in 
which optimal conditions of sample collection, storage and transportation are not available 
(O'Shea & Cane, 2004) by the use of real-time PCR. Therefore, real time PCR may therefore 
be suitable in aiding detection of low levels of virus as in this case.
In summary, the data obtained from this study provides additional evidence of variation in 
RSV strains that is probably an important feature of the epidemiology of RSV infection (Peret 
et al., 1998). There appears to be yearly replacement of the most common genotype, the 
genotypes predominating in one year usually becoming less abundant the following season. 
The mechanism that accounts for this however, still remains unclear. It has been suggested 
that the combination of local factors e.g. herd immunity to the previous circulating/prevalent
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strain, and possible fitness of the circulating virus, together with global spread have an impact 
on circulation of strains in a community (Madhi et al., 2003, Peret et al., 1998). Certainly the 
relationship between viral genetic variation, infection/disease and transmission will add to this 
complex relationship (White et al., 2005). In this respect, successful variants may persist and 
remain dominant for more than one season as seen in the years 2004 and 2005 in Kilifi where 
NP4 (RSV A group) predominated. Also, as group A viruses were seen in all 4 epidemics, the 
higher variability displayed in this group may have an added advantage allowing for its higher 
worldwide predominance (Anderson et al., 1991, Cane et al., 1994, Hall et al., 1990, Imaz et 
al., 2000). Finally, this study highlights the fact that RSV epidemiology is similar to those 
taking place around the world, although some distinct clusters were described (Scott et al., 
2004).
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CHAPTER SEVEN 
The level and duration of RSV-specific maternal IgG and its 
association with risk factors in infants in Kilifi, Kenya
7.1 Introduction
Current knowledge and possible limitations, with respect to RSV-specific matAb levels and 
the characteristics of the loss of matAb, are described in chapter 3. Briefly, infants acquire
tktransplacental matAb from the 28 week of gestation (chapter 3). At delivery, cord blood 
levels of IgG (both total and specific IgG) reflect those of the mother. Maternally derived 
specific Abs have been demonstrated to provide protection from infectious diseases including
c_
RSV (Brandenburg et al., 1997, Caceres et al., 2 0 0 0 , Glezen et al., 1981, Ogilvie et al., 1981, 
Roca et al., 2002). Various factors have also been identified that affect matAb levels and 
hence the efficiency of placental transfer. These factors were previously discussed (Section 
3.2.3) and include: newborn GA, maternal malaria, maternal nutritional status, maternal 
exposure to RSV (this indirectly can be extrapolated to when the child is bom), maternal HTV 
status (if the child’s status at birth is known, one can then extrapolate back to the mother’s 
status). In the present study, the effect of the following risk factors on matAb decay and cord 
titres were investigated using multiple linear regression analysis (Ab titres on age variable in 
days): cord blood levels (divided into quartiles), birth order (divided into 3 levels, 1, 2 and 3 
being representative of 1st- 3rd birth, 4th-6th birth and > 6  births respectively), birth weight level 
(divided into 2 levels, less than and greater than 2.5kg) and birth in or out of an epidemic 
period
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The durability of the immune response was investigated through changes with age in 
proportion with total IgG and this allowed for the decay rate or T1/2 of RSV specific matlgG 
(this being the time taken for Ab concentration to decrease to half) to be calculated.
7.2 Objectives
The objectives of this chapter are:
• to describe the main characteristics of the study group;
• to investigate cord blood levels of children who experienced an infection and those 
who did not under 6  months of life;
• to define a cut-off value for RSV seropositivity for the whole population;
• to present a simple model for the rate of decay of RSV-specific matAbs;
• to fit a simple model to age prevalence data; and
• to investigate the effect of risk factors on both cord titres and rate of decay.
7.3 Definitions
• - Ab titres were reported as standardized arbitrary units (AU). As the concentration of
standards was unknown, the lowest dilution, 1:50, was arbitrarily assigned a value of 
1 0 0 0  AU and the remaining diluted standards appropriately designated.
• Seroconversion was defined in two ways (i) as at least a 2-fold (0.3 log AU), and (ii) as 
at least a 4-fold (0.6 log AU) or greater rise in titres between 2 samples collected 
consecutively.
• IF AT confirmed serological responses (IFAT-CSR) were defined as seroconyersions 
occurring between acute and convalescent sera collected approximately 1 month apart 
on identification of IF AT positive NWs.
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• ELISA confirmed serological responses (ELISA-CSR) were defined as 
seroconversions occurring between two consecutively collected samples that included 
both 3 month and acute/convalescent sera.
• Seropositivity was defined as an Ab titre of >1.495 log AU.
The matAb prevalence and the effect of risk factors were thus assessed on the seropositive 
population up to 6  months of life. To ensure that only matAbs were measured, infants with any 
evidence of IFAT-CSR or ELISA-CSR at either seroconversion levels were excluded and the 
‘pristine’ rate of decay for the seropositive population, together with effect of risk factors 
calculated.
7.4 The analysis procedure
This involved the following steps.
(1) Undertake regression diagnostics as a means of ensuring that the model chosen fitted 
the population.
(2) Identify further outliers by plotting histograms of gradients of children under 6  month 
of life (population to be used in calculating RSV-specific matAb decline).
(3) Establish cut-off values of seropositivity in the population, and confirm validity of 
these values by investigating their placement in frequency distribution plots.
(4) Investigate duration of seropositivity at a cut-off level of 1.5 (defined from the assay 
and 28% of the population was seronegative) and 2.0 (where 50% of population was 
seronegative).
(5) Calculate ‘pristine’ rate of decay of RSV matAb by omitting children who experience 
any infection- both IF AT- and ELISA-CSR in the first 6  months of life. This gave 2
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groups- infected and non-infected populations that were subsequently investigated 
together with the association of possible risk factors using,
a. Student’s t-test
b. Linear regression analysis to control for mutiple risk factors and confounders
(6 ) Investigate cord blood titres in the 2 above groups using
a. Student’s t-test
b. Linear regression analysis
\
7.5 Methods/Statistical Analysis
All data analysis was undertaken using Stata 9.0™. The concentration of RSV-specific Abs (in 
AU) in infants was determined using a modified ELISA method (Wilson et al., 2000) as 
earlier described (section 4.5.2.5). The data are highly positively skewed and as a result all 
analyses were carried out after the transformation of anti-RSV Ab serological levels from 
arbitrary units (AU) to logio AU. All log values are to the base 10 unless otherwise indicated.
A cut-off value for seropositivity was determined by the following two methods below:
(1) From observations of Ab decay curves of individual infants: it was observed that 
matAb levels reached a minimal level by 5-6 months of age. Therefore, the mean of 
Ab titres ± 2SD within this age bracket for individuals in the population who did not 
experience any IF AT positively identified infection in the first 6  months was 
calculated.
(2) From the ELISA assay: this was calculated as the point at which the assay could detect 
the highest titre without specificity being compromised. Pooled adult sera (standard)
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were assayed 4 times in duplicate over a dilution range of 1:25 to 1:51200 in 2-fold 
steps.
Passively acquired IgG is subject to an exponential decay rate (Sato et al., 1979). Therefore, 
RSV-specific matAb decay was calculated using the linear regression model. Several 
assumptions underlie the linear regression model and have to be taken into consideration 
before analysis. They include the following:
(1) Each observation should be independent of the others.
(2) The values of the outcome variable, Ab titres in log AU follow a Normal distribution.
(3) Variability in Ab titres (log AU), as assessed by the variance or standard deviation, 
should be the same for each value of age.
(4) The relation between the 2 variables, Ab titres (log AU) and age should be linear.
(5) There is homogeneity of variance or the error of the variance is constant 
(homoscedasticity).
Non-violation of these assumptions of regression was investigated using regression 
diagnostics. With regards to modeling the parameters (Section 3.3 for more details) with Ab 
titres (log AU) as the response variable and age under 6  months as predictor, linear regression 
was first undertaken on the whole data set, then this population was split into 2 : non-infected 
(those who did not experience any infection, IF AT- or ELISA-CSR, infections under 6  months 
of age) and infected (those who experienced at least 1 infection, IF AT- or ELISA-CSR, 
infection under 6  months of age). Infections were defined using both seroconversion levels, 2- 
and 4-fold change in Ab titre. Furthermore, analysis was carried out on the entire population, 
which included both the seropositive and seronegative populations (so as not to bias the
outcome). However, with regards to the seronegative population, Ab titres below 1.459 log 
AU were adjusted to 1.224 log AU (the mean of the seronegative population, Appendix XIa).
Initially data were analyzed independent of possible hierarchy within the data i.e. 1-level 
models where measurement error was the only possible source of uncertainty. However, as 
there were multiple measurements on individuals, there was a possible lack of independence 
between repeated observations. We attempted to account for this clustering by using random 
effects data regression models (XT models, ST AT A™ 9.1 www.stata.com). Finally, as there is 
a significant dependence of Ab titres on age, as well as on other risk factors, a multiple linear 
regression analysis was carried out to examine whether their effects significantly improved the 
model fit. The differences were further investigated in the under 6  month population using the 
Student’s t-test, the level of statistical significance being set to P=0.05. The main variables 
(all categorical) studied inclusive of age were: (i) cord levels, (ii) weight at birth, (iii) whether 
the child was bom in or out of an epidemic and (iv) birth order of child. All main effects of 
these variables were examined in a forward regression model. During the modelling process, 
variables that did not substantially (P>0.05) increase the fit of the model based on an increase 
in adjusted R2 (goodness of fit) were omitted.
All results reported are for the seropositive (as defined above, Ab titres > 1.495 log AU) 
population. Two-fold seroconversion levels will be compared to the commonly reported 4-fold 
level.
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7.6 Results
7.6.1 Descriptive Analysis of study population
From the 503 infants who were analyzed, a total of 361 cord bloods, 2,777 three monthly sera 
samples, 295 acute and 272 convalescent blood samples were collected.
Table 7.1. General characteristics of the cohort
Characteristics Frequency Percent
Sex: Male 314 49.45
Female 321 50.55
Weight at birth (kg): < 2 27 4.77
2-3 270 47.70
3-4 261 46.11
> 4 8 1.41
Birth order: 1st 142 28.7
2 nd 105 21.3
3rd 74 15.0
4th 73 14.8
5th 41 8.3
> 5 59 11.9
7.6.2 Determination of cut-off for seropositivity
From observations of Ab decay curves of individual infants it was observed that Ab titres 
reached a minimum level at 5 months. Therefore, the average Ab titres at 5 months for the 
population of infants who did not experience any infection within the first 6 months, was 
calculated as 1.55 (±0.47) log AU. The high and low cut-off values were calculated as being 
2.49 and 0.61 log AU respectively. However, at this cut-off level for seropositivity, the 
negative and positive sera could not be clearly distinguished.
From the ELISA assay, the linear portion of the standard curve was identified as occurring 
between dilutions 1:50 (arbitrarily assigned 1000 units, or AU) and 1:1600 (31.25 AU) as
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shown in Figure 7.1. We therefore made the assumption that 31.25 AU (1.495 log AU) is 
about at the lower limit of sensitivity of the assay and therefore took this as the cut-off for 
seropositivity. This is the cut-off value that is used throughout the analysis, unless otherwise 
stated.
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Figure 7.1. Two-fold serial dilution carried out on pooled adult sera lower threshold cut-off 
indicated. Each dilution was carried out in duplicate and the experiment carried out in 
triplicate. The error bars denote standard deviation.
7.6.3 Frequency distribution of RSV-specific antibody titres
The cut-off for seropositivity from the ELISA assay was confirmed from the bimodal 
frequency distribution of Ab titres of all sera (Figure 7.2a). Additionally this seropositive cut­
off was investigated by age group (Figure 7.2 b-c). The frequency distribution of Abs is 
approximately a log-normal distribution. It was noted that the major region of RSV matAb 
decay occurred below 6  months of age. The higher and increasing proportions of infants with 
acquired RSV-specific Abs occurred after 12 months of age.
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Figure 7.2. Frequency distribution of antibody titres (log AU) for the entire population (a) and 
for the population by age groups in months (b & c). Cut-off between seropositive and 
seronegative is shown by dashed red line at around 1.5 (log AU).
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It should be noted that the number of samples in each month of age was very variable, but 
predominantly at cord, 2, 5 months etc because of the 3 monthly sampling regimen.
7.6.4 Duration of RSV seropositivity
The age seroprevalence profile for the whole population excluding known IFAT-CSR is 
depicted below in Figure 7.3a. At the cut-off level (1.495 log AU) for seropositivity, it was 
noted that the seronegative population comprised 28% of the total. At birth 97% of infants 
were bom with RSV-specific matAbs, which appeared to gradually decline with time, 
eventually reaching a nadir of approximately 35% at 8-9 month. Thereafter, the proportion 
seropositive rose quite rapidly to 50% at 10-12 months, and to 92% by the time infants 
attained 31-36 months of age (Figure 7.3a),
age (mo) age (mo)
Figure 7.3. Age-seroprevalence profile (a) at assay cut-off level of seropositivity, 1.49 log AU 
and (b) at a cut-off of seropositivity of 2.0 log AU. Numbers indicated above each bar are 
number of children seropositive per total children in each age group.
If the level of seropositivity was raised to 2.0, where 50% of the population was defined as 
being seronegative, then the proportion of infants at birth with RSV matAbs dropped to 94%. 
By 5 months of life only 7% of children remained seropositive and a low average of
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approximately 12% in ages 5-10 months. Above 12 months of age, there was a steady 
increase in the proportion seropositive with age, presumably acquired from infection, with 
70% in age group 25-35 months.
7.6.5 Characterization of RSV-specific antibody
7.6.5.1 Concentration o f RSV-specific antibodies with age
The mean Ab titre for seropositive infants is depicted in Figure 7.4. It was noted that matAb 
declined over the first six months of life to a minimum mean Ab titre level of 62.85 (sd± 2.15) 
AU; thereafter, there was a rise in titres (acquired immunity) over time. From the scatter plot 
of Ab titres with age for the < 6  month old infants, it was seen that Ab titres for the majority of 
infants, Ab titres declined with time. As infants became older, an increase in Ab titres was 
observed, and by the time infants attained 24+ months, the majority had Ab titres above the 
cut-off level of seropositivity. RSV-specific Ab titres for all samples and by different age 
groups are shown in Figure 7.5 a-e.
D>o_J
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Figure 7.4. Mean antibody titres for all samples defined as seropositive by age. The vertical 
lines indicate the variance.
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Figure 7.5. Scatter plots of RSV-specific antibody levels (log AU) for all samples (a) and by 
age group (b-e) for cohort children in Kilifi, Kenya. The cut-off for seropositivity is depicted by 
the dashed red line (log AU=1.495).
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7. 6.5.2 Analysis of the antibody response model
As the rate of decay of matAb was assumed to occur exponentially in this population, a linear 
regression model was used on all the data points for children less than 6 months of age 
irrespective of whether they experienced an IF AT- or ELISA-CSR (Figure 7.6) and the rate of 
decay calculated.
CM
150 2001 0 0  
Age (days)
0 50
Figure 7.6. Scatter plots of Ab titres (log AU) during the first 6  months of life with predicted 
line of fit (maroon line) by simple linear regression (rate of decay (slope), m=-0.008 log 
AU/day; intercept, c=2.928 log AU)
To calculate the ‘pristine’ rate of decay in the seropositive population, infants who 
experienced at least 1 infection, whether IFAT-CSR or ELISA-CSR at both seroconversion 
levels, were excluded. This gave 2 population groups- non-infected and infected population 
(refer back to section 7.5) A random effects mixed model to account for the multiple 
measurements per child, was used, in which both the random effects (RE) and the fixed effects 
(FE) approach were compared to each other. No significant difference occurred between 
outcome measures by these two types of models, and hence the RE model was employed for 
all subsequent analysis.
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The ‘pristine’ half life (T1/2) in days of RSV-specific matAb for the seropositive population 
was 79 days (95% Cl: 75.8, 81.4) whilst the mean duration (in days) of RSV-specific matAbs 
was 113 (95% Cl: 109.3, 117.4) when infections were omitted at the 4-fold seroconversion 
level. These values were seen to be similar to the non-infected population in which infections 
at the 2 -fold level were excluded and for the whole population group which was inclusive of 
infections at either seroconversion levels (Table 7.2).
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7.6.6 Identification of outliers
7.6.6.1 Regression Diagnostics
Regression diagnostics allows for the verification that the data set meets the assumptions 
underlying linear regression Additionally, this also allowed for. the investigation of the 
effects of possible outliers, observations with large residuals, as well as and for their influence 
on the analysis (http://www.ats.ucla.edu/stat/stata/webbooks/reg/chapter2 /statareg2 .htm; 
Altman, 1991). An observation is said to be influential if by removing it from the regression 
model, it results in substantial changes in the estimate of coefficients. This is not a strict 
assumption of regression but such extreme values can have a significant effect on estimates of 
the model parameters,
A plot of residuals of predicted values against age (Figure 7.7a) revealed no pattern, and thus, 
the residual variance was homoscedastic (if there was variability in the variance, 
heteroscedasticity, the residuals would have been seen for example, to increase with age); 
while the studentized residuals identified one possible outlier (Appendix X). An outlier with 
leverage is defined as an observation with an extreme value on a predictor variable, therefore 
having undue influence (http ://www.ats .ucla.edu/stat/stata/webbooks/reg/chapter2 /statareg2  .htm: 
Hamilton, 2006). A plot of leverage versus residual squared, as a quick means of visually 
checking for outliers with leverage and hence influence, was constructed (Figure 7.7b). This 
identified an outlier in addition to that identified by the studentized residuals. Omission of 
these possible outliers from the model had no effect on model parameters, and so these data 
points were retained in the model.
167
100
age_days
150 200
— i---------------------------------------------- 1—
.01 .02 
Normalized residual squared
.03
Figure 7.7. Regression diagnostic plots following log-linear regression on RSV-specific Ab 
levels in children < 6  months. Where (a) residual-versus-predictor, age (in days) and (b) 
leverage-versus-residual-squared. The horizontal red line marks the means of leverage, and 
the vertical red line, the squared residuals. The green elliptical circles mark possible outliers. 
Note: this data set is of children < 6  months, although scale is expanded to 200 days as 
clustered data was spread out in an attempt to look for possible patterns that violate 
regression assumptions
7.6.6.2 Distribution o f gradients
Only children with 3 or more data points (which allowed for directional analysis) between 0-6 
months were considered when testing for possible differences and associations with risk 
factors, between the half-life (Ti/2) of RSV-specific matAbs in the infected and non-infected 
population. A histogram plot of gradients (Appendix Xlb) identified several outliers, which 
were thus omitted.
7.6.7 Student’s t-test: possible differences in cord blood titres of non-infected and 
infected population’s
Possible differences in cord blood levels of both infected and non-infected populations were 
evaluated using a two-sample t-test with unequal variances. Its association with risk factors 
was also evaluated at the two previously defined seroconversion levels.
Initially, a plot of cord blood levels by date of birth which distinguished between infants bom 
in and out of epidemics (Figure 7.8) appeared to show no differences between cord levels in or 
out of an epidemic.
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Figure 7.8. Cord blood levels in relation to date of birth, depicting children bom in (N=242)
■ and out (N=119) ♦  of epidemics
In an attempt to tease out possible trends better between those bom in or outside of an 
epidemic, a moving average of 7 days was investigated (Figure 7.9). In the 1st cohort there 
appeared to be no discernable trend, however in the 2nd cohort there appeared to be a slight 
increase in Ab titres as the epidemic season progresses and this was maintained for a while 
into the non-epidemic period whereupon a slight decline was noted with time.
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Figure 7.9. Cord blood levels in relation to date of birth (blue line) with moving average trend 
depicted (red line). Non-epidemic period depicted by shaded area. The (a) 1st and (b) 2nd 
three hundred children recruited to the birth cohort respectively. Green box shows switch in 
Ab titres from a lower to a higher level.
When infants were stratified into those who went on to experience an infection and those who 
did not within the 1st six months of life, there is evidence of a difference (P=0.023) in cord 
blood levels between these 2 groups using the 2-fold seroconversion level, but this evidence
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diminishes (P=0.09) when the 4-fold cut off is used. Mean cord blood levels for the infected 
subgroup were seen to be lower in comparison to the non-infected subgroup (Table 7.3a & b).
Table 7.3a. Two-sample t-test with unequal variances of cord blood titres of infected & non- 
infected samples at 2-fold seroconversion level (Group 0 and 1 denote non-infected and 
infected populations respectively),
Group 1 Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
0 1 287 3.019845 .0297724 .504376 2.961245 3.078446
1 1 74 2.810244 .0854398 .7349807 . 2.639962 2.980525
combined 1 361 2.97688 .0297181 .5646434 2.918437 3.035323
diff 1 .2096018 .0904784 .0298896 .3893139
diff = mean(O) - mean(l) t = 2.3166
Ho: diff = 0 Satterthwaite's degrees of freedom = 91.4 601
Ha: diff < 0 Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 0. 9886 Pr (ITI > It]) = 0.0228 Pr(T > t) = 0.0114
Table 7.3b. Two-sample t-test with unequal variances of cord blood titres of infected & non- 
infected samples at 4-fold seroconversion level (Group 0 and 1 denote non-infected and 
infected populations respectively).
Group 1 Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
G I 293 3.006771 .0302666 .5180811 2.947202 3.066339
1 1 68 2.848085 .0876619 .7228783 2.673111 3.023059
combined 1 361 2.97688 .0297181 .5646434 2.918437 3.035323
diff 1 .1586856 .0927398 -.0257488 - .34312
diff = mean(0) - mean(1) t = 1.7111
Ho: diff = 0 Satterthwaite's degrees of freedom = 83.6533
Ha: diff < 0 Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 0. 9546 Pr (ITI > 1t|) = 0. 0908 Pr(T > t) = 0.0454
Furthermore, when birth in or out of an epidemic period was now taken into consideration, it 
was observed that there existed differences in matAb titres between the 2 population groups 
but only for children born within an epidemic. The matAb levels for the infected population
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group was significantly lower than that for the non-infected group both at the 2-fold 
(P=0.02J) and 4-fold (P=0.048) seroconversion levels (Table 7.4a & b; Appendix XDb i-ii).
Table 7.4a. Two-sample t-test with unequal variances of cord blood titres of infected & non- 
infected samples at 2-fold seroconversion level of children bom in an epidemic (Group 0 and 
1 denote non-infected and infected populations respectively).
Group 1 Obs Mean Std. Err. Std. Dev. [95% Conf.. Interval]
0 1 198 3.011512 .0371283 .5224414 2.938292 3.084732
1 1 44 2.706714 .1227761 .8144046 2.459113 2.954316
combined 1 242 2.956094 .0383185 .5960958 2.880612 3.031576
diff 1 .3047973 .1282672 .0473061 .5622885
diff = mean(0) - mean(l) t 2.3763
Ho: diff = 0 Satterthwaite 's degrees of freedom = 51.1309
Ha: diff < 0 Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 0.9894 Pr(IT| > |t|) = 0.0213 Pr(T > t) = 0.0106
Table 7.4b. Two-sample t-test with unequal variances of cord blood titres of infected & non- 
infected samples at 4-fold seroconversion level of children bom in an epidemic (Group 0 and 
1 denote non-infected and infected populations respectively)
Group 1 Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
0 1 201 3.002002 .0373701 .529813 2.928312 3.075692
1 1 41 2.731032 .1282952 .82149 2.471738 2.990326
combined 1 242 2.956094 .0383185 .5960958 2.880612 3.031576
diff 1 .2709705 .133627 .0021488 .5397922
diff = mean(0) - mean(1) t = 2.0278
Ho: diff = 0 Satterthwaite 's degrees of freedom = 47.0079
Ha: diff < 0 Ha: diff != 0 Ha: diff > 0
Pr(T < t) - 0. 9759 Pr(|T| > It|) = 0 . 0483 Pr(T > t) = 0.0241
The infected infant population with a weight greater than 2.5 kg at birth were observed to have 
significantly (P=0.037) lower matAb levels than the non-infected population but only at the 2- 
fold seroconversion level (Table 7.5, Appendix Xllb iii-v)
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Table 7.5. Two-sample t-test with unequal variances of cord blood titres of infected & non- 
infected samples at 2-fold seroconversion level of children with a birth weight level > 2.5 kg 
(Group 0 and 1 denote non-infected and infected populations respectively)
Group | Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
0 1 208 3.047826 .0331142 .4775796 2.982542 3.11311
1 1 59 2.849631 -.0873015 .6705757 2.674878 3.024384
combined I 267 3.00403 .0325179 .5313462 2.940005 3.068055
diff | .1981949 .0933708 .012209 .3841808
diff = mean(O) - mean(l) t = 2.1227
Ho: diff = 0 Satterthwaite's degrees of freedom = 75.4524
Ha: diff < 0  ' Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 0.9815 P r (IT| > |t|) = 0.0371 Pr(T > t) = 0.0185
7.6.8 Factors associated with cord blood titres
With regards to matAb titres after controlling for birth weight level, birth order levels and 
being bom in or out of an epidemic, both individually and together, the matAb titres for the 
infected groups remained significantly lower when compared to the non-infected groups both 
at the 2- mid 4-fold seroconversion cut-off levels (Table 7.6).
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Table 7.6. Multiple regression models on cord blood levels showing model outcome of main 
effects.
Stratifying
variable(s)
Coefficient of 
independent 
variable (matAbs 
infected- matAbs 
non-infected 
popnsf)
P Adjusted
R2
Birth weight 
levels
2 -fold* -0.2181391 0.003 0.03
4-fold* -0.166283 0.028 0 . 0 1
Bom in epidemic 
2 -fold* -0.217065 0.003 0 . 0 2
4-fold* -0.1647097 0.03 0 . 0 1
Birth order levels
2 -fold* -0.2246853 0 . 0 0 2 0 . 0 2
4-fold* -0.1753541 0 . 0 2 2 0 . 0 1
Born in epidemic 
& birth weight 
levels
2 -fold* -0.2235207 0 . 0 0 2 0.03
4-fold* -0.1705382 0.025 0 . 0 1
Tpopns means populations; *A11 variables were controlled for infection at the indicated 
seroconversion level (see Appendix Xlllb i-viii for more information)
7.6.9 Possible differences in rate of decay of matAbs of non-infected and infected 
populations
A two-sample t-test with unequal variances was used to test the rate of decay or differences in 
gradient of matAb decline in the 2 population subgroups (non-infected and infected-children 
with 3 or more data points), and when stratified by birth in or out of an epidemic period, no 
differences were identified (Appendix Xlla i-iv). However, when considering birth weight 
levels, the gradient of matAb was noted to be significantly steeper at the 2-fold (P=0.014) and 
4-fold (P=0.025) for the infected population compared to the non-infected population group 
but only for infants <2.5 kg (Table 7.7a & b; see Appendix Xlla v-vi). As both cord blood
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levels and birth order were stratified to more than 2  levels, their effects were best examined 
using regression analysis (section 7.6.10).
Table 7.7a. Two-sample t-test with unequal variances of gradient of infected & non-infected 
samples at 2-fold seroconversion level of children with a birth weight level < 2.5 kg (Group 0 
and 1 denote non-infected and infected populations respectively)
Group 1 Obs Mean • Std. Err. Std. Dev. [95% Conf. Interval]
0 1 79 -.0088541 .0004314 .0038341 -.0097129 -.0079953
1 1 20 -.001896 .0025445 .0113792 . -.0072216 .0034297
combined 1 99 -.0074484 .0006719 .006685 -.0087817 -.0061151
diff 1 -.0069582 .0025808 -.0123398 -.0015765
diff - me an(0) - mean(1) t = -2.6961
Ho: diff 0 Satterthwaite's degrees of freedom = 20.1038
Ha: diff < 0 Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 0. 0069 Pr (IT| > 111 ) = 0.0139 Pr(T > t) = 0.9931
Table 7.7b. Two-sample t-test with unequal variances of gradient of infected & non-infected 
samples at 4-fold seroconversion level of children with a birth weight level < 2.5 kg (Group 0 
and 1 denote non-infected and infected populations respectively)
Group | Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
0 1 80. -.0087126 .0004488 .0040144 -.009606 -.0078193
1 1 19 -.0021255 .0026712 .0116434• -.0077374 .0034864
combined | 99 -.0074484 .0006719 .006685 -.0087817 -.0061151
. diff I -.0065871 .0027086 -.0122558 -.0009185
diff = mean(0) - mean(l) t = -2.4319
Ho: diff = 0 Satterthwaite's degrees of freedom = 19.0273
Ha: diff < 0 , Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 0.0125 P r (|T| > |t|) = 0.0251 Pr(T > t) = 0.9875
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7.6.10 Factors associated with the rate of decline of matAb titres over the 1st six months 
oflife
As it was shown that there existed significant differences between the infected and non- 
infected population when taking into consideration some of the known risk factors, multiple 
regression analysis of the risk factors previously defined was carried out by means of the 
following model:
y= c + mixi + ni2X2  mpxp
where y is the rate of decay; c is the intercept; mi the age in days; and Xi are the explanatory or 
risk factor variables, from i= l,p ' i.e. cord blood levels, weight of child at birth etc. This 
allowed for the control of these potential risk factors and the selection of significant 
independent risk factors associated with decline of RSV-specific matAbs and matAb starting 
titres.
It was observed that none of the risk factors (Appendix Xllla i-iii) except for cord blood levels 
were independently associated when the infected population was compared to the non-infected 
population (Table 7.8).
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Table 7.8. Multiple regression models showing model outcome of cord blood levels 
controlling for all other risk factors at the both seroconversion levels
Stratifying
variable
N Coefficient
of
independent
variable
(age)
P Adjusted
R2
Cord levels 181
2 -fold
2 -0.0030211 < 0 . 0 0 1 0.43
3 -0.0043159 < 0 . 0 0 1
4 -0.005967 < 0 . 0 0 1
4-fold 0.43
2 -0.0030468 < 0 . 0 0 1
3 -0.0043251 < 0 . 0 0 1
4 -0.0059972 < 0 . 0 0 1
Cord levels: 2, 3, 4 are middle lower, middle upper and upper quartiles respectively, 
cord level 1 omitted in regression analysis (see Appendix XHIa iv-vii for more information).
Cord blood levels were divided into 4 quartiles (Figure 7.10a) with mean Ab titres being 2.24, 
2.89, 3.19 and 3.60 log AU respectively. Therefore, between the 1st and 2nd, 2nd and 3rd and 3rd 
and 4th quartiles there was a 4.5-, 2- and 2.6-fold difference between Ab titres respectively. 
Figure 7.10b showed that the decay rate in each quartile were all constant and equal for each 
starting level of cord Ab.
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Figure 7.10. (a) Frequency of cord Ab levels by quartiles; and (b) predicted 
matAb decay rate in each quartile by multiple regression analysis. Predicted
regression lines for lower quartile , middle lower quartile , middle
upper quartile and upper quartile  are shown.
7.7 Discussion
This study is unique in that there were a high number of study participants and the long 
follow-up time allowed for the extensive monitoring of RSV-specific serological changes 
from birth to approximately 3 years of age. The few studies that have been published all 
showed a decline in matAb levels but do not include 95% Cl, as well, the population of infants 
below three years of age have been small, with the exception of Cox et al., (1998) who 
followed a total of 549 individuals, but with a very wide age range, 0-40 years. Additionally, 
Cox et al (1998) carried out a cross-sectional study design.
RSV infection was investigated in a birth cohort recruited in 2 phases between February -  
May 2002, and December 2002 -  May 2003 respectively, from which a total of 361 cord 
bloods were collected. Cord blood titres and duration of RSV maternally-derived immunity, 
together with their association with risk factors were further explored. The decline of 
seropositivity with age was also examined.
Sera were screened quantitatively for total RSV-specific IgG using a simple ELISA technique, 
adapted from Wilson et al (2000). A cut-off point for seropositivity of 1.495 log AU was 
calculated from the ELISA and was further confirmed from the plot of frequency distribution 
for all sera samples (Figure 7.1 and Figure 7.2a). Maternal transfer was deemed to be efficient 
as approximately 97% of infants displayed RSV-specific matAb at birth. By 6-7 months, 50% 
infants were noted to be still seropositive (Figure 7.3a). This is in contrast to earlier studies 
(Table 3.3, chapter 3) with the exception of the study by (Ebihara et al., 2004), in which 
seroprevalence levels were seen to reach a nadir by 6  months of life, and seroprevalence 
varying from between 2-16% when carried out by the ELISA, and 21% by both the G- and F-
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specific competition ELISA. In the study by Ebihara and colleagues (2004), a similar level of 
prevalence of 48% was observed. However, this was calculated for a wider age class that 
included 4-12 months old children, and furthermore, the numbers being reported are small 
(13/27). The authors do not offer an explanation for their results.
Varying the cut-off levels for seropositivity from approximately 1.5 (ascertained from assay) 
to 2.0 log AU (at this level, 50% of the population were considered seronegative), resulted in a 
quicker decline in seropositivity. A minimum Ab level was reached by 5 months. At this age, 
7% of the population still remained seropositive. Thus, it would appear that on the basis of 
50% of the population being seropositive, perhaps a childhood vaccine can be introduced soon 
after 3 months if it is assumed that matAbs have minimal interference when they get to levels 
below their Tm  levels. With regards to the cut-off level being set at 1.5, in which 72% of the 
population was classified as being seropositive, vaccine intervention would have to be delayed 
considerably to long after 6  months of age-but if you delay this long, you will fail to prevent 
many infections that you can see occurring in this age group. It still therefore remains 
important that the critical vaccination fraction (those fractions of each subpopulation that 
should be vaccinated to achieve protection against RSV) must be better established.
Subclinical or clinical infections as a result of repeat exposure to RSV could account for these 
high levels of seropositivity noted in this population, due to the boosting of matAbs (Cox et 
al., 1998). However, despite repeat attempts by PCR on 80 samples collected around the time 
point when a child was seen to seroconvert despite not showing any clinical symptoms 
(Section 6.4.6) we could not identify virus in these samples. Seroconversion in the absence of 
IF AT confirmed results will be discussed further in chapter 8 . The study design, which thus
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allowed for repeated analysis of a child, the frequent sampling frame and the total number of 
infants (503 infants) followed up, therefore allowed for a better estimate of seroprevalence 
with age in this population in comparison to previous studies, which may have underestimated 
the rate of conversion. Furthermore, an increase in seropositivity was noted especially above 
the age of 8-9 months in this population at the assay seropositive cut-off level and above 12 
months when the cut-off level for seropositivity was raised to 2.0. This could be as a result of 
enhanced development in immune competence (Murphy et al., 1986a, Murphy et al., 1986b). 
However, this estimation of proportion seropositive is probably an underestimation of the 
average age at primary infection as most infants, especially under the age of 6  months do not 
seroconvert following first exposure (Cox et al., 1998).
Despite at least 50% infants being seropositive at 6-7 months age, using the cut-off value of 
1.495 log AU, the rapid decline in RSV-specific Abs over the first 6  months of life is 
consistent with the loss of matAb as previously described (Cox et al., 1998; Brandenburg et 
al., 1997), as noted from the decline in Ab titres (Figure 7.5). In general, it is assumed that 
RSV matAb declines with age following an exponential pattern. Thus, we obtained a constant 
a, which described the rate of decay of RSV matAb that was independent of possible 
infection. This parameter was used to calculate the Ti#.
The ‘pristine’ T1 /2 of RSV-specific matAb in the non-infected population, was estimated as 79 
days (95% Cl: 75.8, 81.4) and matAbs had an average duration of 113 days (95% Cl: 109.3, 
117.4). This T1 /2 is lower than that observed by Cox and others (1998), Hacimustafaoglu et al 
(2004) and Ward et al. (1983) who calculated T1 /2 that varied from between 91.2-100.3 (refer 
back to Table 3.2), although it is not clear as to whether the authors included or excluded
seronegative individuals with infections in their calculation of T1/2 , nor did they include 95% 
CIs. The T1/2 for RSV-specific matAb however, was higher than that for measles, mumps and 
rubella (Caceres et al., 2000, Sato et al., 1979), and human parainfluenza type 3 (Lee et al., 
2001), which vary from 35-40 and 51 days respectively, and hence RSV has a faster rate of 
decay in comparison.
Furthermore, the study suggests that the rate of matAb decay does not differ between the 
population that is inclusive of infections and the non-infected population. This was 
additionally confirmed following the 2 -sample t-test (with unequal variance) on gradients of 
the infected and non-infected population. This therefore implies that RSV infections below 6  
months of age have no effect on the rate of matAb decay. In other words, the presence of 
matAbs has a masking effect on infections under 6  months of life, and thus seroconversions in 
this age group will not be easily identified.
It is thought that cord blood levels can be influenced by various factors that include date of 
birth, being bom in or out of an epidemic period (season) and birth weight (proxy for 
gestational age) as previously described (Glezen et al., 1981, Le Saux et al., 2003, Madhi et 
al., 2006). All cord sera were shown to be seropositive, with infants being bom in or out of an 
epidemic seemingly displaying similar levels in this study. Although this was not clear from a 
plot of moving averages of cord titres of infants recruited in the 1 st phase of the birth cohort, it 
appeared from those infants recruited in the 2 nd phase, that with progressive time, cord titres 
appeared to increase and this was maintained partly into the non-epidemic period whereupon it 
was seen to decline slowly with time. It is assumed that children bom later in an epidemic 
might have higher cord blood levels, because of the probability of increased risk of maternal
infection during pregnancy as the epidemic progresses. This observation is similar to earlier 
studies (Le Saux et al., 2003, Nandapalan et al., 1986) that reported an increase in RSV- 
specific Abs following an RSV epidemic. However the effect of unequal exposure time, or 
time-varying incidence, of infants to an epidemic period should be further explored.
The other risk factors affecting both RSV cord titres and RSV matAb decline were further 
analyzed using both the 2 -sample t-test (with unequal variance) and multiple linear regression 
analysis. With respect to cord blood titres, children who went on to experience an infection 
within 6  months of age were observed to have consistently significantly lower titres in 
comparison to the children who did not experience any infection within this period. This 
difference was further maintained even when season was taken into consideration, both at the 
2- and 4-fold seroconversion levels (Tables 7.5-7.6). This implies that matAbs are protective 
as earlier described (Glezen et al., 1981, Ogilvie et al., 1981, Roca et al., 2002). These authors 
observed that protection against RS V infection in early infancy was correlated with the level 
of matAbs. These observations therefore have implications for the development of a maternal 
vaccine (Hacimustafaoglu et al., 2004, Roca et al., 2002). Interestingly, infected infants with 
greater than 2.5 kg birth weight had significantly lower (P=0.037) matAb titres than those less 
than 2.5 kg, but only at the 2-fold seroconversion level. This is in contrast to knowledge that 
full term infants in comparison to premature have more efficient transfer of matAbs via the 
Brambell Fey receptors, thus have maternal IgG levels approaching adult levels at birth. This 
however is not replicated by preterm infants (de Sierra et al., 1993). The rate of matAb 
decline appeared to be significantly influenced by birth weight levels; the rate for the non- 
infected population appeared to decay at a much slower rate than the infected population 
following analysis by the t-test for infants less than 2.5 kg at birth. However, the use of t-tests
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does not allow for the control of multiple covariates and hence multiple linear regression 
analysis was utilized. r
On using this analysis method and having controlled for all other possible predictor variables, 
it was still observed that cord titres of the infected group remained significantly lower than the 
non-infected population (Table 7.8). Individually, these variables had no effect on the decay
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rate and their predictive power for the model, adjusted R , was extremely low. Inclusion of 
cord levels was able to explain between 41-43% of the model variation (Appendix Xllla). 
However, it still remains important to calculate what the correctly specified model would be 
while taking into consideration the rate of RSV-specific matAb decay in this population in 
order to correctly assess vaccine impact in this population, in the presence of matAbs. The 
model makes the undesirable assumption that the immune system is a one compartment 
model, in other words, RSV matAb decay is only dependent on the inherent characteristics of 
these circulating Abs. Future studies should thus address a multi-compartmental model to 
better understand the constraints within which the immune system functions. However, as it 
stands, this model importantly demonstrates that the rate of decay in infants in Kilifi is 79 
(95% Cl: 75.8, 81.4) days.
The relatively short half-life of RSV matAb of about 2.5 months implies that a childhood 
vaccine could be administered fairly soon after this. However, 8 8 % of the population is still 
seropositive by 4 months, and it is plausible that existing Ab titres could interfere with vaccine 
response and hence childhood vaccines may not be useful in this setting. Alternatively, as high 
levels of matAbs are protective, maternal vaccination might be a better alternative in this 
population. Apart from reducing the potential risk of infection to the mother and hence the
child, a maternal vaccine would augment matAb levels, which in turn would be transferred to 
the infant via transplacental transfer or through breast-feeding, protecting the infant during the 
vulnerable period of life when their immune system is still under-developed. Despite this, it 
still remains a public health issue as to what the recommended age for vaccination should be, 
especially within the developing country setting where a high proportion of the population is 
seen to still be seropositive by 6-7 months of age,
CHAPTER EIGHT
The dynamics of RSV infection within the Kilifi birth cohort: 
characteristics of the RSV IgG specific humoral responses
8.1 Introduction
The pathogenesis of RSV infection has not been fully elucidated and as thus, the 
immunological responses to RSV infection remain of immense interest. The role of Abs 
against RSV culminating in protective immunity (correlates of immunity) was previously 
reviewed (Section 3.5). Although precise correlates of immunity have not been ascertained 
(section 3.5), high titres of neutralizing Ab have been associated with protection against 
disease (section 3.4),
The serum samples collected in this study allowed for the investigation of the dynamics of 
infection within a rural population of Kilifi, Kenya thus allowing for the pattern of acquisition 
of RSV-specific IgG in the general population to be elucidated further. Two types of 
infections were observed during follow-up, those that were clinically confirmed in the 
laboratory by IF AT (IFAT-CSR), and those that were detected by ELISA only (ELISA-CSR), 
but had no corresponding IF AT result (see definitions, section 7.3). Previously, it was shown 
that children who had lower titres of matAb were more likely to go on to be infected (higher 
risk of incidence) compared with children with higher titres of matAb (section 7.6.9). 
Therefore, the effect of cord blood levels, in addition to other factors that included the number 
of previous infections experienced, the effect of previous titres, being bom in or out of an 
epidemic period, on the degree of the Ab response were investigated. Due to the staggered
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recruitment o f the birth cohort, survival analysis was carried out, together with all other data
analysis in Stata 9.0™.
8.2 Objectives
The objectives of this chapter therefore include the following:
• the description of the dynamics of the Ab response following natural RSV infection;
• the investigation into the role of cord blood levels of anti-RSV Ab in relation to 
disease outcome;
• the calculation of the average age of infection stratified by infection type, i.e. 1 °, 2 ° etc;
• the effect of various factors on ensuing incident of infections (both ELISA-CSR and 
IFAT-CSR); and
• the establishment of a protective threshold
8.3 The analysis procedure
This involved the following steps:
(1) Exploration of RSV-IgG responses, serological responses of paired sera samples, and 
exploration of the difference between convalescent and acute samples in different age 
groups.
(2) Examination of individual acute/convalescent responses by infection type, Ist.2nd etc in 
different age groups.
(3) Examination of the proportion of children showing seroconversion with age.
(4) Exploration of the effect of cord blood levels on paired samples and on disease 
outcome.
(5) Estimation of the protective threshold against RSV-associated LRTI.
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(6 ) Examination of the incidence rates of IFAT-CSR and ELISA-CSR and effect of 
various factors, including cord blood levels, age at infection (< 6 , 6-11, 12-23 and 24+ 
months), number of previous infections and being bom in or out of an epidemic, on 
these rates.
8.4 Methods/Statistical Analysis
8.4.1 Survival Analysis
This was performed by the Kaplan-Meier method using Stata™ 9.0 in order to calculate 
incidence rates of infection for the study period. Date of recruitment was considered date of 
entry into the study, whilst date of diagnosis was used to define the outcome date. The data 
were thus evaluated for effects of age and infection type, having taken into account the 
staggered recruitment of the birth cohort. Time-dependent exposure to RSV was taken into 
account by assuming analysis time was calender time. The relative hazard of various factors 
likely to affect the incident rate of both ELISA-CSR and IFAT-CSR were further investigated 
using the exponential regression model
Any difference seen between acute/convalescent Ab titres was quantified by either the 
Student’s 2-tailed t-test with unequal variance, or ANOVA
8.5 Results
8.5.1 RSV-specific IgG responses
On an individual basis, RSV IgG responses were seen to show considerable variation between 
infants. In some instances as noted for infants in Figure 8.1a, there was serological 
identification of cases undetected by surveillance (ELISA-CSR). The temporal pattern of Ab
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responses for these children showed a decline of matAb titres to a minimum by 6-7 months. 
The minimal level reached varied, and it was noted in some instances that the level was below 
the cut-off of seropositivity e.g. for infants 3835 and 3920. Above 12 months, Ab responses 
remained elevated e.g. for infants 3830, 3835, rose gradually then declined as for infant 3920, 
or declined steeply as for infant 4247 post-infection. Also observed was the fact that for some 
children, e.g. infant 3920, no infection was noted before 18 mo despite them experiencing at 
least 2 epidemics. With respect to infants in Figure 8.1b some children were seen to 
experience 1 IF AT confirmed infection, during the 4 year follow-up period. Furthermore, as 
similarly observed for infants in Figure 8.1a, matAb titres declined to a minimum by 6-7 
months, the minimum being observed to be below the cut-off of seropositivity for some 
infants, 3885 and 3748. Under 6  months of age, the ELISA was not able to record rising titres 
between acute/convalescent pairs for IF AT positive cases, such as in infants 4097 and 3748 
(Figure 8.1b). However, above 6  months of age following examination of paired samples, 
rising titres were recorded e.g. in infants 3938 and 3834. Post-infection dynamics revealed that 
either Ab titres remained elevated (infants 3885 and 3938) or quickly declined (infants 4097 
and 3748).
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Figure 8.1a. Serological responses for a  selection of children who showed no clinically
confirmed infections (I FAT negative) over the follow-up period of the study.
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Infants in Figure 8.1c showed similar Ab response kinetics as for infants in Figure 8.1b. 
However, these infants were observed to experience > 1 IF AT confirmed infection, during the 
follow-up period. Still the ELISA failed to record rising titres between acute/convalescent 
pairs for IF AT positive cases under 6  months of age as for infant 3867. Occasionally though, 
seroconversion was noted between acute/convalescent pairs under 6 . months as for infant 3911. 
Again above 6  months of age, rising titres were recorded e.g. in infants 5345, with some 
infants, 5414 and 5345 showing classical boosting. It was observed that post-infection, Ab 
titres quickly declined (infants 5345 and 3867) or gradually declined (infant 3911).
8,5.2 Prevalence of RSV-specific Abs
Following an IF AT positive result, the presence of RSV-specific Abs was tested in paired 
samples by ELISA, acute samples being collected approximately 5- 7 days, and convalescent 
samples 3-6 weeks, post-infection. Of the total number of acute sera collected, 62.7% 
(185/295) were seen to be primary infections. With regards to infants experiencing 2, 3 and > 
3 infections, 26.8% (79/295), 7.1% (21/295) and 3.4% (10/295) IF AT confirmed infections 
respectively were noted (Table 8 .1 ).
Additional serological responses also occurred in the absence of IF AT confirmation (ELISA- 
CSR), although it should be noted that these occurred over a 3-month period rather than the 1- 
month period as between acute/convalescent pairs. Four hundred and ninety-nine (18%) 
missed infections or ELISA-CSR at the 2-fold seroconversion level were identified. With 
regards to ELISA at the 4-fold seroconversion level, an additional 317 (12%) missed 
infections were picked up by the assay. From the ELISA, it was noted that by 12 mo of age,
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54% of infants had experienced their first infection, whilst by 24 mo of age 85% and 48% of 
infants had suffered 1 and 2 RSV infections respectively.
Table 8.1. The frequency of paired sera samples collected following confirmation of positive 
IFAT results during entire follow up period (N=281)
Sample type Whole population (N=281) Under 6 mo population (N=94)
Frequency/percent Frequency/percent
Acute 1 185 (32.74) 57 (37.01)
Acute 2 79 (13.98) 24 (15.58)
Acute 3 21 (3.72) 5 (3.25)
Acute 4 7(1.24) 1 (0.65)
Acute 5 2 (0.35) -
Acute 6 1  (0.18) -
Convalescent 1 165 (29.20) 50 (32.47)
Convalescent 2 76 (13.45) 15(9.74)
Convalescent 3 21 (3.72) 2 (1.30)
Convalescent 4 7(1.24) -
Convalescent 5 1  (0.18) -
Total 565 154
Note: Of these, there were 97, 39, 13 and 5 paired primary, secondary, tertiary and quaternary' sera 
samples respectively.
8.5.3 RSV-specific Ab responses to clinically confirmed RSV infections
RSV-specific Ab responses between acute and convalescent specimen from different age 
groups were explored. The difference between mean Ab titres of convalescent and acute sera 
samples in different age categories is shown below (Figure 8.2).
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Figure 8.2. Mean differences between acute and convalescent titres by age category. [Ab] 
denotes Ab titres
Below 6 months of age, the mean difference was seen to be negative, and above 6 months 
these differences were positive, i.e. convalescent titres were higher than acute titres. The mean 
differences were only significant between paired sera in the < 6 month age group when 
compared to all other age groups, 6-11, 12-23 and 24+ months, in turn (2 tail ^-statistics, 
P=0.008, 0.001 and 0.03 respectively).
With respect to serological responses in individually paired samples (Figure 8.3), it was 
observed that below 6 months of age, for the majority of infants, the acute titres were higher 
than the convalescent titres, only 12.5 % (4/32) of infants showed a 2-fold RSV-specific 
seroconversion. Additionally, there appeared to be a difference in average acute titres of the
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< 3 month old group as compared with the 3-5 month old group. Those of the former group 
were much higher in comparison to the latter group, probably reflecting the decay in matAbs. 
As children got older, the reverse was noted. More children’s acute titres were lower or at the 
same level as their subsequent convalescent sera, and it was observed that with each repeat 
infection, mean convalescent titres appeared to increase towards cord levels (Figure 8.4).
*
1 I cord I 1 1st convalescent
[   I  | 2nd convalescent ISKB1 3rd convalescent
4th convalescent
Figure 8.4. Mean convalescent titres following consecutive infections compared to cord blood 
titres
However, there existed a small proportion of children, about 21%, for whom acute titres still 
remained more elevated than convalescent titres. A similar trend was noted at the 4-fold 
seroconversion level.
The proportion of children exhibiting IFAT-CSR at the 2-fold seroconversion level is shown 
in Figure 8.5; a similar profile was noted at the 4-fold level. It was observed that above 8 
months o f life, there was a marked increase in the rate of seroconversion in comparison to the 
under 8 month olds.
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Figure 8.5. Proportion of children with I FAT positively confirmed infection showing 2-fold 
seroconversion with age.
8.5.4 The effect of cord blood levels on serological responses of paired samples
When the effect of cord blood levels on mean changes of Ab titres between paired samples 
were further investigated, Ab titre differences were noted to be either zero or positive (Figure 
8.6a). When age was taken into account, below 6 months, irrespective of cord level, 
differences between paired sera were seen to be negative or nearly zero. There also appeared 
to be a decline in mean differences between the 2nd and 4th quartiles. Above 6 months of age, 
mean differences were observed to be positive. In the 6-11 month age class, there appeared to 
be a rise in mean difference from the 1st to the 4th quartile level, however, from 12+ months, 
no trend was noted, cord levels appeared to have no effect on serological response between 
acute and convalescent pairs (Figure 8.6b).
199
a
6-11
b
1 2 3 4 1
Cord blood levels Cord blood levels
Figure 8.6. Mean differences between acute and convalescent paired samples. Mean 
differences are stratified by (a) cord blood levels, and (b) cord blood levels and age groups. 
[Ab] denotes Ab titres, 1,2,3,4 represent the lower (mean Ab titres=2.24 log AU), middle lower 
(mean Ab titres= 2.89 log AU), middle upper (mean Ab titres=3.19 log AU) and upper (mean 
Ab titres=3.60 log AU) quartiles, respectively.
8.5.5 The role of cord blood levels with disease outcome
Approximately 15% of pneumonias identified were due to RSV infection (Table 8.2).
Table 8.2. The number of pneumonia episodes in the cohort and those that were due to RSV 
(IFAT confirmed) infections.
Pneumonia status Infection due to RSV
No Yes
No/URTI 6644 0
Mild 635 6 8
Severe 258 61*
Very severe 29 5*
Total 7566 134
*these 2 categories were further classified as severe RSV LRT
When RSV LRTI status was investigated in different age categories and at different cord 
levels, a significant difference (anova, P=0.014) was only noted between the number of 
episodes experienced by each age class. Cord levels had no effect. As noted from Table 8.3, in 
the under 6 and 12-24 month age classes the number of RSV LRTI episodes were similarly 
high, these numbers were observed to be higher than for the 6-11 month age class. As children
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got older the incidence of RSV LRTI was seen to decrease. A trend of decline in severe RSV 
LRTI with age was noted, but this was not significant (anova, P =0.127) between age classes 
(Table 8.3).
Table 8.3. The number of RSV LRTI stratified by age class in months and cord levels
Cord RSV LRTI Severe FtSV LRTI
levels <6 6-11 12-24 24+ <6 6-11 12-24 24+
1 10 3 12 2 7 2 2 —
2 6 3 8 1 3 2 1 —
3 3 5 3 2 2 4 2 —
4 6 6 10 — 4 3 2 —
Total 25 17 33 5 16 11 7 —
8.5.6 Estimation of serological correlates of protection against RSV-associated LRTI
The mean of children who did not experience RSV-associated LRTI was compared to those 
who did using a Student’s t-test with unequal variance. With regards to children who had RSV 
LRTI, approximate Ab titres (within 7 days o f diagnosis) at onset of disease were used if no 
serum sample was available on day of diagnosis. It was found that the mean titres for those 
who did not experience RSV-associated disease was slightly greater (2.14 log AU) than for 
those who did experience disease (1.99 log AU). However, this did not attain statistical 
significance (P= 0.191). It did not matter if differences between children experiencing 
infection and those who did not were explored by individual age classes under 6 months as 
above, Ab titres for the non-infected population consistently remained higher in comparison 
although this did not reach statistical significance.
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8.5.7 Incidence rates of IF AT and ELISA confirmed RSV-associated infections
The incidence rate of RSV infection over the whole follow up period at both the 2- and 4-fold 
ELISA-CSR levels as well as for IFAT-CSR were estimated to be 767, 494 and 403/1000 
child years observation, respectively. Addtionally, the incidence of IFAT-CSR across all ages 
stratified by infection type i.e. primary, secondary and 2 infections or more was calculated to 
be 252, 110 and 41/1000 child years observation, respectively. As age increased, ELISA-CSR 
incident rates were observed to increase (Table 8.4). The relative hazard for infants 6-11, 12- 
23 and 24+ months of age compared to infants <6 months old was 3.3, 4.3 and 5.4 at the 2- 
fold seroconversion level, and 3.5, 5.0 and 6.7 at the 4-fold seroconversion level respectively 
(Table 8.5a & b). However, a general decline was noted in the incident rates for IFAT-CSR 
(Tables 8.4) until 12-23 months with an increase then being noted for children 24+ months of 
age. Children in age class 6-11, 12-23 and 24+ months having a reduced risk of 41, 56 and 
26% respectively in comparison to those < 6 months old (Table 8.5c).
Table 8.4. Incident rates of ELISA-CSR and IFAT-CSR for different age groups
Age category Incidence rates/1000 children years observation (95% Cl)
(months) ELISA-CSR: 2-fold ELISA-CSR: 4-fold IFAT-CSR
< 6 213(156, 293) 121 (79, 183) 647 (540, 775)
6 - 1 1 699 (592, 825) 417 (336, 517) 383 (306, 479)
12-23 930 (842, 1026) 605 (535, 684) 287 (240, 343)
24+ 1161 (980, 1376) 812 (663, 995) 480 (369, 625)
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Table 8.5a. Exponential regression showing the relative harzard with age for ELISA-CSR at
the 2-fold seroconversion level (each age group is compared to < 6 months group)
No. of subjects = 513
No. of failures = 706
Time at risk = 920.7318243
Log likelihood = -655.40553
Number of obs 3689
LR chi2(3) 
Prob > chi2
137.11
0 . 0 0 0 0
t I Haz. Ratio Std. Err. z P>l z I [95% Conf. Interval]
6-11 months | 3.267788 
12-23 months| 4.347199 
24+ months | 5.429922
.5921395
.7296648
.9887798
6.53
8.76
9.29
0.000
0.000
0.000
2.29093
3.128512
3.800066
4.66118
6.040616
7.758825
Table 8.5b. Exponential regression showing the relative harzard with age for ELISA-CSR at 
the 4-fold seroconversion level (each age group is compared to < 6 months group)
No. of subjects 
No. of failures 
Time at risk
513
455
920.7318243
Log likelihood = -606.53134
Number of obs
LR chi2(3) 
Prob > chi2
3689
106.10
0 . 0 0 0 0
• _t I Haz. Ratio Std. Err. z P>l z I .[95% Conf. Interval]
6-11 months | 3.45907 .8294756 5.18 0.000 2.161939 5.534459
12-23 months | 5.014039 1.113812 7.26 0.000 3.244165 7.749479
24+ months I 6.730808 1.595744 8.04 0.000 4.229254 10.712
Table 8.5c. Exponential regression showing the relative harzard with age for IFAT-CSR 
(each age group is compared to < 6 months group)
No. of subjects = 
No. of failures = 
Time ,at risk =
Log likelihood =
513
371
920.7318243
-810.66327
Number of obs
LR chi2(3) 
Prob > chi2
3667
40.36
0 . 0 0 0 0
t I Haz. Ratio Std. Err. z P>l z | [95% Conf. Interval]
6-11 months | .591539 
12-23 months | .4434099 
24+ months | .7421428
.0870034
.0572519
.1211681
-3.57
-6.30
-1.83
0.000
0.000
0.068
.443393
.3442711
.5389067
.7891834
.5710976
1.022025
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A history of 1 or more previous infections was investigated and observed to affect both 
incidence rates of ELISA-CSR at both seroconversion levels, and IFAT-CSR across all age 
groups. The more infections experienced in the past, the higher the incident rate of RSV 
ELISA-CSR infections (Table 8.6).
Table 8.6. The effect of history of previous infection on general incidence rates of ELISA- 
CSR and IFAT-CSR
Previous # of Incidence rates/1000 children years observation (95% Cl)
infections ELISA-CSR: 2-fold ELISA-CSR: 4-fold IFAT-CSR
0 471 (427, 520) 329 (293, 371) 261 (229, 296)
1 3520 (3079, 4025) 2073 (1741, 2468) 4334 (3566, 5268)
2 3924 (3223, 4779) 2141 (1639, 2795) 5112 (3720, 7026)
On adjusting for age, 1 or 2 previous infections had a significant (P<0.05) effect on incident 
rates (Table 8.7a-c, non-shaded area). However, if age categories were taken into account, 
then adjusting for previous infections did not affect incident rates from one age category to the 
next. The rates were observed to be similar (Table 8.7a-c, shaded area).
Table 8.7a. Exponential regression showing the relative hazard after adjusting for indicated 
explanatory variables, for ELISA-CSR at the 2-fold seroconversion level
No. of subjects = 513 Number of obs = 3689
No. of failures = 706
Time at risk = 920.7318243
LR chi2(5) = 633.70
Log likelihood = -407.11028 Prob > chi2 = 0.0000
_t i Haz. Ratio Std. Err. z P>|z| [95% Conf. Interval]
1 past infecn I 6.659138 .5916123 21.34 0.000 5.59494 7.925754
2+ past infecn| 7.745882 .9440657 16. 80 0. 000 6.099956 9.835922
6-11 months 1 2.72735 .4964188 5.51 0. 000 1.909015 3.896479
12-23 months 1 2.513188 .4338695 5.34 0.000 1.791744 3.52512
2 4+ months I 2.227074 .42681 4 .18 0.000 1.529696 3.242381
Note: Each infection (infecn) group is compared to children experiencing no infection; each age group 
is compared to < 6 months group
204
Table 8.7b. Exponential regression showing the relative hazard after adjusting for indicated
explanatory variables for ELISA-CSR at the 4-fold seroconversion level
No. of subjects 
No. of failures 
Time at risk
513
455
920.7318243
Log likelihood = -491.81786
Number of obs
LR chi2(5) 
Prob > chi2
3689
335.53
0 . 0 0 0 0
_t 1 Haz. Ratio Std. Err. z P>|z| [95% Conf.
1 past infecn | 
2+ past infecn|
5.250511
5.336568
____a  r\ •1 ^ T y— -1_____
.5850247
.8471706
14.88
10.55
0 . 0 0 0
0 . 0 0 0
4.220449
3.909627
r\ —i r-v r\ r\6-11 months I 
12-23 months 1 
24+ months I
3 .011761 
3.283962 
3.367328
.7433619
.8292306
5.25
4.93
0 . 0 0 0
0 . 0 0 0
1.879972 
2.107265 
2.078119
6.531975
7.284316
. A _ AA j| A1 )l4 .824914 
5.117729 
5.456327
Note: Each infection (infecn) group is compared to children experiencing no infection; each age group 
is compared to < 6 months group
Table 8.7c. Exponential regression showing the relative hazard after adjusting for indicated 
explanatory variables for IFAT-CSR
No. of subjects = 
No. of failures = 
Time at risk =
513
371
920.7318243
Log likelihood = -571.31574
t | Haz. Ratio Std. Err.
Number of obs
LR chi2(5) 
Prob > chi2
3667
519.05
0 . 0 0 0 0
P> | z | [95% Conf. Interval]
1 past infecn 1 
2+ past infecn| 
6-11 months 
12-23 months | 
24+ months
17.62653 
20.51741
.406901
.4965793
2. 116942 
3.650303
.0526301
.0825216
23.89 0.000
| 16.98 0.000
0 .
-6.95 0.000
-4.21 0.000
13.92957 
14.47716
.3157847 
.3585385
22.30467
29.07782
.6675436
.5243079
.6877672
Note: Each infection (infecn) group is compared to children experiencing no infection; each age group 
is compared to < 6 months group
Incidence rates of both ELISA- and IFAT-CSR appeared to be higher in the lower quartile of 
cord blood titres. Additionally, this rate appeared to increase even further in the upper quartile 
when IFAT-CSR was considered (Table 8.8).
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Table 8.8. The effect cord levels on general incidence rates of ELISA-CSR and IFAT-CSR
Cord levels Incidence rates/1000 children years observation (95% Cl)
ELISA-CSR: 2-fold ELISA-CSR: 4-fold IFAT-CSR
1 873 (737, 1035) 619 (506, 757) 450 (355, 569)
2 659 (547, 795) 408 (321,517) 366 (285, 470)
3 798 (671, 949) 468 (373, 587) 374 (291, 482)
4 782 (652, 938) 539 (433, 671) 526 (421, 657)
Note: cord levels 1-4 are lower, middle lower, middle upper and upper quartile ranges respectively.
It was noted that infants bom within an epidemic had lower rates of infection (Table 8.9) 
although this did not attain statistical significance when comparing ELISA-CSR at both 
seroconversion levels (P=0.36 and P=0.60 at 2- and 4-fold seroconversion levels 
respectively). However, a significantly reduced risk of 21% {P=0.022) was noted for children 
bom in an epidemic compared to those bom outside the epidemic when IFAT-CSRs were 
taken into consideration (Table 8.10).
Table 8.9. The effect of being born in or out of an epidemic on general incidence rates of 
ELISA-CSR and IFAT-CSR
Born in epidemic Incidence rates/1000 children years observation (95% Cl)
ELISA-CSR: 2-fold ELISA-CSR: 4-fold IFAT-CSR
No 799 (714, 895) 509 (441, 586) 461 (397, 535)
Yes 745 (676, 821) 484 (429, 546) 363 (316, 417)
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Table 8.10. Exponential regression showing the relative hazard of being bom in an epidemic 
for IFAT-CSR (comparison to infants bom outside an epidemic)
No. of subjects = 513 
No. of failures = 371
Number of obs = 3667
Time at risk = 920.7318243
LR chi2(1) 5.19
Log likelihood = -828.24424 Prob > chi2 = 0.0227
_t I Haz. Ratio Std. Err. z P>|zI [95% Conf. Interval]
Born in epid | .7881394 .0820228 v -2.29 0.022 .6427134 .9664709
207
8.6 Discussion
This chapter has described the immune profiles of individuals from birth through infancy and 
early childhood. There were patterns of Ab decay and acquisition of RSV-specific responses 
that groups of children appeared to experience. Cord blood levels were seen to vary, although 
generally, the decay of matAb appeared not to be altered by the presence of IF AT positively 
identified infections. In some instances, it appeared that the child did not experience any 
clinically confirmed infection although the assay was able to identify seroconversions (Figure 
8.1a). These serology confirmed infection could have been due to subclinical infections. 
However, it should be borne in mind that asymptomatic infections which lead to the boosting 
of immunity can lead to an over-estimation of the duration of matAb protection against 
symptomatic disease (Wendelboe et al., 2005). On the other hand, other infants experienced 1 
(Figure 8.1b) or > 1 (Figure 8.1c) clinically confirmed infections (IFAT-CSR). Post-infection, 
classical boosting of Ab titres was noted and either Ab titres were observed to remain elevated 
or waned. This may well account for the consistently high seroprevalence levels in this 
population. Alternatively, post-infection Ab titres were observed to decline either quickly or 
gradually*
Our study went on to further demonstrate a significant age-related difference in Ab responses 
to RSV infection during early life, i.e. the ability to develop an immune response to RSV was 
related to the age of the child; those less than 6 - 8  months of age did not consistently induce an 
immunological response (Figure 8.3) as similarly described previously (Chanock et al., 1961, 
McIntosh et al., 1978, Murphy et al., 1986a, Murphy et al., 1986b, Queiroz et al., 2002, 
Richardson et al., 1978, Welliver et al., 1980), and the proportion of children seroconverting 
was low, (-13%). Mean differences in Ab titres between paired acute and convalescent phase
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samples thus were observed to be negative. Additionally, cord levels did not appear to 
influence the rate of seroconversion in this age group, but it seemed that the higher the matAb 
titres a child possessed i.e. cord blood level 4 (under 6  mo of age), the more suppressed their 
immune response (Figure 8 .6 b).
The apparent lack of a humoral immune response to RSV infection in children < 6  months, as 
previously described (Brandenburg et al., 1997) may therefore account for initial RSV- 
associated disease in the presence of matAbs. As well, this may account in part for the failure 
of the development of solid immunity allowing for subsequent re-infections by the virus 
(Murphy et al., 1986b). Other factors that include (i) masking by matAb or its interference 
with IgG-producing cells thus mediating temporary immunosuppression in infants; (ii) 
immaturity of the immune system; and (iii) the placentally acquired matAbs not possessing 
sufficient neutralizing activity against the circulating strains that caused the infection (Parrott 
et al., 1973, Queiroz et al., 2002) possibly due to strain specific deficiencies in matAb cover 
could also account for inefficient immune responses. This inadequate Ab response has 
implications for the design of an infant vaccine.
However, it is not possible to rule out entirely the possibility that the child’s own immune 
response leads to protection against RSV-associated disease, but against the background of 
matAb remains indiscernible. A further complication is the definition of seroconversion in the 
presence of matAb. Simply, seroconversion conventionally refers to a change from negative 
(low pre-response serum) to positive (high post-response serum). However, as matAb are at 
adult levels and hence high, it is highly unlikely that an incompetent immune system will 
achieve titres above these levels. Therefore under 6  mo of age, it remains important to clearly
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define the meaning of seroconversion, as this therefore has implications on calculating an 
effective protective threshold for vaccine efficacy. Is this the change in Ab titre above the 
matAb level at that particular time, or is this the change of Ab titres from the minimum 
baseline titres achieved following matAb decay?
Above 6  months of age, there appeared to be a dramatic increase in the proportion of children 
showing either a 2-or 4-fold IFAT-CSR. Additionally with each successive infection, mean 
convalescent titres were boosted further in comparison to the previous infection perhaps 
implying that each child attains his/her own protective threshold as convalescent titres 
seemingly approached adult levels (cord level titres). In some instances, re-infection with RSV 
in this older age class appeared to be associated with accelerated and more persistent 
development of RSV-specific IgG, which was most likely related to the disappearance of 
matAb from circulation. Cord levels had no effect on the immune responses above 11 months 
of life, although in the 6 - 1 1  month age bracket it appeared that the higher the cord titres a 
child initially had, seroconversion between paired samples occurred at a higher level than 
other cord levels (Figure 8 .6 b). This could be as a result of the child’s immune system still 
being primed from the effects of matAbs and hence seroconversion occurs from this elevated 
level rather than the child’s inherent baseline level.
A significant minority (2 1 %) of children appeared not to seroconvert post-infection (Figure 
8.3). This may be due to late sample collection, in other words by the time the convalescent 
serum was collected, acquired humoral immunity may have already declined. Previous studies 
on the kinetics of the development of Abs to structural proteins of Hantavirus following 
natural infection (Groen et al., 1992) demonstrated different levels of Abs to conserved
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epitopes measured at different stages of the infection. The authors described the Abs as 
developing slowly and hence were either not detected or were detected at very low levels in 
acute and early convalescent sera, whilst in the convalescent phase, their concentration 
increased gradually, reaching the highest levels in late convalescent phase sera. Perhaps a 
similar mechanism exists for RSV and the convalescent samples collected were early phase. 
This may thus explain why it appeared that no seroconversion was noted for this subgroup of 
children.
The risk of re-infection with clinically identified RSV illness decreased with age, from an 
initial infection rate of 252 to 41/1000 child years observation. Previously, Murphy et al. 
(1986a, b) described an enhanced serum Ab response to RSV infection with age. Therefore, 
older infants and children experienced less re-infection when compared with infants less than 
8  months of age. After adjusting for age, a history of 1 or more previous infections 
significantly increased (P<0.05) the relative hazard of a child experiencing further infection, 
whether IFAT-CSR or ELISA-CSR. This seems to imply that other host factors other than age 
at infection dictate a child’s risk of infection. Our results are in contrast to Glezen et al. (1986) 
who previously observed a moderately lower risk for re-infection in children 24-35 months of 
age, although this did not attain statistical significance. Furthermore, very low cord titres 
resulted in an increased rate of RSV incidence. This therefore suggests that low matAb levels 
are not protective against RSV infection. It was also noted that very high titres of cord led to a 
further increase in incidence of clinically confirmed RSV-associated disease. It is hence 
plausible, that a protective threshold for matAbs against clinical RSV does exist, which thus 
allows for optimal protection but does not interfere with the child’s subsequent immune 
response. Lastly, children bom within an RSV season appeared to have a significantly
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(P=0.022) reduced risk of infection by 21%. It thus appears that children bom within an RSV 
season are bom with higher matAbs as earlier inferred (section 7.6.7) and previously described 
by Le Saux and colleagues (2003).
A similar number of RSV LRTI episodes were noted in the under 6  and the 12-24 month age 
groups. It has previously been described that serious RSV-associated disease is most common 
in children 1-11 months old (Anderson et al., 1990, Kim et al., 1973, Parrott et al., 1973). 
Paradoxically, with respect to the lower age group, this is an age coincident with highest titres
i.
of maternally derived RSV Abs (Glezen, 1977, Glezen et al., 1981). Also, it is not entirely 
clear why the older age group in this cohort who are expected to have better developed 
immune systems, should experience similar levels of pneumonia as the under 6  month old 
children. A possible explanation for this is that these children lacked strain-specific Abs and 
were thus susceptible to serious RSV-associated disease. There exist several other factors that 
may contribute to the increased susceptibility to respiratory pathogens in the developing world
9
and these include, indoor air pollution, overcrowding, low immunocompetence, poor nutrition 
and high nasopharyngeal carriage rates of potential bacterial pathogens (Forgie et al., 1991a, 
Forgie et al., 1991b).
A theoretical protective threshold against RSV LRTI of greater than 2.14 log AU is suggested. 
However, it should be noted that this level of Ab titres was only slightly higher than those 
established by the infected group. The numbers are too small to draw any definite conclusions. 
Moreover, a direct comparison to the threshold calculated by (Piedra et al., 2003a) who 
established a minimal protective threshold of titres > 6.0 and > 8.0 log2 (i.e. >1.81 and >2.41 
logio respectively) against RSV associated-hospitalization cannot be made as the authors
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tested for neutralizing Abs to RSV A and B respectively. It thus still remains important to 
properly define the threshold level as this has implications for vaccine design.
The immune response remains multifaceted, involving both host and parasite factors, and their 
contribution to RSV-associated disease severity involves both magnitude and intensity of 
infection playing a crucial role, with this most likely being related to viral load. There exists 
evidence to suggest that the variable regions of RSV show progressive accumulation of amino 
acid changes which may be correlated with antigenic change (Cane & Pringle, 1995). 
Consequently, these antigens could induce protective immune responses that are poorly 
immunogenic i.e. weak inducers of immunity. It is also known that the various genotypes of 
RSV infecting children are highly variable, and hence immune responses to these strains may 
only be detectable if the target antigen accurately reflects the infecting virus (Cane et al., 
1996; Scott et al., 2007). With regards to maternally acquired RSV-specific Abs, it has been 
suggested that their cross-reactive nature may be as a result of 2  different mechanisms or a 
combination of both. They may display strain-specific immunity as a result of mothers 
experiencing multiple infections involving different strains, or strain transcending immunity 
induced as a result of high levels of Abs against virally conserved epitopes also induced by 
repeat infections (Roca et al., 2002). Thus the authors argue that if the latter is the case, then 
mothers lacking Abs specific to the currently circulating virus strain leave their offspring 
vulnerable to infection. An appropriate vaccine should therefore limit infection in the mother 
reducing a major source of infection for the baby, as well, maternally transferred Abs across 
the placenta or by breast-feeding may confer protection to the infant. Nevertheless, a vaccine 
incorporating elements of both RSV group A and B would have to be considered.
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With reference to the child’s acquired immune response, it has long been thought that 
excessive expression of the latter plays a role in disease pathogenesis (Gardner et al., 1970). 
However, recently it was shown that severe RSV LRTI is characterized by inadequate 
adaptive responses, robust viral replication and apoptotic crisis (Welliver et al., 2007). Above 
6  months of age many children were noted to seroconvert in the absence of clinical symptoms, 
clearly reflecting the presence of protective immunity in such children. On the other hand, 
other children became ill with RSV from time to time, implying that some strains are better 
tolerated than others, as resistance to severe RSV-associated disease increases with age 
(Brandt et al., 1973, Glezen et al., 1986, Kim et al., 1973). This seems to suggest that infants 
develop resistance to severe RSV-associated disease at a much slower rate than children, and 
likewise, children at slower rates compared to adults. Could it be then that the constitutive 
difference related to immune responses between children and adults and by extension between 
infants and children, rather than the differential exposure to a sufficient number of protective 
antigenic variants, as recently debated for the acqusition of protective immunity to malaria 
(Hviid, 1998) account for the differences noted between infants and children, and children and 
adults? No doubt, the relative importance of the various types of immune responses which 
include responses to variable and conserved targets (Roca et al-, 2003; Cane et al., 1996) in the 
acquisition and maintenance of protective immunity play a part in the overall response to 
infecting strains and is host dependent. More studies, particularly longitudinal studies, are 
needed to therefore resolve the ambiguities of the immune response to RSV infection.
Future experiments should consider the use of more sensitive biological assays to discern 
between rising titres following infection in the presence of matAbs. Assays that can test for 
RSV specific glycoproteins, F & G, especially IgA F and G should be sought. This can be
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achieved in one of two ways; firstly by using the neutralizing assay. This would give a clearer 
picture of the development of immune response with age. However, these assays have been 
said to measure only a sub-set of Abs which cannot be assumed to include all biologically 
relevant Abs (McGill et al., 2004). An alternative assay is the membrane fluorescence assay. 
This allows for the use of clinical isolates, which replicate to low titres in cell culture, to be 
used as the antigen (McGill et al., 2004, Scott et al., 1976) as well as allowing for higher 
seroconversion rates to be measured. Additionally, as the assay measures Abs to unfixed, cell 
surface proteins thus recognizing Abs to conformation dependent epitopes (Routledge et al., 
1988) this will give a clearer picture of the sub-set of biologically relevant Abs involved in the 
clearance of RSV infection, giving the best assessment of immunity currently available in the 
child (McGill et al., 2004). Additionally, other immunoglobulins should be tested for, both in 
sera and NW samples collected during the entire follow-up period.
To summarize, the components of the immune response to RSV, resulting in protective 
immunity or pathogenesis of the infection still remains to be fully elucidated and have hence 
hindered vaccine development (Anderson & Heilma, 1995, Kimpen, 1996). However, Abs to 
both surface proteins, G and F are thought to be necessary for efficient neutralization of RSV 
infection (Hendry et al., 1988), a potential vaccine must be able to prime protective Abs to the 
intended vims in mothers who no doubt will have already experienced a previous infection 
with a related viral strain. In this manner, maternal:foetal transfer would be efficient and 
following RSV infection, the child would most likely attain or realize near or complete 
protection to severe RSV-associated disease, as their immune response is primed optimally. 
An optimal immune response would stimulate both IgG and IgA Abs working at maximal 
synergy against both F and G proteins of RSV. An immune response to either protein would
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consequently lead to partial protection allowing for re-infection. The interaction to 
immunodominant epitopes however, depends on the recognition of its amino acid sequence in 
conjunction with that of overlapping or adjacent putative receptor sites. These must thus 
remain unmasked and active i.e. not have undergone any mutation, for complete protection. 
Crucial to all this, is a minimal protective threshold of pre-existing antibody, whether matAb 
during primary infection, or the child’s own repertoire during re-infection, must be.realized to 
induce complete protection. Host responses remain important and should also be taken into 
consideration during vaccine design to tease out whether it is the need for several successive 
infections, or the constitutive difference related to immune responses in the host, that leads to 
more complete protection from RSV-associated disease.
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CHAPTER NINE 
Overall Discussion
RSV is the most common cause of childhood viral LRTI in both the developed and developing 
world. It was earlier noted that serum Ab had protective effects against RSV infection (Glezen 
et al., 1981, Groothuis et al., 1995, The IMpact-RSV study group, 1998,), and there was a 
correlation with decreasing levels of IgG RSV Ab in maternal blood and increased risk of 
infection in the off-spring (Roca et al., 2002). Despite this understanding, a precise correlate of 
immunity has not been defined as yet. In order to implement the usage of a RSV vaccine, 
knowledge of the prevalence of RSV infection in all age groups is important, as this not only 
will give a clearer picture of the time of infection, but also allows for the estimation of the 
appropriate age for vaccination.
9.1 Findings and supporting evidence
The main objectives of this study were to examine the roles of passive and acquired Ab to 
RSV infection in infants and young children in Kenya, a developing country. The study was 
carried out from 2002-2005. In summary, the main findings from this research are:
1. Approximately 97% of infants were bom with RSV-specific matAbs, which was 
indicative of efficient matAb transfer during the last trimester of gestation, although 
these levels were variable.
2. Although it appeared that seasonal changes had no bearing on matAb levels and levels
were similar in children bom in or out of an RSV epidemic period, children bom
within an RSV season appeared to have a significantly (P=0.022) reduced risk of
IFAT-CSR of 21%. Additionally, RSV-specific matAb titres were significantly lower
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for infants who went on to experience infection (IFAT-CSR or ELISA-CSR) within the 
first 6  months of life in comparison to those who did not.
3. The rates of RSV-specific matAb decay for both the infected and non-infected 
population groups were shown to be the same; however RSV-specific cord levels 
significantly influenced these rates.
4. RSV matAb T 1/2 was calculated to be around 79 days with a mean duration of 111 
days, whilst loss of seropositivity over the first 6  months of life occurred in a delayed 
manner, with 50% of children still being seropositive by 6  months.
5. By 12 and 24 months, 54% and 85% of infants had experienced their first and second 
RSV infection respectively as identified by IF AT.
6 . The majority of children under the age of 6  months of age, despite having clinically 
confirmed infections (IFAT-CSR), did not show any seroconversion. Above 6  months 
of age, some children were observed to experience boosting of Ab titres (ELISA-CSR) 
in the absence of virologically confirmed infections. Yet others experience one or more 
virologically confirmed infection (IFAT-CSR). Ab responses showed considerable 
variability. With each successive infection, convalescent titres were boosted towards 
adult levels.
7. RSV A comprised 98% of the circulating strain in epidemic 1, RSV A and B were 
similarly distributed in epidemic 2, whilst in both epidemics 3 and 4 RSV A comprised 
100% and 98%, respectively of circulating subgroup. The same strain was seen to 
cause both RSV-associated URTI and LRTIs.
8 . The risk of re-infection with clinically identified RSV illness decreased with age, from 
an initial infection rate of 252 to 41/1000 child years observation. A history of 1 or
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more previous infections, having adjusted for age, resulted in a significant increase in 
incidence of RSV infection, identified by both ELISA- and IFAT-CSR.
Thus, data from this study lend further support for the ubiquitous nature of RSV in Kilifi, 
Kenya as similarly reported in other parts of the world, representing a major health burden.
A simple regression model to calculate the rate of decline in RSV matAb was used. These data 
were slightly lower than what has been previously been reported in the literature (Cox et aL, 
1998, Hacimustafaoglu et al., 2004, Ward et al., 1983), except for Brandenburg et al. (1997) 
who reported a much lower rate of 26 days.
9.2 Generalisability of study findings
RSV is one of the important WHO recognized diseases causing a major burden and targeted 
for vaccine control (www.who.int/vaccine research/diseases/portfolio/en/index.htmfi. As thus, 
there remains an urgent need for a better understanding of the clinical impact of RSV in 
developing nations (Robertson et al., 2004, Wright & Cutts, 2 0 0 0 ). The study demonstrated 
that at a population level, matAb declined rapidly over the first 6  months of age as expected 
and subsequently, a gradual increase in Ab titres was seen with increasing age and infection as 
previously noted (Chanock et al., 1961, McIntosh et al., 1978, Murphy et al., 1986a, Murphy 
et al., 1986b, Queiroz et al., 2002, Richardson et al., 1978, Welliver et al., 1980). At the 
individual level, it was noted that each child experienced its own characteristic immune 
response (Figure 8.1). However, the establishment of a protective threshold against RSV- 
associated disease and the rate of loss of seroprevalence following both the loss of matAb and 
acquired immunity, remain important parameters for vaccine design. This community-based
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longitudinal study has given important insight into the Ab dynamics in a developing country 
and from the data a correlate for immunity can be inferred, as well as the appropriate age for 
vaccination. It seems likely therefore that vaccination in early childhood, which would thus 
delay infection to the 2 nd year or later when the child’s immune system is more mature, may 
be sufficient enough for control of severe RSV-associated disease in early childhood'. 
However, it is highly doubtful that Abs induced by vaccination would be more durable than 
those that arise following natural infection as was previously reported for measles, whereby 
measles vaccines elicited lower Ab titres than that observed after natural disease (Black, 1989, 
Jenks et al., 1988).
9.3 Limitations of the study
(i) Frequency of sampling: it is possible that due to the quick decay of Ab titres, a 
small proportion of infections may have been missed or were not adequately captured 
due to the 3 monthly sampling frame. As well, the 1 month interval between paired 
samples did not allow for optimal capture of Ab dynamics. Shorter sampling 
frequencies may thus resolve this, allowing for better interpretation of RSV-specific 
Ab kinetics especially in the first year of life and especially following infection (LAFT- 
CSR and ELISA-CSR), as post-infection, not all resulting immune responses persisted. 
Some responses were observed to sharply decline to a minimum even within a period 
of 2 weeks. A shorter sampling frame however, may still prove difficult due to ethical 
issues.
(ii) Measures of immunity: the measurement of ELISA binding titres using a crude 
extract is an indirect measurement of functional Abs. It would have been more suitable 
to measure NtAb titres to get a direct measurement of functional Ab following
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infection and in the presence of matAbs. Furthermore, the use of A2 rather than the 
currently circulating strain in the assay procedure could have led to an under 
estimation of seroconversion due to poor cross-reactivity (Roca et al., 2003).
(iii) Problems in identifying the infecting virus: we showed that many infections 
during the study period were identified by serology but were not detected by clinical 
surveillance (ELISA-CSR). However, repeated attempts to measure RSV by PCR in 
nasal samples collected in the interveming period between 2 consecutive 3 monthly 
sera that were seen to show seroconversions (ELISA-CSR) and might have accounted 
for these changes in Ab titres, proved futile. The use of more sensitive assays, such as 
real time PCR or the establishment of collected NW in culture as a means of viral 
amplification could improve sensitivity. The cell culture laboratory and real time PCR 
analysis are now established in Kilifi and this would now be possible-
9.3.1 Limitations in our understanding of the problem
There still exist many deficiencies in our understanding of the duration of RSV-specific 
immunity as well as the variable response of infants after natural infection as also noted by 
previous studies (Cox et al., 1998, Fisher et al., 1997, Kasel et al., 1987, Murphy et al., 1986a, 
Murphy et al., 1986b, Wagner et al., 1989). This may be in part be due to the fact that there is 
no clear seological marker for protective immunity against RSV. Most importantly however, 
these data as with previous studies (Murphy et al., 1986a, Queiroz et al., 2002) suggest that 
age plays an important role affecting the infant’s ability to develop RSV-specific immune 
responses, it appears that at least by 3 years postinfection, immunity against severe RSV- 
associated disease is established, but, immunity against re-infection is not attained. Studies 
controlling for the levels of circulating RSV in the population are important, as asymptomatic
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infections can boost the level of immunity and can thus lead to an overestimation of the 
duration of protection against symptomatic disease (Wendelboe et al., 2005). Other factors 
contributing to the difficulty in measuring immune responses as well as the limited 
comparability between studies include the use of different assays, the ultilization of different 
case definitions, surveillance methods and reporting systems.
Further studies to distinguish between the interplay of waning immunity and boosting of RSV 
acquired immunity post-infection, together with the transmission dynamics in the population, 
will aid determination of the optimal age and frequency of immunizations and hence their role 
in RSV control, as it may then be possible to improve the control of the disease through an 
optimal vaccination strategy which takes into accont both waning immunity and earlier 
susceptibility of infants (Rouderfer et al., 1994) to be implemented.
9.4 Future work
The restricted humoral responses in young children following RSV infection should be taken 
into consideration during vaccine development. Furthermore, HTV has an important impact on 
the immune response and RSV-associated disease, resulting in immune suppression and would 
therefore cause exacerbated disease in immunocompromised individuals, as well as causing 
prolonged shedding (Madhi et al., 2001). Therefore future studies should aim to collect data 
on HTV status. Moreover, the measurement of these humoral responses should not be 
restricted to only IgG, but other Ig classes as a means of distinguishing between matAb 
responses and the child’s own response, especially under 6  month of age, in addition to 
distinguishing between primary and other immune responses.
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Due to the quick decline in matAb as well as the loss of acquired Ab, it is necessary to visit 
cohort children at shorter intervals in order to get better estimates on the rate of loss of RSV- 
specific antibody. Furthermore, it is pertinent to establish the titres of NtAb to circulating 
strains using such assays as MFAT and future studies should take this into consideration. 
Additionally, regular sampling even in the non-epidemic periods should be considered, as 
repeat exposure to virus probably has an important role in boosting Ab titres. A constant 
supply of susceptible individuals would predict transmission of infection, and hence the 
observed clinical epidemics would be generated by strain variation (Cox et al., 1998). This 
would give an indirect indication of circulating strain, allowing for one to establish the role of 
cross-protectiveness. This in turn would inform on the protective threshold with regards to 
circulating strain, rather than the prototype, that should be attained to give protection against 
RSV disease.
Finally, in light of the fact that efficient transfer of matAbs from mother-to-child occurs, and 
the quick decay of the latter as well as of acquired Ab thus allowing for re-infections, it could 
be suggested that to minimize severe RSV disease, maternal vaccination should be considered; 
as well, children would then have to be vaccinated at a later age, perhaps repeatedly. These 
alternatives to vaccine strategies should be further explored. The optimal age for vaccination 
will depend on the definition of the minimal protective/interfering titre and this depends on 
vaccine strain and dose (Whittle et al., 1988).
In conclusion, it appears that matAbs do offer some protection although a small proportion of 
infected infants are seen to develop LRTI and may require hospitalization. A number of 
isolates of RSV were seen to co-circulate in the community, with the same strain causing both
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URTIs and LRTIs, humoral immune responses and Ab seroconversion between acute and 
convalescent infant sera were demonstrable for all age groups tested.
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APPENDIX I
WHO child growth standards
un -
O -
O -
in -
o  _
5 6 7 8 9 101 2 3 40
Age groups
Note: wfh: weight-for height z scores; Age groups 0: 0-89; 1: 90-179; 2: 180-269; 3: 270-359; 4: 360- 
449; 5: 450-539; 6: 540- 629; 7: 630-719; 8: 720-809; 9: 810- 899; 10: > 900 days respectively
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Histogram of weight-for-height for children in cohort
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APPENDIX 
II 
RSV 
Study: home visit form
APPENDIX III
RSV Study: sick child clinic visit
QUESTIONNAIRE
FIELD WOKER
complete page 1 + record Oxygen Sat/Pulsc/Wcight/Axillary temp on page 2 
KBC# [ ][ ][ ][ ][ ]
RSV # [ ] [ ] [ ]
Child Name [ ] [ ] [ ]
Date o f Birth | || |/[ |[ |/| | [ ] dd/mm/yy
Date today [ ][ ]/[ ][ ]/[ ] [  ] dd/mm/yy
Visit type [ ] active (referral.by FW) [ ] passive (self-referral) -Tick one box
IF ACTIVE REFERRAL (ie referred by FWfrom home) - Refer to clinician to complete 
only pages 2-3
IF PASSIVE REFERRAL (ie mother se lf referred) -  F W  complete the below
1. Ask mother - has child had a fever in the last 7 days? [ ] y/n
2. Has the child a temperature >37.49C (see page 2) [ ] y/n
If either 1 or 2 is 'yes' then do blood slide.
3. Blood slide taken [ ] y/n
4. Blood slide result [ ] +/-
5. Ask mother - has the child had difficulty in breathing in last 7 days? [ ] y/n
6. Ask mother - which of the key symptoms in the last 7 days? [ ]
7. Observe the child to have difficulty breathing today? [ ] y/n
8. Observe which key symptoms today ? [ ]
9. Is a nasal washing required? [ ] y/n
10. NW time | || ]:[ || | hh:mm
11. NW result [ ] +/-
12. Breathing rate (cycles /  min) [ ][ ]
13. Does child have fast breathing for age [ j y/n
14. Refund single (whole shillings) [ |[ ] ksh
Key symptoms: cough c„ fever f, nasal discharge/congestion dc
Now refer child to clinician  ........next page
RSV study - sick child visit. MJ/DJN 3 June, 2002 1
KBC# [ ][ ][ ][ ][ ] RSV# [ ] [ ] [ ]
To be completed by CLINICIAN 
HISTORY
How long has the child been sick?  .............................     [ ][ ] DAYS
What is/are the main problenis?(Please answer Y/N)
FEVER................................................!...................................... . ...............................[ ]
COUGH............. ........................................................................................................[ J
RUNNING NOSE/NASAL DTSCIIARGE/NAS AL CONGESTION............... [ ]
DIFFICULTY IN BREATHING    [ ]
OT HERS(specify below).....................................................>.............  [ ]
PHYSICAL EXAMINATION
OXYGEN SATURATION 
AXILLARY TEMPERATURE 
WEIGHT 
HEART RATE
COUGH HEARD
HOARSENESS
SORE THROAT
RHINITIS
PHARYNGITIS
CYANOSIS
EAR INFECTION
CONXUCTIVITIS
PROSTRATED
RESPIRATORY RATE
NASAL FLARING
INDRAWING
CRACKLES
WHEEZES
STRIDOR
][■ ] [ ]%
] [ ] [ ] [ ]C
] [ ] [ ] [ ]kg
] [ ] [ ]/min
] Y/N 
] Y/N 
] Y/N 
] Y/N 
] Y/N
] y /n  
] y /n
] Y/N
] y /n
][
] Y/N 
] Y/N
] y /n
] Y/N 
.1 Y/N
FW to 
complete
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APPENDIX IV
Information and consent form for birth cohort child.
STUDY OF A MAJOR CAUSE OF PNEUMONIA IN KILIFI DISTRICT
Information and consent form for birth cohort child.
PURPOSE OF STUDY
Chest infections are one of the biggest health problems for children in Kilifi District. We know 
the cause and the right treatment for many of these, but in some cases this is not yet known.
We are investigating an infection caused by a germ (vims) that is known to be a major cause of 
chest infections throughout the world. The vims is called Respiratory Syncytial Vims or RSV.
For infants who are infected in their first year of life the symptoms can be severe enough for the 
parents to feel a need to take the child to hospital. This condition is distressing both to the infant 
and to the family, although is rarely life threatening. There are no dmgs in routine use for 
reducing the symptoms, and currently no vaccine to prevent infection. However, much work is 
being carried out to develop a vaccine to prevent infection.
The purpose of this study is to identify how important is RSV in Kilifi District, and to find out how 
the vims is transmitted and maintained within the population. Results of both would be of great 
value in developing and eventually implementing a vaccine against this disease.
WHO IS ORGANISING THE STUDY
The study is organised by the Kenya Medical Research Institute (KEMRI) GGMRC, Kilifi District > 
Hospital (KDH) in collaboration with groups from outside Kenya (Universities in England) who 
have specific knowledge of the disease under study.
YOUR INVOLVEMENT
You are already enrolled in a Birth Cohort Study of Malaria and Pneumonia (pneumococcal) 
disease mn by KEMRI CGMRC. We are asking you to involve your newly bom child in another 
study of pneumonia in which we will monitor the child for infections of the nose and lungs that 
may be due to RSV. The method of monitoring is EITHER through you bringing your child to 
the hospital when he / she has symptoms of a cold or a chest infection, OR through weekly 
visits during the outbreaks of these problems (which occur each year) of our survey staff to 
your house to check on the child’s health. If you decide to enroll we will record information on 
your pregnancy, details of your child (weight length), and household information (location, 
number of siblings, household details).
We will monitor your child until the end of year 2004 which is a period of three years [insert 2 
years as appropriate].
If the child has signs of nose or chest infection that might be due to RSV we will collect a nasal 
specimen (fluid from the nose) in which we will check for the vims. If our tests confirm that the 
child is infected with RSV we will request a small sample of blood (less than half a teaspoon) 
and saliva soon after and again after 3-4 weeks by which to see how the child’s immune 
defenses are reacting.
Additionally, every 3 months we will collect a sample of saliva. You have already agreed for 
blood samples to be collected from your child every three months as part of the malaria and 
pneumococcal pneumonia study. For this RSV study, we would like to use a small amount of
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these blood samples and {where appropriate} we would also like you to continue to bring your 
child in for 3 monthly blood sampling until the end of the study period. The samples are to look 
for evidence of the infection.
(Where appropriate} We will also ask for a swab from the nose and throat each week in the first 
year during the main season of RSV, to assist in identifying the disease.
HOW DO WE COLLECT SAMPLES
Nasal specimens will be collected by washing out the nasal passage with some harmless fluid. 
The fluid is squirted into one nostril using a syringe [demonstrate device] and collected as it 
returns through the same or the other nostril. This procedure, conducted by trained staff, 
causes no harm to the infant, and whilst being a little uncomfortable, should clear the nasal 
passage making breathing more easy.
We collect saliva using a small clean sponge on the end of a plastic stick [show the device].
The sponge is brushed around the teeth and gums for half a minute - like using a toothbrush. 
This is painless, and without risk. Our staff will show how it is done.
Blood collection is by trained personnel. We will collect a sample of 2ml as much as will fit in 
this tube [demonstrate a 2ml tube].
{Where appropriate} Nasal and throat swabs are collected using cotton buds on the end of a 
wire support. This brushed against the back of the throat (throat swab [show device]) or 
inserted into the nose and brushed against the wall of the inner nose (nasal swab [show 
device]).
RISKS AND BENEFITS OF THE STUDY
All of the tests described above (taking blood or collecting fluid from the nose or mouth) are 
commonly used tests in clinics in many countries. They carry no danger for your child. Some of 
the procedures may be slightly uncomfortable, we try to ensure that this is not a problem by 
using highly trained staff to perform the tests.
Your child will benefit from having coughs, chest infections and fever investigated more quickly 
than would usually be the case because they are being seen more often. If your child is unwell 
at any time during the study, s/he can attend the research clinic at KDH and we will provide, 
without charge, examination and routine investigations (such as malaria tests) and medications 
(such a treatment for malaria, chest, skin or ear infections). Throughout the study period if our 
field worker asks you to attend the clinic with the child because s/he is unwell, or you bring the 
child to the clinic because you yourself have identified signs of nose or lung infection in the child 
(signs that we will explain), we will refund reasonable costs of your return travel fare. Because 
our funds are strictly limited we can only offer these benefits to the child involved in the study.
The other main benefit of research studies is in helping to improve understanding of disease, 
which may lead to better ways of preventing and treating these diseases. This benefits children 
and families in Kilifi District as a whole, as well as in other parts of Kenya
WHAT HAPPENS TO THESE SAMPLES AND THE INFORMATION COLLECTED 
The samples are sent to the laboratory at Kilifi Hospital where they will be tested to identify if 
your child is infected with RSV, or has had the infection in the recent past. To protect the 
privacy of your child, we will keep the records of this study under a code number rather than 
by name. We will keep the records in locked files and only study staff will be allowed to look
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at them. The name of your child or other facts that might point to him/her will not appear when 
we present this study or publish its results.
We would also like to store any blood/saliva/nasal washings that are left over after we do your 
tests. We plan to use these samples for studies we may do in the future. The samples will be 
labeled with a number, not a name, and if further information is required, e.g. to identify that 
this sample comes from your child, this information will only be provided to the researchers if 
the new study has been scrutinised and approved by the National Ethical Committee in 
KEMRI. You can decline to let us store your child's blood and saliva for use in other research 
projects and still be in this study.
MORE INFORMATION
Please feel free to ask any questions about the study. You are free to join in the study or not. 
You may also decide to withdraw your child from the study at any time, for any reason. If, 
after discussing this with us, you decide to allow your child to join the study we would like you 
to sign this form.
We have given you a copy of this consent form. When you sign below, it shows that you 
agree to join the study. If there is any part of this form which you do not understand be sure to 
ask questions about it. Do not sign until you have full answers to all your questions. When 
you are ready to be part of the study, please tick one of the two boxes and print and sign your 
name on the lines below.
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Consent form for infant cohort study.
STUDY OF A MAJOR CAUSE OF PNEUMONIA IN KILIFI DISTRICT
To Mother
• Have you read, or had read to you, the invitation letter?
• Have you had an opportunity to ask questions and discuss this study?
• Have you received satisfactory answers to those questions?
• Have you received enough information about the study?
• Do you understand that you are free to withdraw your child from the study
- at any time
- without having to give a reason why
- without affecting your child's access to medical provision
I wish my child [nam e]_____________________________to take part in the study
I also give consent for my child's blood/saliva/nasal samples to be stored at KEMRI 
under the conditions above
I do not give consent for my child's blood to be stored at KEMRI for future research
Print Name:__________ :___________ '
Signature________________________________ Date____________
Household number/registration ______________ _______ __
Witness
I observed the process of consent. The parent/guardian of the prospective participant read 
this form, was given the chance to ask questions, appeared to accept the answers, and 
signed to enroll his/her child in the study.
Name:____________ _________ ___________
Signature________________________________ Date________________________
The study co-ordinator is Dr James Nokes. If you have any questions about the ethics of this 
study you can contact Dr Charles Mbogo, at KEMRI/Wellcome Trust, Kilifi District Hospital or 
telephone Kilifi 22535.
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APPENDIX V 
Sources of Reagents, Equipment and Consumables
Reagents
Supplier Reagent
Alta Bioscience, Birmingham, UK 1st round MPX PCR primer mix
2nd round MPX PCR primer mix
N gene primer mix
Ambion (Europe) Ltd, Huntingdon, 
Cambridgeshire
RNase Zap®
Amersham Biosciences, 
Buckinghamshire, UK
pd(N)6 Random hexamer 5’-phospate, 
sodium salt
BDH (Merck Ltd), Leicester, UK Hydrogen peroxide
Tween-20
Birmingham University, Division of 
Immunity & Infection, Medical 
School,UK
RSV A2 strain (ATCC VR-1540)
Chemicon International, Inc, USA Light Diagnostics™ Respiratory 
Syncytial Virus direct 
immunofluorescence assay (DFA)
Dako, Cambridgeshire, UK Goat anti-mouse IgG-HRP gamma- 
chain spec (2 mL)
Rabbit anti-human IgG HRP gamma- 
chain spec (2 mL)
European Cell Culture Collection, 
Porton Down, UK
HEp-2 cells (ECACC 86030501/CCL- 
23)
RSV A2 strain (ATCC VR-1540)
Fisher Scientific, Leicestershire, UK Absolute ethanol
Acetone
Sulphuric acid
Gibco-BRL Life Technologies Ltd, 
Paisley, UK
Agarose (electrophoresis grade)
MEM Non essential amino acids 
(100X), liquid without L-Glutamine
Minimal Essential Media (MEM) with 
Earles salts+ L-Glutamine
D-PBS powder (10 L)
PBS 0.01 pH 7.2 (100 tablets)
penicillin/streptomycin
Trypsin-EDTA (IX)
Invitrogen Ltd. Paisley, UK Agarose
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Supplier Reagent
New England Biolabs (UK), Herts, UK Hind III (10,000 Units)
Pst I (10,000 Units)
Bgl 11(10,000 Units)
Hae III (3,000 Units)
Rsa I (1,000 Units)
Qiagen Ltd. West Sussex, UK QIAamp Viral RNA Mini kit
Omni script Reverse Transcriptase kit
Taq PCR Master Mix kit
Sigma-Aldrich Co Ltd, Dorset, UK Amphotericin B
Ethidium bromide
Fetal bovine serum, certified (heat 
inactivated) 500ml
HEPES buffer solution (1M)
Nonidet P40 substitute
O-phenylendiamine dihydrochloride 
tables (30 mg)
Tescos Supermarket, UK Marvel Dried skimmed milk
Warwick University, UK Hep2 cells
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Equipment and Consumables
Supplier Equipment/Consumable
Alpha Laboratories Ltd, Hampshire, 
UK
Apex 2.0 mL microtubes
Apex screw cap white
BD Biosciences, Cambridge UK BD Falcon ™ 15 mL high-clarity 
polypropylene conical centrifuge tube
Gilson Medical Electronics, France Gilson pipetman: P10, P I00, P200, 
P1000
Dynex Technologies, Ashford, UK Immulon-2 HB flat bottom 96 well 
microtitre plates
Eppendorf, Cambridge, UK Eppendorf Centrifuge 5415D
Multichannel pipettor
Jencons, Bedfordshire, UK Cryovials 1.2 mL
Fisher Scientific, Leicestershire, UK Nalgene Mr. Frosty
Tissue culture flask: 125cm + 0.2um 
filtered caps, 75cm2 + 0.2 um filtered 
caps, 25cm2 angle neck+ 0.2um filtered 
caps
Cell Scraper blade length 320 mm 
blade width 17.5 mm
Phillip-Harris Scientific, UK Glass balls 3.7-4.1mm undrilled (500g)
Sarstedt, Leicester, UK Aeroseal filter tip autoclavabale: 10 p.L, 
100 pL, 200 pL, 1000 pL
Microcentrifuge tube natural 
polypropylene with safety cap. 0.5 mL, 
1.5 mL
Centrifuge tubes: 15 mL, 50 mL
Pipette tips: blue (1000 pL), yellow 
(200 pL)
Serological sterile pipette. 1 mL, 5 mL, 
10 mL, 25 mL
Transparent ELISA plate sealers
Sigma-Aldrich Co Ltd, Dorset, UK IKA mini MS 1 mixer
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APPENDIX VI 
Growth stages non-infected and infected cultured HEp-2 cells
Photo: Panels A-B, day 3 and panels C-D, day 4 HEp-2 cells post-inoculation with RSV A2. 
Panels A and C and panels B and D are infected cells and mock-infected (control) cells 
respectively. (Magnification: X100 objective)
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APPENDIX VII 
Sequences of primers used and amplicon sizes
(Cane & Pringle, 1991, Stockton et al., 1998)
Primer Gene
Position
Sequence 5’ to 3’ Amplicon 
size (bp)
N Gene Primer
Mix
N1 N GGAAC AAGTTGTTGAGGTTT ATGAAT ATGC
N2 N CTTCTGCTGTCAAGTCTAGTACACTGTAGT
1st Round MPX 
Primer Mix 
AH 1 A HA CAGATGCAGACACAATATGT 1,015
AH1 FI 1 HA AAACCGGCAATGGCTCCAAA
RSV AB F N GT CTTAC AGCCGT GATT AGG 838
RSV AB R P GGGCTTTCTTTGGTTACTTC
BHAD11 HA TGT1T1CACCCATATTGGGC 900
BHAA HA GTGACTGGTGTGATACCACT
AH3 A HA CAGATTGAAGTGACTAATGC 883
AH3 D ll HA GTTTCTCTGGTACATTCCGC
2nd Round MPX 
Primer Mix 
AH1 B HA ATAGGCTACCATGCGAACAA 944
AH1 E ll HA CTTAGTCCTGTAACCATCCT
AH3B HA AGCAAAGCTTTCAGCAACTG 591
AH3C11 HA GCTTCCATTTGGAGTGATGC
BHAB HA CA11'llGCAAATCTCAAAGG 767
BHAC11 HA TGGAGGCAATCTGCTTCACC
RSV A F N GATGTTACGGTGGGGAGTCT 334
RSV A R N GTACACTGTAGTTAATCACA
RSV B F N AATGCTAAGATGGGGAGTTC 183
RSV B R N GA AATTGAGTT AATGAC AGC
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APPENDIX VIII 
Modified Lysate preparation/ELISA procedure
(Note: Modifications to assays indicated in bold)
Materials
Nonidet-P40 (NP40)
PBS
Cell scraper
15 mL falcon tube
Vibra-Cell™ ultra-sonicator (Sonics & Materials, Inc)
Nunc-Immuno™ MaxiSorp™
1. When extensive CPE (50-75%) is noted in infected HEp-2cells, scrape cells into medium, and 
place in a centrifuge tube, similarly for control flasks.
2. Spin at 352 X g for 10 min and then decant off supernatant (CAUTION: Infectious)
3. Resuspend pellet in 10 mL PBS, spin at 352 X g for 10 min.
4. Decant off supernatant (CAUTION: Infectious).
5. Resuspend in 10 mL sterile water + 0.5% NP40 and vortex very hard.
6 . Spin at 352 X g for 10 min.
7. Place 10 mL of supernatant into 15 mL falcon tube previously cut into half and then
sonicate at 70% amplitude, 3X 1 min cycles with 1 sec pulse and 1 sec pause (to allow for
maximal virus liberation from cells).
8. Pool respective lysates and then vortex hard.
9. Aliquot supernatant in 2ml quantities and store at -70°C until further use.
Plate Preparation
1. Dilution of lysate must first be determined. Dilute above lysate e.g. 1:2, 4, 8 , 16, 32, 64 (both 
infected and uninfected) in PBS (coating buffer). Add 25 pi to each well (always do wells in 
triplicate) of 96-well MaxiSorp™ plates.
2. Allow lysate to adsord to wells over night at 37°C in a rotating incubator (to ensure optimal 
binding of proteins and hence reduce non-specific binding).
3. Flick off coating buffer and proceed with ELISA assay below.
ELISA Assay
1. Block plates with 200 pL/well with 5% Marvel in PBS and then seal plates and incubate for 1 hr 
at 37°C.
2. Flick off block and bang plate on paper towel.
3. Meanwhile dilute sera and control (adult serum) in block (i.e. 5% Marvel in PBS) 1:100
4. Also carry out serial dilution of standard (pooled adult sera) starting 1:50 to 1:1600
5. Add 100 pL/well of serum, control in every plate and one set of standard per run, all in duplicate, 
and re-seal plates and incubate for 1.5 hr at 37°C.
6 . Wash plates using plate washer 6  times with 200 pLl PBS-T.
7. Dilute the secondary antibody, goat anti-human HRP conjugated 1:1000 in block and add 100 pL 
to each well.
8 . Incubate at 37°C for 1 hour and wash as above.
9. Develop with 100 pL O-phenylenediamine per well (30 mg tablet in 30 mL PBS, add 30 pL 
fresh H20 2) for 1 0  min. Prepare just before use. (Care, carcinogenic).
10. Add 50 pL 2.5 M H2S04 per well to quench the reaction.
11. Read at 492 nm.
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APPENDIX IX 
Distribution of nasal wash sample results and type of samples 
collected
(a) Table 1. NW results from entire follow up period
NW results Frequency Percent
Negative 7,905 93.1
Equivocal 110 1.3
No result 21 0.2
Positive 457 5.4
TOTAL 8,493 100.0
(b) Table 2. Frequency of type of samples collected from infants during entire follow up 
period
Sample type Frequency Percent
Cord 361 10
3 month 2,765 75
Acute 295 8
Convalescent 270 7
Total 3,691 100
(c) Table 3. The number of sera samples per child available under 6  months of life used 
to carry out regression analysis/antibody response model
No of samples No of children Percent
1 503 41.54
2 422 34.85
3 207 17.09
4 58 4.79
5 18 1.49
6 3 0.25
Total 1211 100
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APPENDIX X 
Stem-and- leaf plot for r (Studentized residuals)
_4* 41
- 3 . 7665
-3 * 4432211
- 2 . 87
- 2 * 443322111100000
- 1 . 99999888887776 6 6 6 6 6 6 6 6 6 6 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
- 1 * 4444 444444 4444 4 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1  . . . (90)
- 0 . 99999 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8  . . . (197)
- 0 * 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4  . . . (248)
0 * 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  . .  . (309)
0 . 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5  ___ (281)
1 * 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1  . . . ( 2 0 2 )
1 . 55555 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7  . . . (123)
2 * 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3  . . . (92)
2 . 55555 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7  . . . (114)
3* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2  . . - (90)
3 . 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 8 8 8 8 8 8 8 8 8 8 8 8  . . . (83)
4* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2  . . . (106)
4 . 55 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 8 8 8  . . . ( 1 0 2 )
5* 000000000 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4 4  44 4 . . . (72)
5 . 55555 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8  . . . ( 1 0 2 )
6 * 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2  . . . (98)
6 . 555 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7  . . . (90)
7* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3  . . . ( 1 0 0 )
7 . 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 8 8 8 8  . . . (99)
8 * 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3  . . . (80)
8 . 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7  . . . (94)
9* 0000000000000 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4  44 44 4444 44 44
9. 5 5 5 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 8 8 8 8 8 8 8 8 8 8 8 8 9 9 9 9 9 9 9 9 9 9
1 0 * 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3  . . . (83)
1 0 . 5555555555 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 8 8 8 8 8 8 8 9 9 9 9 9
1 1 * 000000000000000111 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 4 4 4 4  44 4444 44 444
1 1 . 55555 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 8 8 8 8 8 8 8 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
1 2 * 00000000000011111111 1 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 4
1 2 . 55 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 8 8 8 8 8 8 8 9 9 9 9 9 9
13* 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1111222222333333334  44 44 4 444
13. 5555555 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 8 8 8 8 8 8 8 9 9 9 9 9 9 9 9
14* 00000000001 1 1 1 1 1 2 2 2 3 3 3 3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 4 4
14 . 5555555 5 5 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 8 8 8 8 8 8 8 9 9 9 9 9 9 9 9 9 9 9
15* 0000001111111111 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 4  44 44444
15 . 555555555666 6 6 6 7 7 7 7 7 8 8 8 8 9 9 9 9 9 9 9 9
16* 00000111111111133333444444
16 . 5555555556666 6 6 6 7 7 7 7 7 8 8 8 8 8 9 9
17* 0001111111222333444
17. 5555566667779
18* 0002234444
18. .557788
19* 012344
19 . 577
2 0 * 1224
2 0 . 57788
2 1 *
2 1 . 8
2 2 * 04
2 2 . 6
23*
23 .
0
24*
2 4 .
25*'
25 .
26*
26 .
27*
27 .
28*
28 . ^ —  — X
29*
Note: Outlier indicted by green ellipse
APPENDIX XI
(a) Histogram of seronegative population under 6mo of life
lo g _ a u
1.2 1.4 1.6
Mean for seronegative population is 1.224 logAU, this was used in the regression analysis 
(Table 7.4) where all infants below the seropositive cut-off value had their antibody titres 
adjusted to the mean of the seropositive population
(b) A histogram of gradients of infants under 6  mo of life, (a) showing outliers encircled 
with green elliptical circle and (b) with outliers omitted.
.1 .2 .3
Rate of RSV matAb decay
-.04 -.02 0 .02 
Rate of RSV matAb decay
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APPENDIX XII 
Student t-tests
(a) Gradients
(i) Two-sample t-test with unequal variances of gradients of infected & non-infected samples, at 2-fold 
seroconversion level (Group 0 and 1 denote non-infected and infected populations respectively)
Group | Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
0 1 316 -.0090059 .0002029 .0036069 -.0094051 -.0086067
1 1 106 -.0069163 .0014075 .0144915 -.0097072 -.0041254
combined | 422 -.008481 .0003862 .0079331 -.0092401 -.0077219
diff | -.0020896 .0014221 -.004908 .0007288
diff = mean(O) - mean(l) t = -1.4694
Ho: diff = 0 Satterthwaite's degrees of freedom = 109.393
Ha: diff < 0 Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 0.0723 Pr(|T| > |t|) = 0.1446 Pr(T > t) = 0.9277.
(ii) Two-sample t-test with unequal variances of gradients of infected & non-infected samples, at 4-fold 
seroconversion level (Group 0 and 1 denote non-infected and infected populations respectively)
Group | Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
0 1 ■ 322 -.0088983 .0002078 .0037282 -.009307 -.0084895
1 1 100 -.0071374 .0014838 .0148381 -.0100816 -.0041933
combined I 422 7.008481 .0003862 .0079331 -.0092401 -.0077219
diff | -.0017608 .0014983 -.0047324 .0012107
diff = mean(0) - mean(l) t = -1.1752
Ho: diff = 0 Satterthwaite1s degrees of freedom = 102.908
Ha: diff < 0  Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 0.1213 P r (|T| > |t|) = 0.2426 ' Pr(T > t) = 0.8787
(iii) Two-sample t-test with unequal variances of gradients of infected & non-infected samples, at 2-fold 
seroconversion level of kids bom outside an epidemic (Group 0 and 1 denote non-infected and infected 
populations respectively)
Group | Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
' 0 | 119 -.0084241 .0002889 .0031511 -.0089961 -.0078521
1 1 52 -.0072467 .0006688 .0048231 -.0085895 -.005904
combined | . 171 -.0080661 .0002878 .0037638 -.0086342 -.0074979
diff | -.0011774 .0007286 -.0026301 .0002754
diff = mean(0) - mean(l) t = -1.6160
Ho: diff = 0 Satterthwaite's degrees of freedom = 70.7368
Ha: diff < 0 Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 0.0553 Pr(|T| > |t|) = 0.1105 Pr(T > t) = 0.9447
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(iv)Two-sample t-test with unequal variances of gradients of infected & non-infected samples, at 2-fold 
seroconversion level of kids bom inside an epidemic (Group 0 and 1 denote non-infected and infected 
populations respectively)
Group 1 Obs Mean Std. Err. Std. Dev. [95% Conf.. Interval]
0 1 197 -.0093573 .0002722 .0038211 -.0098942 -.0088204
1 1 54 -.0065981 .0026993 - .0198356 -.0120122 -.001184
combined 1 251 -.0087637 .0006189 .0098056 -.0099827 -.0075448
diff 1 -.0027592 .002713 -.0081982 .0026797
diff = mean(0) - mean(1) t = -1.0171
Ho: diff = 0 Satterthwaite1s degrees of freedom = 54.0822
Ha: diff < 0 Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 0 . 1568 Pr (1 T | > 111 ) = 0.3137 . Pr(T > t) = 0.8432
Neither were differences in rate of decay between the 2 population groups observed 
when stratified by epidemic at 4-fold seroconversion level
(v) Two-sample t-test with unequal variances of gradients of infected & non-infected samples at 2-fold 
seroconversion level of kids with a birth weight level > 2.5 kg (Group 0 and 1 denote non-infected and 
infected populations respectively)
Group | Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
0 1 237 -.0090565 .0002296 .0035349 -.0095088 -.0086041
1 1 86 -.0080838 .0016109 .0149386 -.0112867 -.004881
combined I 323 -.0087975 .0004597 .0082615 -.0097019 -.0078931
diff | -.0009727 .0016272 -.0042061 .0022607
diff = mean(O) - mean(l) t = -0.5978
Ho: diff = 0 Satterthwaite's degrees of freedom = 88.47 61
Ha: diff < 0 Ha: diff != 0 Ha: diff'> 0 -
Pr(T < t) = 0.2758 Pr(|T| > |t|) = 0.5515 Pr(T > t) = 0.7242
(vi)Two-sample t-test with unequal variances of gradients of infected & non-infected samples at 4-fold 
seroconversion level of kids with a birth weight level > 2.5 kg (Group 0 and 1 denote non-infected and 
infected populations respectively)
Group | Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
0 1 
1 1
242
81
-.0089596
-.0083131
■ .0002337 
.0017018
.0036353
.0153163
-.00942
-.0116998
-.0084993
-.0049264
combined | 323 -.0087975 .0004597 .0082615 -.0097019 -.0078931
diff | -.0006466 .0017178 -.0040631 .00277
diff = mean(0) - mean(l) t = -0.3764
Ho: diff = 0 Satterthwaite1s degrees of freedom = 83.0356
Ha: diff < 0  Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 0.3538 Pr(|T| > |t|) = 0.7076 Pr(T > t) = 0.6462
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(b) Cord fylpqd tjtres
(i)Two-sample West with unequal variances of cord blood titres of infected & non-infected samples at 2- 
fold serp9pnvetsion level of kids J)orn outside an epidemic (Group 0 and 1 denote non-infected and infected 
pppulqtious respectively)
Group | Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
0 1 89 3.038385 .0491793 . .4639563 2.940652 3.136119
1 1 30 2.962086 . 1058686 .5798664 2.745561 3.178612
combined | 119 3.01915 .0453069 .4942397 2.92943 3.10887
diff | .076299 .1167338 -.1592431 .3118412
diff = mean(O) - mean(l) t = 0.6536
Ho: diff = 0 Satterthwaite's degrees of freedom = 42.2183
Ha: diff < 0 Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 0.7415 Pr(IT| > |t|) = 0.5169 Pr(T > t) = 0.2585
(ii) Two-sample t-test with unequal variances of cord blood titres of infected & non-infected samples at 4- 
fold seroconversion level of kids bom outside an epidemic (Group 0 and 1 denote non-infected and infected 
populations respectively)
Group | Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
0 1 92 3.017189 .0515181 .4941441 2.914855 3.119524
11-.. 27 3.025833 .0969801 .5039234 2.826488 • 3.225179
combined I 119 3.01915 .0453069 .4942397 2.92943 3.10887
diff | -.008644 .1098146 -.2302913 .2130033
diff = mean(0) - mean(l) t = -0.0787
Ho: diff = 0 Satterthwaite1s degrees of freedom = 41.7939
Ha: diff < 0 Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 0.4688 Pr(IT| > |t|) = 0.9376 Pr(T > t) = 0.5312
(iii) Two-sample t-test with unequal variances of cord blood titres of infected & non-infected samples at 2- 
fold seroconversion level of kids with a birth weight level < 2.5 kg (Group 0 and 1 denote non-infected and 
infected populations respectively)
Group | Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
0 1 79 2.946175 .0636349 .565599 2.819488 3.072863
1 1 15 2.65532 .2478656 .9599793 2.123702 3.186939
combined*1 94 ■ 2.899762 .0667244 . 6469172 2.767261 3.032264
diff 1 .290855 .2559038 -.2519311 .8336412
. diff = me an (0) - mean(1) t 1.1366
Ho: diff - 0 Satterthwaite1s degrees o f freedom = 15.8939
Ha: diff < 0 Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 0.8637 Pr (1 T | > 111 ) = 0.2726 Pr(T > t) = 0.1363
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(iv) Two-sample t-test with unequal variances of cord blood titres of infected & non-infected samples at 4- 
fold seroconversion level of kids with a birth weight level < 2.5 kg (Group 0 and 1 denote non-infected and 
infected populations respectively
Group | Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
0 | 
1 1
80
14
2.938939
2.675898
. 0632497 
.2653313
.5657229
.9927787
2.813043
2.102684
3.064834
3.249111
combined | 94 2.899762 .0667244 .6469172 2.767261 3.032264
diff | .2630409 .2727659 -.3200542 .846136
diff = 
Ho: diff =
me an (0) - 
0
mean(1)
Satterthwaite1s degrees
t ^
of freedom ;
0.9643 
= 14.5117
Ha: diff 
Pr(T < t) =
< 0 
0.8247 Pr ( |
Ha: diff ! 
T I > 11 | ) =
= 0 
0.3507
Ha: diff > 0 
Pr(T > t) = 0.1753
(v) Two-sample t-test with unequal variances of cord blood titres of infected & non-infected i 
fold seroconversion level of kids with a birth weight level > 2 .5  kg (Group 0 and 1 denote no: 
infected populations respectively
Group | Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
0 1 
1 1
213
54
3.032248
2.892726
.0341252
.087026
.4980407
.639508
2.96498
2.718174
3.099516
3.067279
combined | 267 3.004 03 .0325179 .5313462 2.940005 3.068055
diff | .1395213 .0934776 -.0469074 .32595
diff = 
Ho: diff =
mean(O) - 
0
mean(1)
Satterthwaite's degrees
t :
of freedom :
1.4926 
= 70.1374
Ha: diff 
Pr(T < t) =
< 0 
0.9300 Pr( |
Ha: diff ! 
T I > It | ) =
= 0 
0.1400
. Ha: diff > 0 
Pr(T > t) = 0.0700
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APPENDIX XIII 
Multiple regression models
In all subsequent analysis, bw level implies birth weight level; e~2fold_level and e~4fold_level, infection 
at the 2-and 4-fold levels respectively; bom_in_epi, birth in or out of epidemic period; _Iquart_le~2 to le~4, 
cord levels 1-4 (i.e. lower, middle lower, middle upper and upper quartile ranges respectively) and
_Iparity_l~2 to 1~3, parity levels 2-3 (ie 4th-6th birth and > 6 births respectively)
(a) Gradients
(i) Controlling for birth weight level & infection at 2-fold seroconversion level
Source SS df
Model
Residual
.000046452
'.006701236
Total
MS
2 .000023226
206 .00003253
.006747688 208 .000032441
Number of obs = 
F ( 2,, 206) =
Prob > F 
R-squared =
Adj R-squared = 
Root MSE
209 
0.71 
. 0.4909 
0.0069 
-0.0028 
.0057
b age days I Coef. Std. Err. t P> 111 [95% Conf. Interval]
bw level | 
e~2fold le~l | 
cons |
-.0007008
.0008743
-.0084243
.0009701 -0.72 
.0008153 1.07 
.0008632 -9.76
0.471
0.285
0.000
-.0026133
-.0007332
-.0101262
.0012118 
.0024818 
t .0067224
No difference at 4-fold seroconversion level either
(ii) Controlling for birth in or out o f epidemic period & infection at 2-fold seroconversion
Source | SS ' df _ MS Number of obs 
F ( 2, 206) 
Prob > F 
R-squared 
Adj R-squared 
Root MSE
209 
0.92 
= 0.4008 
= 0.0088 
= -0.0008 
.0057
Model | 
Residual I
.000059629
.006688059
2 .000029814 
206 .000032466
Total | .006747688 208 .000032441
b age days | Coef. Std. Err. t P> 11 | [95% Conf. Interval]
born in epi I 
e~2fold le~l | 
cons |
-.0007745
.0006355
-.0084415
.0008037 -0.96 
.0008102 ' 0.78 
.0007189 -11.74
0.336
0.434
0.000
-.002359
-.000962
-.0098588
.00081
.0022329
-.0070242
No difference at 4-fold seroconversion level either
(iii) Controlling for parity levels & infection at 2-fold seroconversion level
Source SS df MS
 + ■----------------------------------------
Model | ’.000061847 3 .000020616
Residual | .006572738 197 .000033364
   +---------------------------------------------
Total | .006634585 200 .000033173
Number of obs = 201
F ( 3, 197) = 0.62
Prob > F  = 0.6042
R-squared - 0.0093
Adj R-squared = -0.0058 
Root MSE = .00578
b age days | Coef. Std. Err. t P> 111
Iparity 1~2 I .0006905 .0009913 0.70 0.487
Iparity 1~3 I .0012502 .0015288 0.82 0.414
e~2fold le~l I .0007423 .0008304 0.89 0.372
cons | -.0092237 .0006007 -15.36 0.000
[95% Conf. Interval]
-.0012645 .0026455
-.0017647 .0042652
-.0008953 .0023799
-.0104083 -.0080392
No difference at 4-fold seroconversion level either
(iv) Controlling for cord blood titres & infection at 2-fold seroconversion level
cord levels Iquart lev 1-4 (naturally coded; Iquart lev 1 omitted)
Source SS df MS
Model
Residual
.000831496
.001047813
4 .000207874
176 5.9535e-06
Total .001879309 180 .000010441
Number of obs = 181
F ( 4, 176) = 34.92
Prob > F - 0.0000
R-squared = 0.4424
Adj R-squared = 0.4298
Root MSE .00244
b age days I Coef. Std. Err. t P>|t.| [95% Conf. Interval]
Iquart le~2 | -.0030211 .0005178 -5.83 0.000 -.004043 -.0019992
Iquart.le~3 | -.0043159 .0005289 -8.16 0.000 -.0053596 -.0032721
Iquart le~4 I -.005967 .0005346 -11.16 0.000 -.0070221 -.0049118
e~2fold le~l 1 .0006289 .0003857 1.63 0.105 -.0001323 .0013901
cons | -.0054697 .0004192 -13.05 0.000 -.0062969 -.0046424
(v) Controlling for cord blood titres & infection at 4-fold seroconversion level
cord levels Iquart lev 1-4 (naturally coded; _Iquart_lev 1 omitted)
Source SS df MS
Model
Residual
.000823533
.001055776
4 .000205883
176 5.9987e-06
Total .001879309 180 .000010441
Number of obs = 181
F ( 4, 176) = 34.32
Prob > F = 0.0000
R-squared 0.4382
A d j  R-squared - 0.4254
Root MSE .00245
.. b age days | Coef. Std. Err. . t P> 111 [95% Conf. Interval]
Iquart le~2 | -.0030468 .0005196 -5.86 0.000 -.0040724 -.0020213
Iquart le~3 | -.0043251 .0005315 -8.14 0.000 -.0053741 -.0032761
Iquart le~4 | -.0059972 .000536 -11.19 0.000 -.0070551 -.0049393
e~4fold le~l | .0004512 .0003941 1.15 0.254 -.0003265 .0012289
cons | -.0053829 .0004181 -12.87 0.000 -.006208 -.0045577
(vi) Controlling for all potential risk factors & infection at 2-fold seroconversion level
p a r i t y  l e v e l s  
c o r d  l e v e l s
S o u r c e  I
_ I p a r i t y _ l e _ l - 3  
I q u a r t  l e v  1 - 4
SS d f
( n a t u r a l l y  c o d e d ;  _ I p a r i t y _ l e _ l  o m i t t e d )  
( n a t u r a l l y  c o d e d ;  _ I q u a r t  l e v _ l  o m i t t e d )
MS
Model
Residual
. 0 0 0 7 7 0 5 8 1
. 0 0 0 9 9 4 4 2 2
T o t a l . 0 0 1 7 6 5 0 0 3
8  . 0 0 0 0 9 6 3 2 3
1 6 4  6 . 0 6 3 5 e - 0 6
1 7 2  . 0 0 0 0 1 0 2 6 2
N u m be r  o f  o b s  = 1 7 3
F ( 8 , 1 6 4 )  = 1 5 . 8 9
P r o b  > F = 0 . 0 0 0 0
R - s q u a r e d  = 0 . 4 3 6 6
A d j  R - s q u a r e d  = 0 .  4 0 9 1
R o o t  MSE . 0 0 2 4 6
b  a g e  d a y s  | C o e f . S t d .  E r r . t P> 111 [95% C o n f . I n t e r v a l ]
b o r n  i n  e p i  | - . 0 0 0 3 3 5 8 . 0 0 0 3 9 6 2 - 0 . 8 5 0 . 3 9 8 - . 0 0 1 1 1 8 2 . 0 0 0 4 4 6 6
b w  l e v e l  | . 0 0 0 1 5 8 7 . 0 0 0 4 8 3 1 0 . 3 3 0 . 7 4 3 - . 0 0 0 7 9 5 1 . 0 0 1 1 1 2 5
I p a r i t y  1 - 2  I . 0 0 0 3 9 5 9 . 0 0 0 4 5 3 3 0 . 8 7 0 . 3 8 4 - . 0 0 0 4 9 9 1 . 0 0 1 2 9 0 8
I p a r i t y  1 - 3  | . 0 0 0 0 3 . 0 0 0 7 0 7 8 0 . 0 4 0 . 9 6 6 - . 0 0 1 3 6 7 5 . 0 0 1 4 2 7 6
I q u a r t  l e ~ 2  | - . 0 0 2 8 7 5 9 . 0 0 0 5 4 2 6 - 5 . 3 0 0  . 0 0 0 ^ - . 0 0 3 9 4 7 3 - . 0 0 1 8 0 4 5
I q u a r t  l e ~ 3  | - . 0 0 4 3 0 9 3 . 0 0 0 5 6 2 1 - 7  . 67 0.000 - . 0 0 5 4 1 9 2 - . 0 0 3 1 9 9 3
I q u a r t  l e ~ 4  | - . 0 0 5 8 5 7 9 . 0 0 0 5 5 5 7 - 1 0 . 5 4 0.000 - . 0 0 6 9 5 5 1 - . 0 0 4 7 6 0 8
e ~ 2 f o l d _ l e ~ l  I . 0 0 0 5 5 6 2 . 0 0 0 4 1 1 . 3 6 0 . 1 7 7 - . 0 0 0 2 5 3 4 . 0 0 1 3 6 5 7
c o n s  | - . 0 0 5 5 5 9 7 . 0 0 0 6 5 6 9 - 8 . 4 6 0.000 - . 0 0 6 8 5 6 9 - . 0 0 4 2 6 2 6
(vii) Controlling for all potential risk factors & infection at 4-fold seroconversion level
parity_levels . _Iparity_le_l-3 (naturally coded; _Iparity_le_l omitted)
cord levels _Iquart_lev_l-4 (naturally coded; _Iquart_lev_l omitted)
Source I SS df MS Number of obs = 173
. F( 8, 164) = 15.63
Mode1 | .000763591 8 .000095449 . Prob > F = 0.0000
Residual I .001001412 164 6.1062e-06 R-squared 0.4326
Ad j R-squared 0.4 050
Total | .001765003 172 .000010262 Root. MSE .00247
b age days I Coef. Std. Err. t P> 111 [95% Conf. Interval]
born in epi | -.0003438 .0003976 -0 .86 0.388 -.0011288 .0004412
bw level I .0002143 .0004831 0.44 0.658 -.0007396 .0011682
Iparity 1-2 | .0003823 .0004549 0.84 0.402 -.0005158 .0012804
Iparity 1-3 | .0000434 .0007119 0.06 0.951 -.0013622 .0014491
Iquart le~2 | -.0029115 .0005443 -5.35 0.000 -.0039861 -.0018368
Iquart le~3 I -.0043424 .000565 -7 . 68 0.000 -.0054581 -.0032267
Iquart le~4 I -.0058945 .0005567 -10.59 0.000 -.0069936 -.0047953
e~4fold le~l I .0003458 .0004186 0.83 0.410 -.0004808 .0011724
cons | -.0054901 .0006579 -8.34 0.000 -.0067892 -.004191
(b) Cord blood titres
(i) Controlling for birth weight level &  infection at 2-fold seroconversion level
Source I SS df MS Number of obs 361 
5.70 
= 0.0037 
= 0.0309 
= 0.0255 
= .55741-
Mode1 | 
Residual I’
3.54282361
111.233148
2 1.77141181 
358 .310707118
r v jjo /
Prob > F 
R-squared 
Adj R-squared 
Root MSETotal | 114.775972 360 .318822144
log au | Coef. Std. Err. t P>|t | [95% Conf. Interval]
bw level | 
e~2fold_le~l I 
cons |
.1176612 
-.2181391 
2.934572 ■
.0670007 1.76 
.0728353 -2.99 
'. 0586556 50.03
0.080
0.003
0.000
-.0141032
-.3613779
2.819219
.2494255
-.0749003
3.049925
(ii) Controlling for birth weight level &  infection at 4-fold seroconversion level
Source | SS df MS Number of obs 
F( 2, 358) 
Prob > F 
R-squared 
Adj R-squared 
Root MSE
361 
3. 62 
= 0.0277 
= 0.0198 
= 0.0144 
= .56058
Model | 
Residual I
2.27641504
112.499557
2 1.13820752 
.358 .314244572
Total | 114 .775972 360 .318822144
log au | Coef. Std. Err. t P> 11 | [95% Conf. Interval]
bw level I 
e~4fold_le~l I 
cons |
.1131323
-.166283
2.924528
.0673514 1.68 
.0755924 -2.20 
.0589048 49.65
0.094
0.028
0.000
-.0193218 
-.314944 
. 2.808685
.2455864
-.0176221
3.040371
(iii) Controlling for birth in or out o f epidemic period & infection at 2-fold seroconversion
Source | SS . df MS Number of obs 
F ( 2, 358) 
Prob > F 
R-squared 
Adj R-squared 
Root MSE
361 
4 . 92 
= 0.0078 
= 0.0268 
= 0.0213 
= .55859
Model | 
Residual I
3.07057252
111.705399
2 1.53528626 
'358 .312026255
Total | 114.775972 360 .318822144
log au | Coef. Std. Err. t P>|t I [95% Conf. Interval]
born in epi | 
e~2fold le~l I 
cons |
-.0783123
-.217065
3.073873
.062752 -1.25 
.0730721 -2.97 
.054419 56.49
0.213
0.003
0.000
-.2017211
-.3607695
2.966852
.0450965
-.0733604
3.180894
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(iv) Controlling for birth in or out o f epidemic period & infection at 4-fold seroconversion level
/
Source | SS df MS Number of obs 
F ( 2, 358) 
Prob > F 
R-squared 
Adj R-squared 
Root MSE
361 
2.86 
= 0.0584 
= 0.0157 
= 0.0102 
= .56174
Model | 
Residual |
1.80733401
112.968638
2
358
.903667005 
.315554854
Total | 114.775972 360 .318822144
log au | Coef. Std. Err. t P> 111 [95% Conf. Interval]
born in epi I 
e~4fold le~l I 
cons |
-.0725221
-.1647097
3.056522
.0630448 -1.15 
.0757952 -2.17 
.0542906 56.30
0.251
0.030
0.000
-.1965067
-.3137695
2.949753
.0514625
-.0156499
3.16329
(v) Controlling for parity levels & infection at 2-fold seroconversion level
parity levels Iparity le 1-3 (naturally coded; Iparity le 1 omitted) •
Source | SS df MS Number of obs 
F ( '3, 344) 
Prob > F 
R-squared 
Adj R-squared 
Root MSE
348 
3.73 
= 0.0116 
= 0.0315 
= 0.0231 
= .54853
Model | 
Residual I
3.36668764
103.505417
3
344
1.12222921
.300887841
Total | 106.872105 347 .307988775
log au | Coef. Std. Err. t p> 111 [95% Conf. Interval]
Iparity -1~2 | 
Iparity 1~3 | 
e~2fold_le~l I 
cons |
.0634102 ■ 
.1146711 
-.2246853 
2.991718
.0695672 0.91 
.109699 1.05 
.0735484 -3.05 
.0390545 76.60
•0.363
0.297
0.002
0.000
-.0734204
-.1010941
-.3693465
2.914902
• .2002407 
.3304362 
-.0800241 
3.068534
(vi) Controlling for parity levels & infection at 4-foldi seroconversion level
parity levels Iparity le 1-3 (naturally coded; Iparity le 1 omitted)
Source I SS df MS Number of obs 
F ( 3, 344) 
Prob > F 
R-squared 
Adj R-squared 
Root MSE
348 
2.36 
= 0.0710 
= 0.0202 
= 0.0117 
= .55173
Model | 
Residual |
2.15829552 
104.713809
3
34 4
.71943184
.304400609
Total | 106.872105 347 .307988775
log au | Coef. Std. Err. t p> 111 [95% Conf. Interval]
Iparity 1~2 | 
Iparity 1~3 I 
e~4fold le~l I 
cons |
.0708385 
.1173114 
-.1753541 
2.976745
.0698812 1.01 
.1104075 1.06 
.0764933 -2.29 
.0387356 76.85
0.311
0.289
0.022
0.000
-.0666097
-.0998474
-.3258075
2.900557
.2082868
.3344702
-.0249008
3.052933
i(vii) Controlling for all parameters & infection at 2-fold seroconversion level
parity levels Iparity le _i-3 (naturally coded; _Iparity le 1 <omitted)
Source I ss • df MS. Number of obs 
F( 5, 342) 
Prob > F 
R-squared 
Adj R-squared 
Root MSE
348 
2.86 
= 0.0153 
= 0.0401 
= 0.0261 
= .54769
Model | 
Residual |
4.2845187
102.587586
5
342
.85690374
.299963703
Total | 106.872105. 347 .307988775
log au | Coef. Std. Err t P> 11 | [95% Conf. Interval]
bw level I 
born in epi | 
Iparity 1~2 I 
Iparity 1~3 I 
e~2fold_le~l | 
cons |
.1060265
-.0368811
.0653385
.1073177
-.2366209
2.339824
.0685473
.0635888
.0695399
.1097712
.073806
.082255
1.55
-0.58
0.94
0.98
-3.21
35.74
0.123
0.562
0.348
0.329
0.001
0.000
-.0288008.
-.1619553
-.0714412
-.1085941
-.3817918
2.778034
.2408538
.0881932
.2021182
.3232295
-.09145
3.101613
(viii) Controlling for all parameters & infection at 4-fold seroconversion level
parity levels Iparity le _l-3 (naturally coded; _Iparity le 1 omitted)
Source I SS • df MS Number of obs - 34 8 
F ( 5, 342) = 1.96 
Prob > F = 0.0837 
R-squared = 0.027 9 
Adj R-squared = 0.0137 
Root MSE = .55116
Model | 
Residual |
2.98023236 
103.891873
5
342
.59604647.1
.303777405
Total | 106.872105 347 • .307988775
log au | Coef. Std. Err. t P> 111 [95% Conf. Interval]
bw level I 
born in epi I 
Iparity 1~2 I 
Iparity 1~3 | 
e~4fold le~l | 
cons |
.1020746 
-.0313095 
.073159 
.1109427 
-.1856068 
2.923366
.0689668 1.48 
.0639353 -0.49 
.0698888 1.05 
.1105297 1.00 
.0767014 -2.42 
.0824405 35.46
0.140
0.625
0.296
0.316
0.016
0.000
-.0335778 .2377271 
-.1570654 .0944465 
-.064307 .'210625 
-.1064608 .3283463 
-.3364727. -.0347409 
2.761212 3.085521
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